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ABSTRACT 
 
Atherosclerosis can be initiated by pro-inflammatory activation of endothelial cells (EC) 
which leads to the recruitment of leukocytes to the vessel wall, and also by endothelial 
apoptosis which elevates the permeability of arteries to lipoproteins. The greater curvature of 
the aorta is exposed to high shear and is protected from EC apoptosis, inflammation and 
atherosclerosis, whereas the lesser curvature is exposed to low shear and is susceptible to 
atherosclerosis. Pro-inflammatory mediators (e.g. TNFα, LPS) trigger phosphorylation of c-
Jun N-terminal kinase (JNK) and p38 MAP kinases to positively regulate these process and 
influence atherosclerosis.  
 
I examined the effects of JNK activation on EC physiology at atherosusceptible sites. En face 
staining revealed that phosphorylation of JNK in EC occurs constitutively at the susceptible 
site of the murine aortic arch and can be enhanced by LPS treatment. In contrast, JNK 
activation was suppressed at the protected site by mitogen-activated protein kinase 
phosphatase-1 (MKP-1), a negative regulator of JNK and p38 MAP kinases. To study the 
function of JNK and p38 in vascular endothelium, I identified the transcriptional programs 
that they regulate by applying specific pharmacological inhibitors to cultured EC and 
assessing the transcriptome using microarrays. Functional annotation revealed that JNK and 
p38 positively regulate the expression of numerous pro-inflammatory and pro-apoptotic 
molecules. Subsequent gene silencing studies demonstrated that JNK1 positively regulates 
pro-apoptotic molecule expression in EC. I validated my findings in vivo by analyzing EC in 
aortae of wild-type, JNK1
-/-
 and MKP-1
-/-
 mice. I observed that EC at an atherosusceptible 
site express pro-apoptotic proteins and are primed for apoptosis and proliferation in response 
to LPS through a JNK1-dependent mechanism, whereas EC at a protected site expressed 
lower levels of pro-apoptotic molecules and was protected from injury by MKP-1.  
 
These findings indicate that the spatial variation of JNK1 activity delineates the spatial 
distribution of apoptosis and turnover of EC in arteries, and may influence the punctuate 
development of atherosclerotic lesions.   
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INFLAMMATION 
 
Inflammation involves complex physiological changes in a tissue and its microcirculation in 
response to tissue injury or infection. Celsius in the 1
st
 century A.D was the first to describe 
the four main sign of inflammation as rubor (redness), tumor (swelling), with calor (heat) 
and dolor (pain) to which Virchow later added the fifth sign as function laesa (loss of 
function)
1
. It is characterised by the generation of inflammatory mediators and recruitment of 
circulating leukocytes in to the extravascular tissue through activated endothelial cells (EC).  
 
Several pro-inflammatory agents are known to activate EC including microbial products (e.g. 
lipopolysaccharide; LPS) and pro-inflammatory cytokines (e.g. TNFα, IL-1) which may be 
secreted by injured or activated cells including monocytes, macrophages, neutrophils, 
lymphocytes and several non-immune cell types including EC and fibroblasts. These agents 
induce numerous pro-inflammatory proteins on endothelial surfaces including adhesion 
molecules (e.g. E-selectin, VCAM), cytokines, chemokines (e.g. MCP-1), matrix 
metalloproteinases and growth factors. 
 
Activation of endothelium during inflammation 
 
In the past, the endothelium was considered to be inert, described as a „layer of nucleated 
cellophane‟, with only non-reactive barrier properties, such as presentation of a non-
thrombogenic surface for blood flow and defence against pro-inflammatory insults. However 
it is now clear that under physiological conditions, EC control the transport of plasma 
molecules, employing bidirectional receptor-mediated and receptor-independent transcytosis 
and endocytosis, to regulate vascular tone and to synthesise and secrete a large variety of 
factors. In addition, EC are involved in the regulation of cholesterol and lipid homeostasis, 
signal transduction, immunity, inflammation and haemostasis
2
. By virtue of its location the 
endothelium is exposed to various biochemical forces which lead to differential regulation of 
transcriptional programmes.  
 
EC are activated during the onset of an inflammatory response resulting in changes in the 
permeability of the endothelium to leukocytes through expression of selectins and adhesion 
molecules on the cell surface. Under pathological conditions such as hyperlipidaemia or 
hyperglycemia, alterations in endothelial function precede the development of atherosclerotic 
~ 16 ~ 
 
plaques and contribute decisively to their perpetuation and to the clinical manifestations of 
vascular diseases.  
 
Transmigration of leukocytes into the sub-endothelial space involves a number of steps 
starting with rolling across endothelial surfaces mediated by selectins (e.g. E-selectin), 
activation mediated by chemokines and arrest regulated by integrins (e.g. VCAM-1, 
ICAM1)
3
. Adhesion strengthening and spreading, intravascular crawling and paracellular and 
transcellular transmigration then follow leading to leukocyte accumulation in sub-endothelial 
tissues (Figure 1).  
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Figure 1: The leukocyte adhesion cascade 
 
 
 
The figure above illustrates the various stages involved in signaling of leukocytes to infiltrate 
the vascular endothelium. Adapted from Le K et al 
3
. 
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Inflammatory mediators released at the site of an infection are known to activate EC. They 
are divided in to endogenous and exogenous mediators. Endogenous mediators such as 
cytokines (e.g. TNFα4, IL-1), chemokines and interferons are secreted by immune and non-
immune cell types and elicit an inflammatory attack. Exogenous mediators are specific 
bacterial surface molecules known as Pathogen-Associated Molecular Patterns (PAMPs) and 
act through Toll-like receptors (TLRs) on a variety of leukocytes resulting in an 
inflammatory response. PAMPs include microbial products such as LPS
5, 6
, tidoglycans, 
lipoteichoic acids, sugar mannose, bacterial and viral nucleic acid, mannose rich glycans and 
double stranded RNA.  
 
Tumor necrosis factor (TNFα) 
 
TNFα was identified in 1975 as a pleiotropic cytokine produced by macrophages capable of 
inducing cytotoxicity in a tumor cell line
7. The human TNFα gene was cloned in 1984 and 
has since then been linked with both inflammatory and cell death activities and is thought to 
play a role in the pathogenesis of atherosclerosis. TNFα is produced as a homotrimer 
transmembrane protein that undergoes proteolytic cleavage by TNF-alpha converting enzyme 
(TACE) to release the soluble cytokine. TNFα either binds to TNF-R1 that is expressed in 
most tissues or TNF-R2 found only in immune and endothelial cells
8
.  
 
Downstream of receptor-ligand binding, several pathways can be initiated (Figure 2) 
including, activation of NF-κB, activation of the MAPK pathway and induction of death 
signaling
9
. These pathways are not entirely independent and cross-talk can occur between 
them. The NF-κB pathway mediates the activation of genes involved in cell survival, 
proliferation, inflammatory responses and anti-apoptotic signaling
10
. Of the three major 
MAPK cascades, TNFα induces a strong activation of JNK and p38 can also activate ERK. 
The JNK pathway is involved in multiple processes including cell differentiation, 
proliferation and apoptosis
11. TNFα plays a minor role in the induction of death signaling 
compared to its pro-inflammatory role because NF-κB exerts anti-apoptotic effects which 
mask the death-inducing capabilities of TNFα. Studies have demonstrated that TNFα plays a 
role in several auto-immune and inflammatory diseases such as rheumatoid arthritis
12
.  
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Figure 2: TNFα signaling pathway 
 
 
 
Schematic representation of the TNFα signaling pathway showing its role in NF-κB and 
MAPK signaling as well as apoptosis
13
. Abbreviations: aPKC, atypical PKC; cIAPs, cellular 
inhibitors of apoptosis; FADD, Fas-associated death domain protein; IKK, IκB kinase; JNK, 
c-Jun N-terminal kinase; RIP1, receptor-interacting protein 1; TNFα, tumor necrosis factor α; 
TNFR1, TNF receptor type 1; TRAF2, TNF-receptor-associated factor 2. 
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Lipopolysaccharide (LPS)  
 
LPS is the major component of the outer membrane of gram-negative bacteria and 
contributes to the structural integrity of the microbe. It is an endotoxin that is released once 
the bacteria are lysed, resulting in a potent inflammatory response. Activation by LPS 
constitutes the first step in a cascade of events believed to lead to the manifestation of Gram-
negative sepsis, a condition that results in approximately 20,000 annual deaths in the US. 
 
LPS binds to toll-like-receptor 4 (TR4) to promote the secretion of inflammatory cytokines 
through the activation of transcription factors such as NF-κB and AP-1 in many cell types 
including macrophages
14. In Immunology, the term „LPS challenge‟ is referred to the process 
of exposing a subject to LPS which may act as a toxin and elicit an inflammatory response. 
Upon LPS recognition, TLR4 undergoes oligomerization and recruits its downstream 
adaptors through interactions with the TIR (Toll-interleukin-1 receptor) domains. LPS/TLR4 
signaling can be separated into MyD88-dependent and MyD88-independent pathways, which 
mediate the activation of pro-inflammatory cytokines and type I interferon (INF) genes as 
illustrated in Figure 3.  
 
LPS has been shown to initiate multiple intracellular signaling events, including the 
activation of NF-κB, which ultimately leads to the synthesis and release of a number of pro-
inflammatory mediators, including interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 
(IL-8), and TNFα15 and Type 1 interferons including interferon α (IFNα) and interferon β 
(IFNβ).   
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Figure 3: LPS-induced TLR4 signaling pathway 
 
 
 
Schematic representation of the LPS signaling divided in to the MyD88-dependent and 
MyD88-independent pathways. Adapted from Lu et al 
15
. Abbreviations: CD14, Cluster of 
differentiation14; LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide; MD-2, 
Monomeric recombinant 2; MyD88, Myeloid differentiation primary response gene 88; 
TIRAP, Toll-like receptor adaptor protein; TRAM, TRIF-related adaptor molecule; TRIF, 
TIR-domain-containing adapter-inducing interferon-β; TLR4, toll-like-receptor 4. 
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Inflammation-related signaling pathways 
 
Activation of EC by cytokines or endotoxin triggers transcription of pro-inflammatory genes 
e.g. E-selectin, VCAM, IL-8 and MCP-1 via NF-B and MAPK signaling pathways3, 16-18. 
 
NF-κB 
 
NF-κB belongs to a family of transcription factors that play an important role in coordinating 
immune and inflammatory responses
19, 20
. In mammals the family consists of 5 members NF-
κB-1 (p105/p50), NF-κB-2 (p100/p52), Rel A (p65), Rel B and c-Rel. The most abundant 
form of NF-κB in endothelial cells is the p50/p65 heterodimer that is sequestered in the 
cytoplasm by inhibitory IκB proteins (Figure 4). Upon activation by inflammatory cytokines, 
IκBs undergo serine phosphorylation via IKK2 and are subsequently degraded, allowing NF-
κB to translocate to the nucleus to induce expression of target genes21 (Figure 4). NF-κB is a 
major player in pro-inflammatory signaling pathways. Once translocated to the nucleus the 
NF-κB dimer binds to promoters of pro-inflammatory genes such as E-selectin, VCAM-1, 
ICAM-1, IL-8 and MCP-1
22
. NF-κB also controls cell survival by enhancing transcription of 
various anti-apoptotic genes like cellular FLICE-inhibitory protein (c-FLIP), Bcl-2
23, 24
, Bcl-
xL, A1, X-chromosome-liked inhibitor of apoptosis (XIAP), GADD45β
25, 26
 and manganese 
superoxide dismutase (MnSOD)
27, 28
. This concept is consistent with previous observations 
that A20, an inhibitor of NF-κB, can sensitise some cell types to apoptosis by reducing NF-
κB-mediated activation of cytoprotective genes29. 
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Figure 4: NF-κB pathway 
 
 
 
 
KEY: MAPKK kinase, Mitogen activated protein kinase kinase kinase; MEKK3, MAP/ERK 
Kinase-Kinase-3; IKK, Inhibitor of kappa B kinase; I-κB, Inhibitor of kappa B; NF- κB, 
Nuclear factor kappa B; VCAM-1, Vascular adhesion molecule 1; IL-8, Interleukin 8; 
MnSOD, Manganese superoxide dismutase; GADD45β, Growth arrest and DNA-damage-
inducible 45β. 
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Mitogen activated protein kinases (MAPK)  
 
The MAP kinase cascade is one of the most ancient and evolutionary conserved signal 
transduction pathways. There are three major members of the MAP kinase family in 
mammalian cells; namely extracellular signal-regulated protein kinase (ERK), c-Jun-NH2 
terminal kinase (JNK) and p38 MAP kinase. They are activated by conserved kinase cascades 
leading to dual phosphorylation in the regulatory loop between kinase sub-domains VII and 
VIII
30
 at the tripeptide motif Theronine-Xaa-Tyrosine (T-X-Y). 
 
p38  
 
p38, a 38kDa protein, phosphorylated in response to LPS
31
 and other stimuli has 4 isoforms 
of which α and β are ubiquitously expressed while γ and δ are differentially expressed in 
different tissues
32
. p38γ expression is reported during skeletal muscle differentiation33, 34 
whereas p38δ is more developmentally regulated33, 35 and is expressed in lungs, pancreas, 
small intestine, kidney and testis
36
 during development. p38 is activated by MKK3/6 and 
upstream MAPKK kinases (including MEKK3, TAK1 and ASK1) and subsequently 
regulates AP-1 transcription factors including ATF-2
37
 (Figure 5). In addition, p38 can 
activate MAP kinase-activated protein kinase-2 (MK-2) which regulates the stability of 
transcripts in IL-1 stimulated cells
38, 39
 and heat-shock protein 27 (HSP27) to modulate 
cytoskeleton remodelling
40. Several TNFα-inducible genes including VCAM-1 and COX-2 
have been shown to be regulated by p38 activation in primary HUVEC
41
, implicating a role 
for p38 in endothelial cell activation during inflammation
42, 43
.  
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Figure 5: p38 MAP kinase pathway 
 
 
 
KEY: MAPKK kinase, Mitogen activated protein kinase kinase kinase; MEKK3, MAP/ERK 
Kinase-Kinase-3; TAK1, TGFβ-activated kinase; DLK, Dual leucine zipper bearing kinase; 
MLK3, Mixed lineage kinase-3; ASK1, Apoptosis Signal-regulating Kinase; MKK3, MAP 
kinase kinase 3; MKK6, MAP kinase kinase 6; AP-1, Activating protein 1; ATF2, Activating 
transcription factor 2; MAPKAPK, MAP kinase activating protein kinase; HSP27, Heat-
shock protein 27. 
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JNK 
 
JNK, a 54kDa protein, was initially described as a stress-activated protein kinase on the basis 
of its activation in response to inhibition of protein synthesis
44
. The JNK protein kinases are 
encoded by three genes JNK1, JNK2 and JNK3; of which JNK1 and JNK2 are ubiquitously 
expressed
45
. JNK3 however is expressed only in the brain, heart and testis
45
. Activation of 
JNK by pro-inflammatory cytokines requires the activity of upstream MAPK kinases 
(including MKK4 and MKK7) and MAPKK kinases (including MEKK1, MEKK3, TAK1 
and ASK1)
37
. Once activated JNK phosphorylates ATF-2, Elk-1 and c-Jun transcription 
factors within the AP-1 superfamily
11
 (Figure 6). In EC it induces expression of pro-
inflammatory molecules via the TNFα pathway46. JNK has been shown to play a role in 
TNFα induced E-selectin expression47 by phosphorylating ATF-2 and c-jun transcription 
factors
4
. 
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Figure 6: JNK pathway 
 
 
 
KEY: MAPKK kinase, Mitogen activated protein kinase kinase kinase; MEKK1, MAP/ERK 
Kinase-Kinase-1; MEKK3, MAP/ERK Kinase-Kinase-3; TAK1, TGFβ-activated kinase; 
ASK1, Apoptosis Signal-regulating Kinase; MKK4, MAP kinase kinase 4; MKK7, MAP 
kinase kinase 7; JNK, c-Jun-NH2 terminal kinase; AP-1, Activating protein 1; c-jun, 
transcription factor downstream of JNK; ATF2, Activating transcription factor 2; Elk-1, Ets 
LiKe gene1.  
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CELL DEATH 
 
Cell death occurs when there is an irreversible loss of integrated cellular function. Necrosis 
describes an unprogrammed form of death caused by external factors, such as infection, 
toxins or trauma. In contrast, programmed cell death (PCD) is death mediated by an active 
intracellular program.  
 
Necrosis (from the Greek „dead‟) can result from acute tissue injury and provoke an 
inflammatory response. It typically begins with cell swelling, chromatin digestion, and 
disruption of the plasma membrane and organelle membranes. Late necrosis is characterized 
by extensive DNA hydrolysis, vacuolation of the endoplasmic reticulum, organelle 
breakdown and cell lysis
48
. The release of intracellular content after plasma membrane 
rupture is a powerful initiator of inflammation.  
 
PCD involves a series of biochemical events leading to characteristic changes in cell 
morphology and physiology and subsequent death. PCD comprises several subtypes, as 
revealed by electron
 
microscopy. Apoptosis or type I programmed cell death is characterized 
by
 
condensation of cytoplasm and preservation of organelles, essentially
 
without autophagic 
degradation. Autophagic cell death or type II programmed
 
cell death exhibits extensive 
autophagic degradation of Golgi apparatus,
 
polyribosomes and endoplasmatic reticulum, 
which precedes nuclear
 
destruction
49, 50
. Other forms of programmed cell death include 
anoikis, almost identical to apoptosis except in its induction which involves breakdown in 
cell-cell contact; cornification, a form of cell death exclusive to the eyes; excitotoxicity, 
pathological process by which nerve cells are damaged and Wallerian degeneration, axonal 
injury leading to a nerve fibre being crushed or cut off. This thesis will however focus mainly 
on type I programmed cell death i.e. apoptosis.  
 
Apoptosis and necrosis are characterised by distinct changes in cellular morphology and 
physiology as summarised in Table 1 and Figure 7.  
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Figure 7: Morphology of Necrosis versus Apoptosis 
 
 
 
Formation of membrane bubbles followed by disorganization of cytoplasm, homogeneous 
nuclear condensation and final chromatin disintegration within flattened polygonal cell 
remnants still attached to the substrate are typical of necrosis. Severe shrinkage, rounding and 
blebbing of highly refringent cells followed by chromatin condensation and fragmentation, as 
well as detaching from the substrate, are the main morphological features of apoptosis. Most 
of the resultant fragments of cells (apoptotic bodies) are phagocytosed. The apoptotic body 
within a phagosome undergoes enzymatic digestion which morphologically resembles 
necrosis and has thus been termed "secondary necrosis'
48, 51
. Image adapted from Duvall and 
Wyllie
48
. 
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Table 1: Differences between Necrosis and Apoptosis 
 
Necrosis Apoptosis 
Always pathological Physiological or pathological 
Sheets of cells Single cells 
Energy independent Energy dependent 
Cell swelling Cell shrinkage 
Membrane integrity lost Membrane integrity maintained 
No role for mitochondria Role for mitochondria and cytochrome c 
Leak of lysosomal enzymes No leak of lysosomal enzymes 
Nuclei lost Characteristic nuclear changes 
Do not form Apoptotic bodies form 
No DNA cleavage DNA cleavage 
No activation Activation of specific proteases 
Not regulated Regulated process 
Not conserved Evolutionarily conserved 
Dead cells ingested by macrophages Dead cells ingested by neighbouring cells 
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Apoptosis  
 
The principle of apoptosis was first described by Carl Vogt in 1842 while studying the 
development of the midwife toad. The actual term apoptosis meaning „dropping off‟ was 
coined in 1972 by Kerr et al 
52
.  
 
Apoptosis is the process of programmed cell death that involves a series of biochemical 
events that lead to a variety of morphological changes, including blebbing, changes to the cell 
membrane such as loss of membrane asymmetry and attachment, cell shrinkage, nuclear 
fragmentation, chromatin condensation, and chromosomal DNA fragmentation. 
 
During the early process of apoptosis, cell shrinkage and pyknosis are visible by light 
microscopy. With cell shrinkage, the cells are smaller in size, the cytoplasm is dense and the 
organelles are more tightly packed. Pyknosis is the result of chromatin condensation and this 
is a highly characteristic feature of apoptosis. This is followed by extensive plasma 
membrane blebbing and separation of cell fragments into apoptotic bodies during a process 
called budding. Apoptotic bodies consist of cytoplasm with tightly packed organelles with or 
without a nuclear fragment. The organelle integrity is still maintained and organelles are 
enclosed within an intact plasma membrane. These bodies are subsequently phagocytosed by 
macrophages, parenchymal cells, or neoplastic cells and degraded within phagolysosomes. 
There is essentially no inflammatory reaction associated with the process of apoptosis or with 
the removal of apoptotic cells because: (1) apoptotic cells do not release their cellular 
constituents into the surrounding interstitial tissue; (2) they are quickly phagocytosed by 
surrounding cells thus likely preventing secondary necrosis; and, (3) the engulfing cells do 
not produce inflammatory cytokines
53, 54
. 
 
Apoptosis is considered
 
a vital component of various processes including normal cell
 
turnover, proper development and functioning of the immune system,
 
hormone-dependent 
atrophy, embryonic development and chemical-induced
 
cell death. Inappropriate apoptosis 
(either too little or too
 
much) is a factor in many human conditions including 
neurodegenerative
 
diseases, ischemic damage, autoimmune disorders and many types
 
of 
cancer
55-58
. For example, conventional anti-cancer therapies, such as chemotherapy and 
radiotherapy, trigger tumor cell apoptosis via the pro-apoptotic transcription factor p53. 
Without p53 function, tumor cells evade apoptosis and can continue to proliferate, despite 
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genetic instabilities that are caused by chemotherapy or irradiation. Apoptosis is recognized 
as the principal cause of cardiac muscle death which is regarded as a contributing factor for 
IR injury, myocardial infarction and heart failure
59
.  
 
Caspases 
 
Caspases are cysteine proteases that play a central role in orchestrating the apoptotic process. 
The importance of caspases in apoptosis was established in 1993 by Robert Horvitz as he 
found that the ced-3 gene was required for the cell death that took place during the 
development of the nematode C. elegans. Yuan et al found that the protein encoded by the 
ced-3 gene was the cysteine protease with similar properties to the mammalian interleukin-1-
beta converting enzyme (ICE); now known as caspase-1, which at the time was the only 
known caspase
60
. Other mammalian caspases were subsequently identified and are now 
named using the common caspase nomenclature.  
 
Caspases are synthesized as relatively inactive zymogens that become activated by scaffold-
mediated transactivation or by cleavage via upstream proteases in an intracellular cascade
61
. 
At least 7 of the 14 known caspases play an important role in apoptosis and are divided in to 
initiator and effector caspases. Initiator caspases include caspase-2, -8, -9 and -10 and are 
auto-activated through cognate scaffold proteins that form complexes known as 
apoptosomes
62
. Effector caspases which include caspase-3, -6 and -7 are activated by 
upstream initiator caspases through proteolytic cleavage
61
. Once activated, effector caspases 
cleave a variety of intracellular polypeptides, including major structural elements of the 
cytoplasm and nucleus, components of the DNA repair machinery, and a number of protein 
kinases.  
 
Caspases are the central regulators for driving the apoptotic response and among them 
caspase-3 activation is regarded essential as it is most frequently activated during apoptosis 
and catalyzes the specific cleavage of many key cellular proteins. Porter and Janicke came to 
the conclusion that caspase-3 is essential in a tissue-, cell type and death stimulus-specific 
manner. They also noted that caspase-3 is essential for some of the characteristic changes in 
cell morphology and is indispensable for apoptotic chromatin condensation and DNA 
fragmentation associated with the completion of apoptosis
63
.  
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Caspase-3 is essential for normal brain development and survival as caspase-3 knockout mice 
are born at a low frequency and die after only a few weeks
64
. These mice have striking skull 
defects with ectopic masses of supernumerary cells representing interrupted apoptosis during 
neuronal development, but not in other organs or tissues. Thus, Porter and Janicke
63
 conclude 
that caspase-3 may lie at the heart of an essential neuronal death pathway. 
 
Caspase activation is regulated at several different levels: (1) zymogen gene transcription
65
; 
(2) through anti-apoptotic proteins e.g. c-FLIP (c-FLICE inhibitory protein)
66
, members of 
the Bcl-2 family
67
; and (3) IAPs (inhibitor of apoptosis proteins) that bind to and inhibit 
active caspases
68
.   
 
Pro-apoptotic signaling 
 
Apoptosis is known to occur by two major pathways, (1) the extrinsic or death receptor-
mediated pathway and (2) the intrinsic pathway, mediated via the mitochondria and 
endoplasmic reticulum as depicted in Figure 8
69
. Both pathways are regulated by their own 
sets of initiator caspases and converge at the level of the effector caspases. 
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Figure 8: Extrinsic and intrinsic pathways of apoptosis  
 
 
 
Extrinsic pathway is regulated through the death receptors while the intrinsic pathway is 
mediated by mitochondrial and the endoplasmic reticulum pathways. Adapted from Gupta et 
al 
69
. Abbreviations: AIF, Apoptosis-inducing factor; Apaf-1, Apoptotic protease activating 
factor 1;    Bcl-2, B-cell lymphoma 2; Bcl-xL, anti-apoptotic Bcl-2 protein; Bid, pro-apoptotic 
Bcl-2 protein; c-FLIP, cellular FLICE-like inhibitory protein; cyto c, cytochrome c; Endo G, 
endonuclease G; IAPs, Inhibitor of Apoptosis proteins; IP3R, Inositol trisphosphate receptor; 
Smac/DIABLO, Second mitochondria-derived activator of caspase/direct inhibitor
 
of 
apoptosis-binding protein with low pI. 
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Extrinsic pathway 
 
As the name implies, the extrinsic pathway begins outside the cell and triggers apoptosis in 
response to activation of specific pro-apoptotic receptors by extracellular ligands. Death 
receptors which include; FasR (Fas-receptor) and a sub-group of TNFR (TNF receptors), 
contain a cytoplasmic death domain (DD) that play a key role in this pathway. These death 
domains mediate receptor interaction with death domain containing adaptor proteins through 
binding of a death ligand. Numerous death ligands and corresponding death receptors have 
been described including FasL/FasR, TNFα/TNFR1, Apo3L/DR3, (Apo3L; TNF-ligand 
superfamily member 12 or TWEAK, DR; Death receptor) Apo2L/DR4 (Apo2L; TNF-related 
apoptosis-inducing ligand or TRAIL) and Apo2L/DR5. Death ligands are constitutively 
homotrimeric and following interaction with the receptor, the cytoplasmic DD of death 
receptors undergo trimerization. Since cytoplasmic domains of death receptors lack 
enzymatic activity they recruit a set of adaptor proteins, such as FADD (Fas-associated death 
domain), TRADD (TNF receptor 1-associated death domain), RIP1 (receptor-interacting 
protein 1) and TRAF2 (TNFR-associated factor 2) by protein-protein interaction
70, 71
. Ligand-
receptor complexes along with adaptor proteins and initiator caspases (caspase-8, caspase-10) 
rapidly assemble to form a DISC (death-inducing signaling complex). In the DISC, initiator 
caspases are activated by homodimerization, without undergoing cleavage and are released 
from the DISC into the cytoplasm where they activate the same set of effector caspases that 
are activated by the intrinsic pathway leading to DNA fragmentation and apoptosis
63
.  
 
The sequence of events that define the extrinsic phase of apoptosis are best characterized with 
the FasL/FasR and TNFα/TNFR1 models72. FasL binding to FasR leads to DISC formation 
involving FADD which activates caspase-8 or caspase-10 to initiate apoptosis
73. TNFα binds 
to its receptor TNFR1 and recruits TRADD as a platform adaptor which in turn assembles 
different signaling complexes through secondary adaptors. One type of DISC involves FADD 
and caspase-8 and triggers apoptosis in a manner similar to the other death receptors
74
. DISC 
assembly leads to cleavage of effector pro-caspases, thus triggering the caspase cascade. 
Activation of the TNFα pathway can also recruit TRAF2 which couples receptor engagement 
to the JNK cascade, stimulating the AP-1 transcription factors
75, 76
. TNFR activation has also 
been known to involve RIP1 (receptor-interacting protein 1)
77
 which when bound to the 
FADD-caspase-8 complex, links receptor stimulation to the IKK (inhibitor of κB-kinase) 
cascade, activating the NF-κB transcription factor78, 79. RIP1 is a dual function molecule and 
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its functionality is dependent on the ubiquitination state. In the absence of ubiquitination, 
RIP1 serves as a pro-apoptotic signaling molecule by engaging caspase-8
80
. Consistent with a 
role for RIP1 in regulating apoptosis, mice lacking RIP1 display extensive apoptosis and do 
not survive beyond 3 days after birth
78
. RIP1 is also known to positively regulate caspase 
independent apoptosis known as necroptosis
81
. When apoptotic cell death is blocked by 
caspase inhibitors, necroptosis is activated as an alternative cell death pathway
82
 and RIP1 
activity is crucial for this alternative pathway induced by FasR, and TNFR
83
.  
 
Intrinsic pathway 
 
The intrinsic apoptotic pathway is initiated from within the cell by activation of p53 tumor-
suppressor protein in response to DNA damage, defective cell cycle, detachment from the 
extracellular matrix, hypoxia, loss of survival factors or other types of severe cell distress. 
p53 then induces transcriptional up-regulation of pro-apoptotic members of the Bcl-2 family 
of proteins
84
. The BCL-2 (B-cell lymphoma-2) gene super-family are divided in to (1) pro-
apoptotic Bax, Bak, Bad, Bid and (2) anti-apoptotic proteins including Bcl-2, Bcl-XL, A1
85
. 
The pro-apoptotic Bcl-2 proteins allow permeabilization of the mitochondrial membrane 
whilst the anti-apoptotic Bcl-2 and Bcl-XL act to prevent permeabilization of the outer 
membrane by inhibiting the action of the pro-apoptotic Bax and/or Bak
86
. The intrinsic 
pathway hinges on the balance of activity between pro- and anti-apoptotic members of the 
Bcl-2 superfamily of proteins which regulate the permeability of the mitochondrial 
membrane
87
. 
 
p53-induced pro-apoptotic Bcl-2 proteins alter the mitochondrial permeability causing 
cytochrome c (involved in electron transport) and SMAC/DIABLO (a pro-apoptotic protein) 
to translocate from the inter membrane space of the mitochondria into the cytosol
86, 88
. 
Cytochrome c then interacts with Apaf-1 (adaptor apoptotic protease activating factor-1) 
forming a large multiprotein structure known as the apoptosome. Assembly of the 
apoptosome is highly regulated and its primary function seems to be multimerization and 
allosteric regulation of the catalytic activity of caspase-9
62
. Initiator caspase-9 is recruited 
into the apoptosome and activated from within the apoptosome, which in turn activates the 
downstream effector caspases-3, -6, and -7
89
. As part of the intrinsic apoptotic pathway, the 
SMAC/DIABLO protein released from the mitochondria promotes apoptosis by directly 
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interacting with IAPs and disrupting their ability to inactivate the caspase enzymes
89, 90
. The 
extrinsic and intrinsic pathways leading to apoptosis are known to cross-talk through caspase-
8 mediated cleavage of Bid to tBid which triggers cytochrome c release from the 
mitochondria
91
. 
 
Recent studies point to the ER as another sub-cellular compartment implicated in apoptotic 
execution. Alterations in Ca
2+
 homeostasis and accumulation of misfolded proteins in the ER 
cause ER stress. Prolonged ER stress can result in the activation of Bad and/or caspase-12, 
and execute apoptosis
92
. 
 
Role of JNK in apoptosis  
 
Chen et al in 1996 showed for the first time a link between JNK activation and cell death 
while studying γ radiation–induced apoptosis93. Subsequent studies using JNK1 and JNK2 
knockouts have been carried out to appreciate the role of JNK in apoptotic signaling. JNK 
knockout mouse embryonic fibroblasts (MEFs) showed resistance to apoptosis in response to 
UV irradiation, DNA-alkylating agent methyl methanesulfate and inhibition of protein 
synthesis by anisomycin. The basis of its physiological response can be correlated with the 
lack of mitochondrial depolarization, cytochrome c release and the activation of the caspase 
cascade
94
. JNK inhibition has been shown to attenuate apoptosis of hepatocytes and 
sinusoidal EC during hepatic ischemia/reperfusion (I/R) injury. Hepatic injury due to I/R 
occurs during several conditions including transplantation, liver tumor resection and 
circulatory shock. Uehara, et al demonstrated that JNK activity was a major mediator of 
hepatic I/R injury. They used ATP-competitive, reversible and highly selective JNK 
inhibitors to show a decrease in caspase-3 activation, cytochrome c release from 
mitochondria, and lipid peroxidation. JNK inhibition transiently blocked phosphorylation of 
c-jun at an early time point after reperfusion, as well as the subsequent AP-1 activation. JNK 
inhibition also blocked the upregulation of the pro-apoptotic Bak protein and the degradation 
of Bid. Thus, JNK activity induces cell death
95
.  
 
It has also been shown that a nonpeptide ATP competitive JNK inhibitor AS601245 
decreased cardiomyocyte apoptosis and infarct size in a rat cardiac I/R model
96
. JNK 
activation primarily occurred in the reperfusion phase in response to generation of reactive 
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oxygen species (ROS). Similarly, the JNK inhibitor SP600125 was shown to improve I/R 
injury in the transplantation of rat lungs
97
. The functional consequences of JNK activation 
appear to be cell-type and signal specific
11, 98
. Hochedlinger et al have shown JNK1
-/-
 
fibroblasts are more resistant to UV-induced cell death compared to JNK2
-/-
. They also 
mentioned that the role of JNK activation leading to c-jun phosphorylation by TNFα does not 
correlate with cell death. Furthermore, lack of either JNK resulted in marginally increased 
sensitivity to cell death, suggesting a protective signal. The overall results suggested that 
JNK1 is necessary for UV-induced cell death but not for TNFα-induced cell death in 
fibroblasts
99
. In a more recent study, Liu et al demonstrated suppressed TNFα-induced 
apoptosis in JNK1 null fibroblasts but increased levels in JNK2 null cells. They showed that 
caspase-3 activity and subsequent percentage of apoptotic cells in response to TNFα 
treatment was significantly lower in JNK1
-/- 
suggesting that JNK1 is needed for caspase-3 
activation and the resultant apoptosis
75
. The exact role of JNKs, their activation and role in 
apoptosis remains to be elucidated. 
 
JNK3 which is selectively expressed in neuronal tissue has a similar role in regulating 
apoptosis and may serve as a useful therapeutic target for neurodegenerative diseases such as 
Parkinson‟s and Alzheimer‟s disease. Yang et al showed a decrease in hippocampal neuron 
apoptosis induced by excitotoxic glutamate-receptor agonist kainic acid
100
. 
 
JNK drives apoptosis through several processes. Activated JNK translocates to the nucleus 
where it phosphorylates and transactivates c-jun
11, 98
 leading to the formation of AP-1 
transcription factors which induce pro-apoptotic molecules. cDNA microarray analysis 
revealed that vinblastine induced apoptosis plays a role in the JNK-c-jun-AP-1 pathway and 
results in the expression of pro-apoptotic factors such as TNFα and Bak101. JNK can also 
phosphorylate several other transcription factors including p53 whereby it inhibits ubiquitin-
mediated degradation of p53 which is critically required for the apoptotic pathway
102
. Since 
the transcription factor p53 is known to be involved in the expression of several pro-apoptotic 
genes such as Bax
103
, Fas receptor and apoptotic peptidase activating factor 1 (Apaf-1)
104
, it 
is possible that activated JNK is involved in the p53-mediated regulation of pro-apoptotic 
genes. Another study looked at the mechanism of JNK regulated apoptosis in LPS stimulated 
EC and reported JNK activation through TRAF6 in that set-up
105
. Downstream of JNK 
activation, studies have revealed phosphorylation and inactivation of anti-apoptotic Bcl-xL 
and Bcl-2 that aid in the release of cytochrome c from the mitochondria
106, 107
. 
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Similarly, Deng et al have shown that TNFα-induced JNK activation cleaved pro-apoptotic 
Bid into jBid which translocated to the mitochondria and released Smac/DIABLO. The 
released Smac/DIABLO then disrupted the TRAF2-cIAP1 complex formation and inhibition 
of caspase activation. They suggested that the JNK pathway was required to relieve the 
inhibition imposed by TRAF2-cIAP1 on caspase-8 activation and induction of apoptosis
108
. 
Finally Karin‟s group demonstrated that prolonged JNK activation leads to activation of an 
E3 ligase called Itch which degrades the cytoprotective protein c-FLIP
109
. 
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ATHEROSCLEROSIS 
 
An artery consists of three morphologically distinct layers (Figure 9). The innermost intima is 
bound by a monolayer of endothelial cells on the luminal side and a sheet of elastic fibres 
known as the internal elastic lamina, on the peripheral side. The normal intima is a very thin 
region and consists of extracellular connective tissue matrix, primarily proteoglycans and 
collagen. The media is the middle layer and consists of smooth muscle cells (SMCs). The 
adventitia is the outermost layer consisting of connective tissue with interspersed fibroblasts 
and SMCs.  
 
Atherosclerosis once thought to be solely dependent upon hypercholesterolemia and more 
recently described as an inflammatory disease, occurs progressively with the accumulation of 
monocytes, T-lymphocytes, lipids and extracellular matrix in the arterial wall resulting in 
occlusion of the vessel lumen
17
. Transport of oxidized low-density lipoprotein
 
(ox-LDL) 
across the endothelium into the artery wall is an important event involved in the development 
of early lesions (fatty streaks). Ox-LDL can
 
damage EC and induce the expression of 
adhesion
 
molecules such as P-selectin and chemotactic factors such as
 
monocyte 
chemoattractant protein-1 (MCP-1) and macrophage colony stimulating
 
factor (CSF) leading 
to the initiation of the adhesion cascade
110
. Once inside the vascular wall, monocytes develop 
in to macrophages expressing scavenger receptors
16
 that bind ox-LDL. This leads to the 
generation of reactive oxygen species (ROS) and conversion of ox-LDL
 
into highly oxidized 
LDL leading to foam cell formation
111
. ROS generated during EC activation is capable of 
destroying biomolecules through oxidation.  
 
Normal metabolic events such as respiration and phagocytosis produce oxidants that can be 
harmful to the vasculature if the toxic effects are not inhibited. Enzymes such as SOD, 
catalase and glutathione
 
peroxidise and non-enzymatic antioxidants including glutathione,
 
help protect against such toxic effects. However, in pathophysiological circumstances,
 
an 
excess of oxidants can overwhelm the scavenging capacity
 
of cellular antioxidant systems. 
The subsequent oxidative stress
 damages the cell‟s lipids, membranes, proteins, and DNA 
resulting in activation of signaling pathways mediating pro-inflammatory responses and CVD 
including atherosclerosis
110
. Thus internalization of oxidized LDL leading to foam cell 
formation and oxidative stress are a hallmark of arterial lesions and plaque formation. 
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Subsequent intimal thickening can lead to plaque rupture, which has a high risk of subsequent 
thrombus-mediated acute clinical events such as myocardial infarction and stroke
112
. 
 
Pathological studies have revealed a defined series of changes in the vessel wall during the 
initiation and progression of atherosclerosis as depicted in Figure 9
112
.  
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Inflammation in atherosclerosis 
 
An important initiating event that occurs during atherogenesis is the retention of LDL and 
other apolipoprotein B (apoB)-containing lipoproteins as a result of interaction with matrix 
components. LDL undergoes oxidative modification as a result of interaction with reactive 
oxygen species (ROS) including products of 12/15 lipoxygenase (12-LO) such as HPETE. 
Oxidation of LDL is inhibited by HDL, which contains the antioxidant protein serum 
paraoxonase (PON1). Minimally oxidized LDL stimulates the overlying endothelial cells to 
produce adhesion molecules, chemotactic proteins such as monocyte chemotactic protein-1 
(MCP-1), and growth factors such as macrophage colony-stimulating factor (M-CSF), 
resulting in the recruitment of monocytes to the vessel wall (Figure 9, 3). Oxidized LDL has 
other effects, such as inhibiting the production of NO, an important mediator of vasodilation 
and expression of endothelial leukocyte adhesion molecules (ELAMs). Oxidized aggregated 
LDLs are recognized by macrophage scavenger receptors such as SR-A, CD36 and CD68 
which aid accumulation of lipoproteins into the macrophages (Figure 9, 4). Scavenger 
receptor expression is mediated by cytokines such as TNFα and interferon-γ (IFN-γ) and aid 
in foam cell formation. The death of foam cells leaves behind a growing mass of extracellular 
lipids and other cell debris which contribute to plaque and fibrous cap formation. The critical 
role of inflammation in atherogenesis has been highlighted by several studies in which 
genetic deletion of TNFα113, IL‐1β114, ICAM‐1115, VCAM‐1116, 117, selectins118, 119 and 
MCP‐1120, 121 reduced lesion formation in atheroprone strains of mice.  
 
Multiple recurrent inflammatory events contribute to the initiation and progression of 
atherosclerosis. EC is the vascular cell that primarily limits the atherosclerotic processes by 
producing several molecules (nitric oxide and prostacyclin), hormones (natriuretic peptides), 
and matrix molecules (heparans and extracellular superoxide dismutase, SOD) that counteract 
these inflammatory events
122
. For example, the vascular tone of blood vessels is mediated by 
a number of humoral factors such as nitric oxide (NO), angiotensin II (Ang II) and 
endothelin; cytokines such as TNFα stimulate NF-κB, JNK and p38 kinase pathways that 
lead to gene transcription of pro-inflammatory molecules
123, 124
. NF-κB is also involved in the 
induction of cytoprotective genes such as A1, Bcl-2 and GADD45β which enables the cell to 
block pro-inflammatory activation in the vascular wall. Thus EC dysfunction as a 
consequence of inflammatory mediator imbalance is believed to be an early event in 
atherogenesis
125
.  
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Apoptosis in atherosclerosis 
 
Cell loss has been linked with atherosclerosis since Virchow‟s observations “thus we have 
here an active process which really produces new tissues, but then hurries on to destruction in 
consequence of its own development” cited by Schwartz and Bennett126. In multiple human 
and animal studies apoptotic cells have been identified in atherosclerotic coronary, carotid 
and aortic arteries
127
. However it has not been established whether apoptosis plays a more 
central role in the initiation or progression of the disease.  
 
Lesauskaite et al suggested that EC apoptosis may lead to exposure of phosphatidylserine on 
the cell membrane which activates thrombin increasing the probability of arterial thrombosis. 
Furthermore, progression of atherosclerosis may be promoted by the formation of apoptotic 
bodies with oxidized phospholipids exposed on the membrane which can also activate 
adhesion of monocytes to the EC wall
128
. Metzler et al investigated the localization and 
activity of JNK
 
in atherosclerotic lesions of high fat fed rabbits. Immunofluorescence
 
analysis 
showed a heterogeneous distribution of total and phosphorylated levels of JNK, mainly
 
localized in cell nuclei of the cap and basal region of the lesion. They also observed that the 
JNK expression in the atherosclerotic lesions coincided with transcription factor p53 and pro-
apoptotic proteins Bax and Bcl-xL. Thus JNK regulated apoptotis via p53 may mediate 
development of atherosclerosis
129
. Apoptosis of smooth muscle cells is usually observed in 
the fibrous portion of an atherosclerotic plaque in which the cells produce collagen important 
for plaque stability. Apoptosis of macrophages contributes to the formation and progression 
of the lipid core and promotes thrombosis of atherosclerotic plaque in damaged arteries
130
. 
Thus the ability to modulate the life or death of a cell
 
is recognized for its immense 
therapeutic potential. Therefore,
 
research continues to focus on the elucidation and analysis
 
of 
the cell cycle machinery and signaling pathways that control
 
cell cycle arrest, apoptosis and 
atherosclerosis.  
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Figure 9: Various stages from functional to diseased vessel wall   
 
1. Structure of a normal large artery 
 
3. Inflammation 
 
5. Formation of fibrous cap 
 
2. Lesion initiation 
 
4. Foam cell formation 
 
6. Complex lesions and thrombosis 
 
 
Schematic diagram showing progression of an artery from normal physiology to complex 
lesions formation and thrombosis. Adapted from Lusis et al 
112
. 
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EC Apoptosis in atherosclerosis 
 
Accumulation of inflammatory cells and lipids in to the intima along with SMC proliferation 
are hallmarks of atherosclerosis. However damage to the endothelium, e.g. due to an 
inflammatory stimulus may disturb vascular homeostasis and function and initiate 
atherosclerosis.  
 
Thus EC damage/apoptosis may result in increased vascular permeability, SMC 
proliferation
131
 and enhance blood coagulation, thus propagating plaque development
132
. 
Since apoptotic cells are procoagulant, activated platelets may accumulate in such areas. Also 
EC denudation, leads to exposure of the underlying extracellular matrix which also promotes 
coagulation and plaque formation
133
.   
 
Kockx et al reviewed the link between EC apoptosis and atherosclerosis and discussed the 
importance of vascular endothelial injury to the pathogenesis of atherosclerosis. They 
suggested that EC in lesion-prone regions, where atherosclerotic plaques preferentially 
develop are characterized by increased EC turnover rates, suggesting a mechanistic link 
between EC turnover and the susceptibility to atherosclerotic plaque development
134
. The 
enhanced turnover is most likely due to increased apoptosis
135
. Interestingly, classical risk 
factors for atherosclerosis such as high glucose concentrations
136
, oxidized LDL
137
, increased 
oxidative stress and angiotensin II stimulate EC apoptosis
138, 139
. 
  
Recently, apoptotic cell death was studied in different stages of atherosclerosis. Apoptosis 
was only found in the advanced atherosclerotic plaques in regions that contain numerous 
foam cells of macrophage origin
140
. Zeng et al showed that a pro-apoptotic molecule X-box 
binding protein 1 (XBP-1), a key signal transducer in endoplasmic reticulum stress response, 
was highly expressed at branch points and areas of atherosclerotic lesions in the arteries of 
ApoE
−/−
 mice. Nonetheless, a causal relationship between apoptosis and atherosclerosis was 
established by enforcing expression of XBP-1 in arterial EC, which enhanced the 
accessibility of lipoproteins and leukocytes to arteries and initiated lesion formation in 
hypercholesterolemic mice
141
.  
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JNK signaling in atherosclerosis 
 
EC activation and injury is a key event in the initiation of atherosclerotic lesions. These 
processes are influenced by cytokines (e.g. TNFα), microbial products (e.g. LPS) and 
mechanical forces which regulate the activity of multiple signaling pathways including the 
NF-κB pathway (see section on inflammation-related signaling pathways‟) and the JNK and 
p38 MAP kinase pathways (see section on „inflammation-related signaling pathways‟). 
 
JNK, which has particular relevance to my studies, has been implicated in vascular 
inflammation and dysfunction in several studies. Animal studies have revealed that JNK can 
be activated in arteries in response to injury
142-144
 and during the development of 
aneurysms
145
 or lesions
129, 146
. Moreover, it was concluded that JNK is involved in the 
pathophysiology of atherosclerosis because gene transfer of a dominant negative form of JNK 
reduced neointimal formation in injured arteries
142
 and genetic deletion of JNK reduced foam 
cell formation and EC dysfunction in hypercholesterolaemia
146, 147
. 
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SHEAR STRESS 
 
Shear stress is a biomechanical force that is determined by blood flow, vessel geometry, fluid 
viscosity and vascular pulsatility that is computationally estimated using fluid dynamics 
models and is expressed in units of dynes/cm
2
 
148
. The parallel frictional drag force of shear 
stress is one of the important blood flow-induced mechanical stresses acting on the vessel 
wall, which also includes the perpendicular force of blood pressure and the cyclic stretch of 
pulsatile flow. Shear stress is a critical factor in maintaining normal physiological vascular 
function including thromboresistance, barrier function and vascular homeostasis. 
 
Vascular shear stress of large arteries typically varies between 5-20 dynes/cm
2
; however, 
significant instantaneous values range from negative measures to nearly 40 dynes/cm
2
 during 
states of increased cardiac output
148
. This continuous exposure to a physiologic range of shear 
stress, especially in straight sections of the artery exposed to unidirectional laminar flow, 
promotes an anti-inflammatory, anti-thrombotic, anti-coagulative, pro-fibrinolytic and anti-
hypertrophic state of the artery wall
149
. Shear is also integrally involved in flow-mediated 
vasodilatation as a means to normalizing mechanical forces and thus helps to maintain 
normal endothelial function. Flow conditions in the artery are specified by the Reynolds 
number (Re), which is the ratio of blood inertial forces to viscous forces i.e. a measure of the 
stability of flow: 
Re = 4ρQ/πμD  
 
where ρ is the density of blood, D is the vessel diameter, μ is the blood viscosity and Q is the 
flow rate. According to Chatzizisis et al for a given geometry, whether the flow will be 
laminar or turbulent is determined by its Re number (Figure 10). For low Re values blood 
flow is undisturbed laminar and for high Re values (typically > 2,000) blood flow is 
turbulent
150
. Whereas when viscous forces and inertial forces are comparable secondary flows 
such as vortices arise, usually seem to develop at arterial bends and bifurcations. Transition to 
turbulence (Figure 10, B to C), where lateral motion of the blood becomes fully randomized 
is dependent on vascular geometries, the presence or absence of luminal stenosis and on flow 
pulsatility
133
. Transient turbulence has been shown to occur in the human aorta at peak 
systole, during heavy dynamic exercise in much of the central arterial system and distal to 
arterial stenosis and aneurysms
148
.  
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Thus, the endothelium is exposed to laminar, oscillatory and disturbed flow patterns
125
. 
Vascular SMCs are also directly or indirectly responsive to shear stress resulting in regulation 
of cell proliferation, migration and differentiation between contractile and secretory 
phenotypes
151
. Hence the vascular wall is continuously fine-tuning its activities in response to 
vascular shear stress.  
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Figure 10: Characteristics of Flow Patterns 
 
 
 
Schematic figure illustrating the characteristics of flow patterns. (A) Undisturbed laminar 
flow is a smooth streamlined flow characterized by concentric layers of blood moving in 
parallel along the course of the artery; (B) disturbed laminar flow is characterized by reversed 
flow (i.e. flow separation, recirculation, and reattachment to forward flow); (C) turbulent 
flow is when the blood velocity at any given point varies continuously over time, even though 
the overall flow is steady. Re = Reynolds number. Adapted from Chatzizsis et al 
150
. 
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Shear stress regulates atherosclerosis 
 
Atherosclerosis occurs at distinct sites of the arterial tree
 
located near branches and bends that 
are exposed to non-uniform
 
hemodynamics, whereas arteries with uniform geometries are 
relatively
 
protected
152, 153
. For example, the inner curvature of the murine aorta contains a 
region that has a high probability of developing atherosclerosis (susceptible site) whereas the 
outer curvature has a low probability of developing atherosclerosis (protected site).  
 
Several lines of evidence
 
suggest that the spatial distribution of atherosclerosis in the arterial 
tree is regulated by shear
 
stress
149
. The magnitude of shear stress at arterial walls
 
is inversely 
correlated with their susceptibility to atherosclerosis.
 
For example, analysis of the murine 
aorta
153
 or human carotid
 
artery
152
 by computational fluid dynamics revealed that regions
 
exposed to high mean shear are protected from disease. Thus atherosclerosis is prompted by 
decreased shear stress and is associated with suppression of normal vascular physiology.   
 
The first evidence implicating shear stress in the localization of atherosclerosis was described 
over 40 years ago by Caro et al 
154
. Recent data obtained using computational fluid dynamic 
simulations in autopsy-based models of coronary arteries, carotid bifurcations and distal 
abdominal aortas showed that areas with low shear stress correlated to the localization of 
atherosclerosis found at autopsy
150
. Further support of the atherogenic role of low shear stress 
comes from in vivo experiments in animal models
155
. According to Chatzizisis et al in vivo 
investigations in humans, using a combination of intravascular ultrasound (IVUS) or 
magnetic resonance imaging and computational fluid dynamics confirmed the mechanistic 
role of low shear stress in the development and progression of atherosclerosis
150
. Thus sites 
of lesion predilection are determined in part by haemodynamic forces acting on EC and the 
molecular mechanism underlying the distinct spatial distribution of lesions is being 
investigated by studying the role of the endothelium which is in direct contact with blood 
flow and the shear stress it generates. 
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Effects of shear stress on EC activation and inflammation 
 
Shear stress regulates atherogenesis by altering EC physiology, which respond via 
mechanosensory receptors expressed at their surface that convert mechanical forces into 
numerous biochemical signals
156, 157
. EC respond to shear stress through activation of a 
PECAM-1 (CD31), VE-cadherin and VEGFR-2 (VEGF receptor-2) tri-molecular complex
156
, 
G‐protein coupled receptors158, ion channels such as K+ channels159, Transforming growth 
factor TGFβ receptor related Smad6 and Smad7160  and receptor tyrosine kinase RTK161. 
 
These mechanosensory receptors, convert mechanical forces into biochemical signals as 
depicted in Figure11
157, 162-174
. High shear laminar flow exerts its atheroprotective effects on 
EC by a number of mechanisms 
162-164, 167, 168, 175
 including inhibition of cell cycle
164
, and by 
suppression of thrombosis
167
 and inflammation
165, 173, 176, 177
. The shear pattern can influence 
the permeability of the endothelial barrier and expression of EC genes such as that for nitric 
oxide synthase (NOS) thus initiating lesion formation (Figure 10, 2).  
 
Several studies suggest that chronic laminar high shear stress suppresses inflammation: i) EC 
adhesion molecule expression is reduced at atheroprotective sites exposed high shear
178, 179
; 
ii) prolonged high shear can suppress the induction of adhesion molecules by pro-
inflammatory cytokines in perfused aortae
165
 or in cultured EC
162, 163, 168, 175
; (iii) high shear 
inhibits the activity of an E-selectin promoter-luciferase reporter, suggesting that shear stress 
regulates E-selectin at a transcriptional level
180
. In contrast, ECs are not protected by low 
shear stress that mimics conditions at atherosusceptible sites
152
. EC adhesion molecules are 
expressed at reduced levels at atheroprotected sites of the murine aorta that are exposed to 
high shear compared to susceptible sites exposed to low/oscillatory shear
178, 179
. Several lines 
of evidence suggest that chronic high shear suppresses vascular inflammation whereas low 
shear has the opposite effects as shown in figure 11
166, 178, 179
. Thus the spatial distribution of 
inflammation in the arterial tree may be regulated by shear stress. For example, it has been 
shown that inflammation and atherosclerosis can be induced in murine carotid arteries by the 
application of a flow-altering device that generates spatial and temporal oscillation of the 
shear stress field
181
. In addition, Sheikh et al have shown that neutrophil adhesion to cultured 
EC can be suppressed by shear stress
173
. High shear stress has also been shown to inhibit the 
induction of VCAM-1 and E-selectin mRNA and protein by TNFα in cultured EC180. In 
addition, high shear prevented VCAM‐1 induction by TNFα in rabbit aortae perfused ex vivo, 
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whereas low shear had the opposite effect
165
. Fluid shear stress also decreased surface 
expression of VCAM‐1 in cultured murine lymph node venule endothelial cells, leading to 
suppression of lymphocyte adhesion
182-184
. 
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Figure 11: Regulation of EC physiology by shear stress  
 
Laminar high shear stress Disturbed low shear stress 
 
 
Steady laminar high shear stress promotes release of factors from endothelial cells that inhibit 
coagulation, migration of leukocytes, and smooth muscle proliferation, while simultaneously 
promoting endothelial cell survival. Conversely, disturbed low shear stress and flow reversal 
shift the profile of secreted factors and expressed surface molecules to one that favours the 
opposite effects, thereby contributing to the development of atherosclerosis. Adapted from 
Traub et al 
166
. Abbreviations: PGI2, prostacyclin; tPA, tissue plasminogen activator; TGF-β, 
transforming growth factor-β; Ang II, angiotensin II; and PDGF, platelet-derived growth 
factor.  
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The mechanism by which high shear stress induces anti-inflammatory activity on ECs is 
unclear. Three reports suggest that chronic laminar high shear stress does not suppress NF-κB 
translocation to the nucleus or binding to target sequences in response to inflammatory 
cytokines
152, 165, 177
. However other studies suggest that NF-κB activity is suppressed by 
acute
185
 or prolonged high shear stress
180
. Data from our laboratory support the former view 
that cultured EC under chronic laminar high shear stress retain the ability to activate NF-κB 
which induces anti-apoptotic molecules such as A1, GADD45β, Bcl-2 members etc186. 
 
Other groups have assessed the effects of shear stress on MAPKs; Surapisitchat et al have 
shown high shear stress to inhibit the activation of JNK in response to TNFα in cultured 
ECs
46
. Yamawaki et al in 2003 observed a reduction in JNK and p38 activation in perfused 
rabbit aortae
165
 and in 2005 reported shear stress to inhibit thioredoxin (TRX) activity 
through induction of thioredoxin-interacting protein (TXNIP); a stress-responsive protein. 
This lead to an increase in TRX binding to ASK1 and consequently ASK1-dependent JNK 
and p38 activity was inhibited
187
. Data from the same group revealed that laminar flow-
induced BMK-1 led to a decrease in JNK activation and subsequent decrease in TNFα 
mediated VCAM-1 expression in EC
188
. In addition, our group demonstrated that high shear 
stress reduces p38 and JNK MAP kinase activities by inducing MKP-1
189
. As MAP kinases 
are important for EC activation, their suppression by high shear stress can explain the anti-
inflammatory effects of flow.  
 
Effects of shear stress on EC apoptosis 
 
Regions
 
that are predisposed to atherosclerosis are characterized by
 
relatively high rates of 
EC injury and turnover
190, 191
. Davies et al showed that EC turnover was increased in 
response to turbulent flow compared to laminar flow, also they observed that turbulent high 
shear stress also increases turnover relative to laminar high shear stress, suggesting that the 
flow pattern rather than the magnitude may be the major determinant of hemodynamically 
induced EC turnover
192
. Further studies by Kaiser et al demonstrated that the lack of 
hemodynamic forces relative to 0.05-0.1dynes/cm
2
 SS triggered apoptosis in EC
193
.  
 
Previous studies have shown that laminar high shear stress can protect cultured EC from 
apoptosis in response to TNFα, serum starvation, H2O2 or oxidized LDL
162, 163, 168, 175
. 
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The mechanisms employed by laminar high shear stress to induce these cytoprotective effects 
are poorly understood but thought to involve PI3K and AKT
157, 162
, upregulation of 
antioxidants
162, 163, 168, 175
, activation of NO synthase
157, 175
 and modulation of cellular 
inhibitor of apoptosis proteins cIAPs
194, 195
 (Figure 12). 
 
In addition, Taba et al reported that laminar shear stress stimulated EC to produce 
prostaglandin J2 which inhibited DNA ladder formation, nuclear fragmentation and caspase-
3-like activity in human umbilical vein endothelial cells (HUVEC). Prostaglandin J2 elevated 
the expression levels of c-IAP1 in a dose and time dependent manner by stabilizing the 
protein inhibited vascular endothelial cell apoptosis
194
. Similarly Jin et al showed that low 
shear stress regulated IAP-2 at a transcriptional level associated with EC apoptosis by the 
suppression of caspase-3 activity
195
. High levels of laminar shear stress can also protect 
human endothelial cells from apoptosis by a mechanism involving up regulation of Bcl-xL 
and decreased mRNA expression of the Fas receptor
196
 and activation of Akt by 
phosphorylation
162
. 
 
Zeng et al looked at the effects of fluid shear stress on apoptosis of cultured HUVEC induced 
by LPS. They observed LPS induced apoptosis in static cultures which was inhibited in 
HUVEC pretreated with 15dynes/cm
2
 shear stress providing a positive link between SS and 
EC viability
5
. Studies by Dimmeler et al using other methods to induce apoptosis such as 
H2O2
197
 or growth factor withdrawal and incubation with TNFα163 also showed a decrease in 
EC apoptosis in response to 15dynes/cm
2
 shear stress measured by abrogation of DNA 
fragmentation and reduction in caspase-3 activation. 
 
Sho et al investigated the role of endothelial
 
cell apoptosis in arterial remodelling and 
revealed that mechanical forces such as subnormal shear stress can induce EC apoptosis. The 
observed that reduced blood flow induced adaptive narrowing of the lumen by decreasing the 
cell number through apoptosis
198
. Tricot et al looked at the relationship between shear stress 
and EC apoptosis in human atherosclerotic plaques and found a 7-fold increase in EC 
apoptosis in the downstream parts of the plaque, where low shear prevails, compared to the 
upstream parts. These results suggest that in vivo
 
local shear stress influences luminal 
endothelial cell apoptosis
 
and may be a major determinant of plaque erosion and 
thrombosis
199
.  
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Figure 12: Effects of laminar shear stress on endothelial apoptosis 
 
 
 
Schematic representing the major pathways involved in mediating inhibitory effects of 
laminar shear stress on endothelial apoptosis. Laminar high shear stress activates PI3K to 
induce eNOS that leads to NO production which inhibits ROS levels and caspase-3 activity, 
thus suppressing apoptosis. Similarly MEK5 activation leads to phosphorylation of Bad that 
inhibits caspase-3 activity and subsequent apoptosis. Adapted from Pi et al 
200
. 
Abbreviations: 14-3-3, signaling protein; Akt, member of protein kinase B; ASK1, apoptosis-
regulating signal kinase; Bad, Bc-2 family member; BMK1, Big mitogen-activated protein 
kinase 1; CuZn-SOD, copper/zinc superoxide dismutase; eNOS, endothelial nitric oxide 
synthase; JNK, c-jun N-terminal kinase; MEK5, MAP kinase 5; NO, nitric oxide; PI3K, 
phosphoinositide 3-kinases; ROS, reactive oxygen species; TRX, Thioredoxin.  
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HYPOTHESIS AND AIMS 
 
The hypothesis of my PhD project was that shear stress influences EC physiological 
responses to pro-inflammatory mediators by altering the activity of JNK and p38 MAP 
kinases.  
 
To address this hypothesis, I concentrated on the following aims  
1. Examine the effects of shear stress on JNK and p38 MAP kinases activation in 
response to TNFα in cultured EC  
2. Assess the spatial distribution of JNK activation in the murine aortic arch and 
correlate this with the spatial distribution of shear stress. 
3. Study the effects of novel JNK and p38 inhibitors on transcriptional programmes 
regulated constitutively and through TNFα by: (i) measuring levels of pro-
inflammatory and cytoprotective transcripts by comparative real time PCR and (ii) by 
conducting a microarray study. 
4. Study the physiological role of selected, novel JNK-regulated molecules in EC 
responses to LPS in vivo.  
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CHAPTER 2: MATERIALS AND METHODS 
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REAGENTS   
 
Tissue culture 
 
The following tissue culture reagents were obtained commercially: M199 (Medium 199 with 
Earle‟s salts and NaHCO3, without L-glutamine; Sigma), Penicillin/streptomycin (Sigma), L-
glutamine (Sigma), Endothelial Cell Growth Factor (ECGF; Sigma), Fetal calf serum (FCS; 
Sigma), gentamycin (Invitrogen),  sodium pyruvate (Invitrogen),  trypsin (MP Biomedical), 
gelatin (Sigma), fibronectin (Sigma), heparin (Pharmacy) and collagenase (Roche). Details of 
growth medium and other buffers are given in Appendix 1.  
 
Cytokines and Pharmacological inhibitors 
 
Human TNFα (R&D, Minneapolis, MN, USA), LPS (E.coli serotype 055:BS, Sigma) and 
DMSO (Dimethyl sulfoxide; D8418; Sigma) were also obtained commercially. Stocks of 
TNFα (100μg/ml) and LPS (5mg/ml) were made using PBS and aliquots were stored at -
80°C. To inhibit JNK and p38 in EC, I used novel small molecule inhibitors provided by 
UCB Celltech (J. Davis, UCB, personal communication). These were identified through 
screening of UCB compounds for novel ATP‐competitive JNK and p38 MAP kinase 
inhibitors. UCB have subsequently carried out extensive studies of the human kinome to 
ensure specificity.  
 
Small molecule inhibitors of JNK (CT536706)
201
 and p38 MAP kinase (CT8730) were 
dissolved in DMSO. Inhibitors were provided as a 10mM stock solution. Commercially 
available peptide inhibitors of JNK SP600125 (GlaxoSmithKline) and p38 SB202190 
(GlaxoSmithKline) were used in parallel to set-up the initial experiments with the UCB 
inhibitors. Equal volumes of DMSO were used for the relevant controls. Figure 13 illustrates 
the structure of the small molecule inhibitor of JNK and commercially available peptide 
inhibitors of JNK and p38. 
 
Antibodies 
 
Details of primary and secondary antibodies used can be found in Table 2 and 3. 
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 Figure 13: JNK and p38 inhibitors 
 
                         
 
 
Not available                                                  
 
Chemical structure of JNK and p38 inhibitors. a) CT536706, b) commercially available 
SP600125, (a, b; JNK inhibitors) c) CT8730 (not available), d) commercially available 
SB202190, (c, d; p38 inhibitors) 
  
a. 
c. 
6 
5 
3 
4 
b. d. 
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Table 2: Primary antibodies 
 
Name Host 
Species 
Source Antigen Isotype Use Dilution 
factor 
Mol. 
Weight 
SAPK/JNK  Rabbit Cell 
Signaling 
Total JNK - WB 
IF 
1:1,000 
1:200 
46kDa 
55kDa 
Phospho-
SAPK/JNK 
Mouse Cell 
Signaling 
Phospho-
JNK 
IgG1 WB 
IF 
1:1,000 
1:200 
46kDa 
55kDa 
JNK1 Mouse BD 
Pharmingen 
JNK1 Monoclonal 
IgG1 
WB 1:1,000 46kDa 
p38  Rabbit Cell 
Signaling 
p38α,β,γ Polyclonal WB 
IF 
1:1,000 
1:200 
43kDa 
Phospho-
p38  
Mouse Cell 
Signaling 
Phospho-
p38  
IgG1 WB 
IF 
1:1,000 
1:200 
43kDa 
Tubulin Mouse  Sigma Human 
tubulin 
IgG1 WB 1:10,000 51kDa 
HSP27 Rabbit Dr Ewa 
Paleology 
Total HSP27 - WB 1:1,000 27kDa 
Phospho 
HSP27 
Mouse Upstate Phospho 
HSP27 
Monoclonal 
IgG 
WB 1:2,000 27kDa 
Pro-
Caspase 3 
Rabbit Abcam N-terminus 
of human 
caspase 3 
Monoclonal WB 
IF 
1:1,000 
1:100 
35kDa 
Cleaved 
Caspase 3 
Rabbit Cell 
Signaling 
Cleaved 
caspase 3 
Polyclonal IF 1:100 17-
19kDa 
RIP1 Mouse BD 
Bioscience 
RIP1 Mouse 
IgG2a 
WB 
IF 
1:2,000 
1:100 
74kDa 
Alexa488 
CD31 
Rat BioLegend PECAM-1 IgG2a IF 1:100 130-
140kDa 
Rhodamine-
Griffonia 
- Vector labs Simplicifolia 
Lectin 1 
- IF 1:1,000 - 
Draq5 - Biostatus DNA - IF 1:10,000 - 
Propidium 
Iodide 
- Biostatus DNA - IF 1:10,000 - 
 
WB, Western blotting; IF, immunofluorescence. 
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Table 3: Secondary antibodies 
 
Name Source Use Concentration 
Goat anti-rabbit IgG Sigma WB 1:10,000 
Goat anti-mouse IgG Sigma WB 1:10,000 
Goat Alexa568 anti-rabbit Invitrogen IF 1:1000 
Goat Alexa568 anti-mouse Invitrogen IF 1:1000 
Anti-FITC-biotin Invitrogen IF 1:400 
Streptavidin Alexa 488  Invitrogen IF 1:200 
 
WB, Western blotting; IF, immunofluorescence. 
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CELL CULTURE 
 
All cell culture work was performed under sterile conditions. See Appendix 1 for medium 
components.  
 
Harvesting and culture of primary human umbilical vein endothelial cells (HUVEC) 
 
Umbilical cords were transferred in transport medium from the maternity ward (with 
informed consent from the mothers) and stored at 4°C for 6h-8h. The umbilical veins were 
then cannulated using a 3-way tap and surgical sutures and perfused with HBSS to flush out 
coagulated blood. Any leaks were stopped using small surgical clips. The cords were then 
perfused with 10-15ml collagenase (0.5mg/ml) and incubated at 37°C for 10min. To optimise 
the cell extraction, cords were massaged for 1-2min to shear away the endothelium. The 
collagenase solution containing HUVEC was then collected in a 50ml falcon tube. The vein 
was subsequently perfused with 15-20ml HBSS
w/o
 to harvest the remaining cells. Cells were 
collected by centrifugation at 1200rpm for 8min using a Heraeus instruments centrifuge 
[275xg]. The cell pellet was resuspended in 5ml growth medium. Cells were then cultured in 
a 25cm
2
 flask coated with 1% gelatin. The following day the medium was changed to remove 
floating red blood cells and debris.  
 
Harvesting and culture of porcine aortic endothelial cells (PAEC) 
 
PAEC were isolated from descending aortae which were collected from a local abattoir. The 
aortae were transferred in transport medium and stored at 4°C for 6h-8h. Firstly, the aortae 
were prepared by tying up all the thoracic branch points individually, using surgical suture 
kits to avoid any leaks. The aortae were then perfused with HBSS
w/o
 and leaky points of the 
vessel were repaired as above. The aortae were then perfused with 20-30 ml collagenase 
(0.5mg/ml) and incubated at 37°C for 20min. To optimise the cell extraction, the aortae were 
massaged for 1-2min to shear away the endothelium. The collagenase solution containing 
PAEC was then collected in a 50ml falcon tube. The aortae were subsequently perfused with 
15-20ml HBSS
w/o
 to harvest the remaining cells. Cells were collected by centrifugation at 
1200rpm for 8min using a Heraeus instruments centrifuge [275xg]. The cell pellet was 
resuspended in 5 ml growth medium. Cells were then cultured in a 25cm
2
 flask coated with 
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1% gelatin. The following day the medium was changed to remove floating red blood cells 
and debris.  
 
Maintenance of primary cells 
 
Cells were split when they reached 80-90% confluency by incubation with trypsin-EDTA for 
5min at 37°C. 20ml HBSS
w/o
 was added to the cell suspension followed by centrifugation at 
1200rpm for 8min using a Heraeus instruments centrifuge [275xg]. Cells were reseeded in 
growth medium at 30-50% confluency and the cycle was continued until a desired number of 
cells were available for experiments. Cells were then grown in 6-well plates or on glass slides 
coated with 25μg/ml fibronectin using growth medium until confluent. Growth medium was 
replaced with basal medium before EC were used in experiments. HUVEC and PAEC were 
used before passage six and nine respectively.  
 
Freezing and thawing cells 
 
In some instances, cells were stored in liquid nitrogen prior to experimentation. To prepare 
cells for freezing, they were trypsinized and then suspended in 1ml FCS containing 10% 
DMSO. The cell suspension was then placed in a step down freezing chamber and store at -
80°C overnight. 24hrs later the frozen vials were stored in liquid nitrogen till further use. To 
thaw out the cells straight away, 500µl pre-warmed growth medium was added to the vial. 
The suspension was then added to 20ml growth medium and cells were collected by 
centrifugation at 1200rpm for 8min using a Heraeus instruments centrifuge [275xg] and 
cultured in a 25cm
2
 flask coated with 1% gelatin.  
 
Exposure of cultured EC to laminar flow 
 
Confluent EC cultures were exposed to high shear (12 dynes/cm
2
) unidirectional laminar flow 
(LF) for 4h-24h using a parallel‐plate flow chamber (Cytodyne, LA Jolla, CA, USA) to 
mimic the effects of arterial shear or left untreated as a control. The parallel-plate flow 
chamber loop consisted of two reservoirs situated one above the other and with a flow 
chamber positioned in between them (see Figure 14). Medium was pumped into the upper 
reservoir and flow was driven through the chamber by the hydrostatic pressure head created 
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by the vertical distance between the reservoirs. The apparatus was gas sterilized (Anderson, 
UK) before being assembled in a laminar flow hood and placed on a workbench heated to 
37°C and connected to a gassing system that maintained a 5% CO2 and 95% air atmosphere.  
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Figure 14: Cytodyne flow system 
 
 
 
Apparatus used to apply laminar flow to EC under sterile conditions. a) parallel-plate flow 
chamber. b) flow loop. 
 
  
a. b. 
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MOLECULAR CELL BIOLOGY 
 
Total RNA isolation 
 
To extract total RNA from cell cultures, an RNeasy mini kit (Qiagen) was used. EC in 6-well 
plates were washed with cold PBS before incubating with 350µl of buffer RLT/1% β-
mercaptoethanol. Cell lysate were combined with an equal volume of 70% ethanol and 
transferred to a spin column prior to centrifugation at 14,000rpm for 15sec in a bench-top 
microfuge. The flow through was then discarded and the column was washed with buffers 
provided by the manufacturer (unknown composition) before eluting the total RNA using 
30µl of RNase-free water. Total RNA concentration was quantified by measuring the optical 
density (OD260nm) using a spectrometer. Purity of the RNA was assessed by calculating the 
OD260/280 and ratios between 1.8-2.1 were considered highly pure. The total RNA was stored 
at -80°C till further use.  
 
RT-PCR  
 
cDNA was synthesised from 1µg of total RNA in reverse transcription reactions. Total RNA 
was incubated at 65°C for 5min in the presence 25μg/ml Oligo (dT), 0.5mM dNTP‟s and 
RNase free H2O and then cooled down on ice for 1min. 5x first strand buffer and 0.1M DTT 
were then added to the reactions which were subsequently incubated at 42°C for 2min. 1µl 
superscript II was added to each sample and incubated at 42°C for 50min. The reaction was 
finally inactivated by incubation at 70°C for 15min. The resulting cDNA was then stored at -
20°C till further use. 
 
Quantitative reverse transcriptase PCR 
 
Transcript levels were quantified by comparative real‐time PCR using gene specific primers 
(Table 4 or 5). The real-time PCR master mix was prepared by adding 5μl cDNA, 10μM each 
primer (forward and reverse), 20μl SYBR green master mix (Sigma) and 5μl water to each 
reaction. Three triplicate reactions were set up in an optical 96-well reaction plate (Bio Rad) 
and real‐time PCR was carried out using the iCycler system (Bio‐Rad, Hercules, CA, USA). 
Reactions were incubated at 94°C for 2 min before thermal cycling at 94°C for 15s, 60°C for 
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60s and 72°C for 60s. Relative gene expression was calculated by comparing the number of 
thermal cycles that were necessary to generate threshold amounts of product (CT). CT was 
calculated for the genes of interest and for the housekeeping gene ß‐actin. For each cDNA 
sample, the CT for ß‐actin was subtracted from the CT for each gene of interest to give the 
parameter ΔCT, thus normalizing the initial amount of total RNA used. The amount of each 
target was calculated as 2
–ΔΔCT
, where ΔΔCT is the difference between the ΔCT of the two 
cDNA samples to be compared. 
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Table 4: Sequences of gene-specific human primers used in quantitative real-time PCR 
 
Gene Forward Reverse 
VCAM-1 5‟-GGTGGGACACAAATAAGGGTTTTGG-3‟ 5‟-CTTGCAATTCTTTTACAGCCTGCC-3‟ 
E-selectin 5‟-GCTCTGCAGCTCGGACAT-3‟ 5‟-GAAAGTCCAGCTACCAAGGGAAT-3‟ 
IL-8 5‟-TGCCAAGGAGTGCTAAAG-3‟ 5‟-CTCCACAACCCTCTGCAC-3‟ 
TLR4 5‟-AGACTTTATTCCCGGTGTGG-3‟ 5‟-AAAGATACACCAGCGGCTCT-3‟ 
CARD6 5‟-CAGGCTCTAATGCCAATTCA-3‟ 5‟-TGGAAAGAGCCAGGAGTTCT-3‟ 
RIP1 5‟-ATATCCCAGTGCCTGAGACC-3‟ 5‟-AGATTCATCTGTTGGTGGCA-3‟ 
BMP2 5‟-GGTTCCTAAGGAGGACGACA-3‟ 5‟-CCAAGTGCTGACACACAACA-3‟ 
BMP4 5‟-GGCTAGCCATTGAGGTGAACT-3‟ 5‟-TCCCACTCCCTTGAGGTAAC-3‟ 
DKK1 5‟-TTCTGAGATGATGGCTCTGG-3‟ 5‟-TGAGAACCGAGTTCAAGGTG-3‟ 
Caspase-3 5‟-TAAATGAATGGGCTGAGCTG-3‟ 5‟-ATGGAGAAATGGGCTGTAGG-3‟ 
Mst-1 5‟-CCTTTCAGCATTGTTCTAGGTG-3‟ 5‟-AAGACCAGGAATCACTAAATCTGTC-3‟ 
PP2A 5‟-CTCGTGGACCATGTATACGC-3‟ 5‟-GGCCCACTCTGTACCAAACT-3‟ 
DPF2 5‟-CCCTTCTTCCTCCTCTCCTT-3‟ 5‟-GTTGCTCCTTTCTCCCTGAG-3‟ 
JAZ 5‟-CATCCACCAGGTGATTTCTG-3‟ 5‟-GTTGCTCCTTTCTCCCTGAG-3‟ 
GADD45β 5‟-GTCGGCCAAGTTGATGAATGT-3‟ 5‟-GGATTTGCAGGGCGATGT-3‟ 
A1 5‟-CACAGGAGAATGGATAAGGCAAA-3‟ 5‟-AGTCATCCAGCCAGATTTAGGTTC-3‟ 
JNK1 5‟-GAAGCTCCACCACCAAAGAT-3‟ 5‟-GGTTCTCTCCTCCAAGTCCA-3‟ 
A20 5‟- CACACAAGGCACTTGGATC -3‟ 5‟- CTGTAGTCCTTTTGAAGCAAGTACTG -3‟ 
HO-1 5‟-CTTCTTCACCTTCCCCAACA-3‟ 5‟-TTCATCACCCTCTGCCTTGA-3‟ 
β-actin 5‟-CTGGAACGGTGAAGGTGACA-3‟ 5‟-AAGGGACTTCCTGTAACAATGCA-3‟ 
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Table 5: Sequences of gene-specific porcine primers used in quantitative real-time PCR 
 
Gene Forward Reverse 
E-selectin 5‟-TTCAAATCCTCCCTTACAC -3‟ 5‟-CATAGAGACCATCAATAGC -3‟ 
HO-1 5‟-CGAGAAGGCTTTAAGCTGGT -3‟ 5‟-TAGACCGGGTTCTCCTTGTT -3‟ 
Cyclofilin 5‟-ATTTGATGATGAGAATTTATCC -3‟ 5‟-ATGCCCTCTTTCACTTTG -3‟ 
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Western blotting 
 
See Appendix 2 for buffer details and Table 2 and 3 for antibody concentrations. 
 
Preparation of cell lysates 
 
Cytosolic lysates were prepared from cultured EC using RIPA lysis buffer. Alternatively, 
total cell lysates were made using lysis buffer AM1 (Transcription factor assay kit, TransAM, 
Active Motif). Protein concentrations were measured using the Bradford assay
202
 and closely 
similar amounts of each sample were tested. 
 
SDS polyacrylamide gel electrophoresis (PAGE), and Western blotting 
 
Cell lysates containing equalised levels of protein combined with lloading buffer were 
denatured by incubation at 98°C for 5min. Proteins were separated on Bis‐Tris 
polyacrylamide 4‐12% gradient gels (Invitrogen) electrophoretically at 200volts for 1hr. The 
size of proteins was determined by reference to a pre-stained standard marker run alongside 
the experimental samples. Proteins were then transferred to a PVDF membrane (Immobilon-P 
Transfer membrane, filter type: PVDF, pore size: 0.45μM (Millipore) by using the 
NuPAGE™ System (Invitrogen) following the manufacturer‟s instructions. Typically a 
potential difference of 25 volts was applied for 1h. Membranes were then incubated in 20ml 
blocking buffer at room temperature for 1h. Membranes were briefly washed three times in 
20ml washing buffer before incubation with primary antibody on a rotating table at room 
temperature for 1h. Subsequently, three consecutive washes of 10min were carried out with 
washing buffer, followed by incubation with HRP‐conjugated secondary antibody at room 
temperature. The washing step was then repeat prior to proteins being detected by applying 
Enhanced ChemiLuminscence (ECL) Western blotting reagents (Perkin Elmer) and exposing 
membranes to autoradiographic films (Biomax light film from Kodak). Films were then 
developed using a Compact X4 automatic X-Ray film developer (X-ograph). 
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c-Jun DNA binding assay 
 
Levels of active c-jun in cell lysates were assessed using a DNA‐binding ELISA. Briefly the 
EC lysate samples were added to a 96-well plate pre-coated with DNA corresponding to the 
AP-1 consensus sequence and were incubated at room temp for 2h. 100µl anti-phospho c-jun 
or anti-c-jun antibodies were then added at room temp for 2h. The wells were then aspirated 
using a glass pipette and suction pump to discard any unbound primary antibody and then 
washed three times for 5min each using 100µl wash buffer. The samples were then incubated 
with HRP-conjugated secondary antibody before adding detecting reagents chromogen and 
stop solution. Levels of phospho-c-jun or total c-jun in each sample were calculated from 
OD450 values by subtracting background measurements made from controls that did not 
contain cell lysates. Levels of active c-jun were defined as the proportion of phospho-c-jun 
compared to total c-jun levels. 
 
Gene silencing 
  
The function of particular genes was studied in cultured EC by gene silencing. RNA 
interference was carried out by electroporation with commercially obtained siRNAs (JNK1-a 
specific siRNA (s11153), JNK1-b specific siRNA (s11154), c-jun-specific siRNA (s7658), 
p38-alpha-a specific siRNA (s3586) and p38-alpha-b specific siRNA (s3585); from Applied 
Biosystems) using the guideline settings (pulse voltage 1350v; pulse width 30msec and pulse 
number 1; MicroPorator). 5x10
5
 HUVECs per well diluted in 10µl transfection medium (see 
Appendix 1); were electroporated with different concentrations of siRNA (10µM, 5µM or 
1µM) before being plated on to 25μg/ml fibronectin coated 6-well plates. 24h post 
transfection, the cells were washed and incubated in growth medium for 24h-48h before 
analysis. 
  
~ 73 ~ 
 
MICROARRAY SET-UP 
 
The set-up was overseen by the MRC Genomic laboratory, Imperial College under the 
supervision of Dr Jayne Dennis. The array set-up comprised of eight different conditions as 
described in Table 7. 
 
High quality total RNA was converted in to cDNA using a GeneChip WT cDNA Synthesis 
and Amplification kit (Affymetrix). The first step was to synthesis first cycle, first strand 
cDNA. T7-(N)6 primer along with poly A controls were added to a PCR tube containing 
100ng of total RNA (total vol. 5μl). The reaction tubes were then mixed by vortexing and 
briefly spun down. Before being placed in a thermocycler (with heated lid) using the 
following settings; 70°C for 5min, 4°C for 2min and then held at 4°C. A master mix 
containing 2.0μl 5x First Strand Buffer, 1.0μl (0.1M) DTT, 0.5μl (10mM) dNTP mix, 0.5μl 
RNase Inhibitor and 1.0μl Superscript II (add last) per reaction was prepared on ice, mixed by 
pipetting and briefly spun down. 5μl of the master mix was added to each reaction tube and 
placed in a thermocycler (with heated lid) using the following settings; 25°C for 10min, 42°C 
for 1h, 70°C for 10min, 4°C for 2min and then held at 4°C.  
 
Once the first cycle, first strand cDNA was complete; the tubes were placed on ice and steps 
were taken to proceed to first cycle, second strand cDNA synthesis. A master mix was 
prepared in a 1.5ml RNase free tube by adding 4.8μl RNase free dH2O, 4.0μl (17.5mM) 
diluted MgCl2, 0.4μl (10mM) dNTP mix, 0.6μl DNA Polymerase I (add last) and 0.2μl 
RNase H (add last)  per reaction. 10μl of the master mix was added to each of the first strand 
reaction tubes and then incubated at 16°C in a thermocycler for 2h without the heated lid 
option. Subsequently the PCR tubes were incubated at 75°C for 10min with the heated lid. 
The reaction tubes were then cooled down in a thermocycler at 4°C for 2min and before 
proceeding to cRNA synthesis. The master mix was prepared at room temperature by adding 
5.0μl 10x IVT buffer, 20.0μl IVT NTP mix and 5.0μl IVT Enzyme mix (add last) per reaction 
to a 1.5ml RNase free tube. 30μl of the mix was then added to the second strand reaction 
tubes and incubated at 37°C for 16 hours in a thermocycler (with heated lid) before being 
held at 4°C.  
 
The cRNA was then immediately purified at room temperature using a GeneChip Sample 
Clean-up Module. Briefly, each sample (~50μl) was transferred to a 1.5ml RNase free tube 
~ 74 ~ 
 
and another 50μl RNase free dH2O was added prior to adding 350μl cRNA Binding Buffer to 
each sample.  Samples were then mixed thoroughly by vortexing for 3 seconds. 250μl of 
100% ethanol was then added to each sample and mixed by pipetting.  The samples were then 
applied to an IVT cRNA Clean-up Spin Column and spun at maximum speed for 15 seconds. 
The spin columns were then transferred to fresh 2ml collection tubes and 500μl of cRNA 
Wash Buffer was added onto the spin columns and spun at maximum speed for 15 seconds. 
The collection tubes were then emptied and 500μl of 80% ethanol was pipetted onto the spin 
columns and again spun at maximum speed for 15 seconds. The collection tubes were then 
emptied and the columns were spun again at maximum speed for 5min to completely dry the 
membrane. The cRNA was then eluted by placing the spin columns into new 1.5ml tubes and 
adding 15μl of RNase-free water directly onto the middle of the spin column membrane and 
incubating at room temperature for 5min before spinning at maximum speed for 1 minute. 
The elution step was repeated with the flow through to ensure high concentration of the elute. 
The concentration of RNA in the elute was calculated by measuring the absorbance of the 
elute at 260nm and 280nm. The first cycle cRNA yield was calculated using the formula 
[concentration x eluate volume] which was expected to be >16μg. Tubes were then placed on 
dry ice to be frozen and then store at -80°C or directly progressed to second cycle, first strand 
cDNA synthesis.  
 
Second cycle, first strand cDNA synthesis involved addition of 1.5μl random primers 
(3μg/μl) to 10μg single stranded cRNA and RNase free dH2O (as required) to give a final 
volume of 8μl per reaction which was then placed in a thermocycler (with heated lid) using 
the following settings; 70°C for 5min, 25°C for 5min, 4°C for 2min and the hold at 4°C. To 
synthesis the cDNA, a master mix was prepared on ice containing 4μl 5x First Strand Buffer, 
2μl (0.1M) DTT, 1.25μl (10mM) dNTP + dUTP and 4.75μl Superscript II (Add last) per 
reaction. 12μl of the master mix was then added to each reaction and placed in thermocycler 
(with heated lid) and run with the following programme; 25°C for 10min, 42°C for 90min, 
70°C for 10min, 4°C for 2min and then held at 4°C. Tubes were kept on ice. The cRNA was 
then hydrolysed by adding 1μl of RNase H to the single stranded cDNA tubes, placed in a 
thermocycler (with heated lid) and run using the following programme; 37°C for 45min, 
95°C for 5min, 4°C for 2min and then held at 4°C. The tubes were then spun briefly. The 
single stranded cDNA was then immediately purified at room temperature using a GeneChip 
Sample Clean-up Module. 
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Briefly, the single stranded cDNA was transferred to new 1.5ml RNase free tubes and 80μl 
RNase free dH2O was added. This was followed by 370μl cDNA binding buffer being added 
and mixed thoroughly by vortexing for 3sec. The samples were then applied to a cDNA spin 
column and spun at maximum speed for 1min. The spin columns were then transferred to 
fresh 2ml collection tubes and 750μl of cDNA wash buffer was placed onto the spin columns 
and spun at maximum speed for 1min. The collection tubes were then emptied and the 
columns were spun again at maximum speed for 5min to completely dry the membrane. The 
cDNA was then eluted by placing the spin columns into new 1.5ml tubes and adding 15μl of 
cDNA elution buffer directly onto the middle of the spin column membrane and incubating at 
room temperature for 3min before spinning at maximum speed for 1 minute. The elution step 
was repeated by adding another 15μl of cDNA elution buffer to the spin columns. The 
concentration was calculated by measuring the absorbance of the elute at 260nm and 280nm. 
The yield of the single stranded cDNA was calculated using the formula [concentration x 
eluate volume] which was expected to be >5.5μg. I.5μl of each sample was then aliquoted out 
for size analysis using the Agilent 2100 Bioanalyser. Remaining samples were placed on dry 
ice to be frozen and then store at -20°C or directly proceeded to fragmentation of single 
stranded cDNA.  
 
cDNA was then cleaved using the restriction enzyme APE1. 5.5μg single stranded cDNA 
was added to a 0.2ml RNase free tube and RNase free dH2O was added to make a final 
volume of 31.2μl. A master mix was then prepared by adding 10μl RNase free H2O, 4.8μl 
10x cDNA Fragmentation buffer, 1μl UDG (10U/μl)  and 1μl APE 1 (1,000U/μl) per 
reaction. 16.8μl of the master mix was added to each reaction and mixed by pipetting, 
followed by a run in the thermocycler (with heated lid) with the following programme; 37°C 
for 60min, 93°C for 2min, 4°C for 2min and the held at 4°C. Once the fragmented cDNA 
samples were ready, a 1.5μl aliquot of each was taken out for size analysis using the Agilent 
2100 Bioanalyser. 1μl of the unfragmented samples (prepared previously) was run along-side 
the fragmented samples for comparison. The optimal fragment size should be ~40-70bp.  
 
The next step was to label the fragmented single stranded DNA. This was achieved by 
preparing a master mix containing: 12μl 5x TdT Buffer, 2μl TdT and 1μl DNA labelling 
reagent (5mM) per reaction. 15μl of the mix was added to 45μl of the fragmented cDNA in a 
new 0.2ml RNase free tube and after mixing by pipetting and brief spinning the tubes were 
placed in a thermocycler (with heated lid) and run the following programme; 37°C for 60min, 
~ 76 ~ 
 
70°C for 10min, 4°C for 2min and held at 4°C. Using a pipette, the volume of labelled extract 
was measured and for each sample sufficient RNase free water was added so that the final 
volume of the labelled extract was 60μl. The samples were then frozen by placing tubes on 
dry ice and stored at -80°C.  
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Figure 15: Flow chart of GeneChip Whole Transcript Assay protocol 
  
Total RNA (100ng)
First cycle, first strand cDNA synthesis
First cycle, second strand cDNA synthesis
First cycle in vitro Transcription using unlabelled ribonucleotides
First cycle, clean-up of cRNA
Second cycle, first strand cDNA synthesis using random primers
cRNA hydrolysis
Clean-up of cDNA
Fragmentation
Terminal labelling
QC1: Bioanalyser trace and concentrations needed (total RNA)
QC2: Concentration, OD value (260/280) and yield (ug) needed (should be at least 10ug)
QC3: Concentration, OD value (260/280) and yield (ug) needed (should be at least 5.5ug)
QC4: Bioanalyser trace needed of samples before and after fragmentation
QC1
QC2
QC3
QC4
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Once the fragmented single stranded cDNA was labeled, it was handed over to the to the 
MRC Genomic laboratory for hybridization to Human Gene 1.0 ST Arrays (Affymetrix) and 
scanning using optimal in-house protocols. This array contains probes that identify 764,885 
transcripts which represents 28,869 genes.  
 
A summary of the GeneChip whole transcript assay is provided as a flow chart in Figure 15. 
 
Data analysis 
 
Once the array chips were scanned, the raw data was analyzed using Resolver® software 
(Rosetta) to quantify changes in transcripts differentially expressed in the experimental 
samples. Each analysis of paired samples would reveal transcripts that were 
unchanged/invariant, signature (i.e. that were statistically different), downregulated and 
upregulated. 
 
The data was processed to identify differentially expressed sequences by comparing the fold 
change between samples. Thus the software was able to identify genes that were regulated by 
JNK or p38 at a basal level or in EC treated with TNFα. Functional annotation of co-
regulated genes was carried out using Database for Annotation, Visualization and Integrated 
Discovery (DAVID) software whereby genes were clustered together in to functional groups 
based on the current literature. The functions of JNK or p38 were inferred by identification of 
functional categories that were enriched in EC treated with the JNK or p38 inhibitor using 
Gene Ontology (GO) and the KEGG pathways. Also heat map visualization of gene-to-term 
relationships were performed to obtain a global overview of the effect of the inhibitors. 
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IN VIVO  STUDIES  
 
See Appendix 3 for buffer details and Table 2 and 3 for antibody concentrations. 
 
Animals 
 
Male C57BL/6 mice purchased from Harlan Olac Ltd and were used between 2 and 3 months 
of age. The MKP-1 knockout mouse strain (MKP-1
-/-
 (C57BL/6)) was obtained from Bristol-
Myers Squibb (via Dr Andy Clark, Kennedy Institute, Imperial) and the JNK1
-/-
 strain was 
obtained from Prof. Roger Davis, University of Massachusetts, USA. Experiments were 
performed using groups of at least 4 animals. All experiments were performed within 
guidelines set out by the Federation of European Laboratory Animal Science Associations. 
 
Treatment 
 
Mice were treated with lipopolysaccharide (LPS) by intraperitoneal injections (4mg/kg) for 
1h, 6h or left untreated as control before sacrificing by CO2 overdose. 
 
Perfusion, fixation and isolation of aorta  
 
Once the animal had been sacrificed, it was pinned down to allow access to the abdomen 
which was cut open till the level of the diaphragm in a caudal to cranial manner before 
cutting through the sternum and removing the ribs. A puncture was then made in the right 
atrium to allow fluid to run freely out of the circulation once the organs were perfused. The 
vasculature was perfused in situ with 20ml cold PBS (injected by inserting a butterfly needle 
into the left ventricle) and then fixed using 20ml fixative (2% formalin or 4% PFA). Once the 
body had stiffened, the heart and aorta were removed by dissection. The tissue was then 
visualised under a dissecting microscope and surrounding tissue and fat was removed from 
the aorta by dissection to prepare the tissue for en face staining. The ascending
 
aorta and arch 
were opened in a highly reproducible manner as described by Iiyama et al and outlined in 
Figure 16
178
. 
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En face Immunofluorescence staining and confocal microscopy 
 
The expression levels of specific proteins were assessed in EC by en face 
immunofluorescence at two regions of the murine aorta: (i) the lesser curvature of the mouse 
aorta, a region that has a high probability (HP) of developing atherosclerosis also known as 
the susceptible site, and (ii) the greater curvature which has a low probability (LP) of 
atherosclerosis and is also referred to as the protected site.  
 
For immunostaining, aortae were permeabilized using 0.5% Triton X‐100, and then blocked 
with 20% serum (corresponding to the species used to raise secondary antibodies) in PBS 
overnight at room temperature. Primary antibodies diluted in PBS were then applied prior to 
incubation for 2h at room temperature. After thorough washing with PBS, samples were 
incubated with secondary antibodies for 2h at room temperature. Samples were then washed 
thoroughly and subsequently incubated with Alexa Fluor 488 conjugated anti‐CD31 antibody 
overnight at 4°C. Following the final wash, tissue samples were stained with DRAQ5 for 
15min. Negative controls included incubation with secondary antibody and isotype matched 
irrelevant antibodies. 
 
The ascending aorta and arch were opened via the greater curvature and prepared by cutting 
transversely between the brachiocephalic and left subclavian artery (point C) and incisions 
were made in the aorta at points A and B as shown in Figure 16 to serve as anatomical 
landmarks.  
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Figure 16: Dissection and mapping of susceptible and protected regions for 
atherosclerotic lesion formation in mice  
 
 
 
Landmarks to work out where to cut the aortae to allow visualisation of the protected and 
susceptible regions. (1). Isolated and cleaned arch and descending mouse aorta, (2). Isolated 
arch, cut along dotted red line, (3). Opened up to reveal the endothelial layer and (4). 
Illustrations to map protected and susceptible regions. A, B, and C correspond to each other 
throughout the figure and are used as visual landmarks to identify the two regions. Adapted 
from Iiyama et al 
178
. 
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Tissues were the mounted with the endothelium facing up using vectorshield mounting 
medium (Vectorlabs) to allow the tissue to set. Images of the endothelial cell monolayer were 
obtained by laser‐scanning confocal microscopy (LSM 510 META; Zeiss, Oberkochen, 
Germany). Protected and susceptible regions were located by using three anatomic landmarks 
as reference points. For every animal, three or four images were obtained from each protected 
and susceptible region. The descending aortae were incubated with secondary antibodies only 
to control for background staining and optimize the confocal settings. The expression of 
particular proteins at each site was assessed by quantification of fluorescence intensity for 
multiple cells (at least 100 per site) using LSM 510 software (Zeiss). 
 
TUNEL staining 
 
See Appendix 4 for buffer information and reagent dilution; and Table 2 and 3 for antibody 
details. 
 
EC apoptosis was assessed in vitro in HUVEC and in vivo in murine aortae by TUNEL 
staining (In situ Cell Death Detection Kit; Roche) which detects fragmented DNA using two 
different approaches. 
 
Immunohistochemical staining 
 
Aortae were fixed with 4% PFA at room temperature for 1h and the tissues were incubated in 
blocking solution for 10min. The aortae were then permeabilized on ice for 5min which was 
followed by incubation with TUNEL solution at 37°C for 20min. To allow visualisation of 
TUNEL positive nuclei under a light microscope, the aorta were incubated with peroxidise 
(POD) converter at 37°C for 20min followed by 3,3' Diaminobenzidine (DAB) substrate at 
room temperature for 10min. To orientate around the tissue, propidium iodide at room 
temperature for 30min was used to stain the nuclei prior to mounting. The aortae were 
washed with PBS for 5min each between incubations.  
 
The staining was repeated in vitro by inducing apoptosis in HUVEC cultured on 25μg/ml 
fibronectin coated cover-slips through serum starvation. Once the cover-slips were mounted 
on to glass slides the monolayer was easily visualised.  
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Immunofluorescent staining 
 
Post TUNEL solution incubation, the tissue were incubated with anti-FITC-biotin antibody at 
room temperature for 3h, followed by Streptavidin Alexa Fluor 488 incubation for 1h. EC 
were identified by co-staining using Griffonia lectin conjugated to Rhodamine (Vector labs) 
and nuclei were co-stained using DRAQ5 (Biostatus). Images of the endothelial cell 
monolayer were obtained by laser‐scanning confocal microscopy (LSM 510 META; Zeiss, 
Oberkochen, Germany). EC were considered apoptotic when TUNEL staining co-localized 
with pyknotic or fragmented nuclei.  
 
STATISTICS 
 
Differences between samples were analyzed using an unpaired Student‟s t-test or a chi-
squared test (*p<0.05, **p<0.01, ***p<0.001). 
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CHAPTER 3: EFFECTS OF ATHEROPROTECTIVE 
BLOOD FLOW ON MAP KINASE ACTIVATION AND 
PRO-INFLAMMATORY GENE EXPRESSION IN 
VASCULAR ENDOTHELIUM: IN VITRO AND IN VIVO 
STUDIES  
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INTRODUCTION 
 
Atherosclerosis develops predominantly at branches and bends which are exposed to 
disturbed patterns of blood flow, whereas regions exposed to uniform flow are protected
152, 
153
. However the molecular mechanisms underlying the spatial distribution of vascular 
inflammation and atherosclerosis are uncertain.   
 
It is believed that blood flow regulates the spatial distribution of atherosclerosis by exerting 
shear stress on the endothelium. High shear stress has been shown the protect EC by 
suppressing inflammation
180, 189, 203
. Previous studies suggest that shear stress can influence 
the activity of MAP kinases
204, 205
. MAP kinases are stimulated by a number of physiological 
stimuli, such as growth factors, hormones, and cytokines (TNFα), and by a wide variety of 
environmental stresses (UV radiation, microbial products such as LPS). In activated EC, 
these MAP kinases are phosphorylated by upstream MAPK kinases
98
 and lead to the 
transcription and translation of pro-inflammatory proteins such as adhesion molecules, 
chemokines and cytokines. Active forms of JNK and p38 phosphorylate AP-1 transcription 
factors such as c-jun, ATF2, c-fos; which subsequently form complexes with NF-κB and bind 
to various promoters to modulate gene transcription of pro-inflammatory molecules such as 
VCAM-1 and adhesion molecules such as E-selectin in EC. 
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Hypothesis and Aims 
 
Because of these conditions, I hypothesize that shear stress modulates transcriptional 
responses to TNFα and pro-inflammatory activation in EC by inhibiting the activity of JNK 
and p38 MAP kinases. 
 
The aims of this project were to 
 Optimize detection of activated MAP kinases by Western blotting and identify 
concentration and times of exposure to TNFα that activate MAP kinases 
 Examine the effects of shear stress on pro-inflammatory activation in vitro 
 Investigate whether activation of JNK and p38 in response to TNFα is inhibited by 
shear stress in cultured EC 
 Assess the spatial distribution of JNK activation in the murine aortic arch and 
correlate this with the spatial distribution of shear stress 
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RESULTS 
 
Induction of pro-inflammatory and cytoprotective molecules by TNFα in HUVEC 
 
In the first instance, I examined the effects of different concentrations of TNFα on HUVEC 
in order to identify an optimal dose for transcriptional activation. 
 
Levels of E-selectin, VCAM-1 and IL-8 were measured using comparative real time PCR. 
Previous studies in this laboratory observed that TNFα did not alter β-actin levels in HUVEC, 
so I decided to use it as a housekeeping gene throughout my studies
206
. I observed that all 
three pro-inflammatory molecules were induced by TNFα in a dose dependent manner 
(Figure 17). All these molecules were induced by 10-20 fold in response to 0.01ng/ml TNFα 
for 2h. VCAM-1 and IL-8 levels were significantly elevated at 1ng/ml TNFα; approximately 
200-fold and 300-fold respectively and did not increase any further with increasing doses of 
TNFα (Figure 17 B, C). However I noticed the greatest induction of 500-fold in E-selectin 
levels at 10ng/ml TNFα (Figure 17 A). TNFα did not lead to any noticeable cell death. 
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Figure 17: Dose dependent activation of HUVEC in response to TNFα  
 
 
HUVEC cultured under static conditions on fibronectin were stimulated with 10ng/ml, 
5ng/ml, 1ng/ml, 0.1ng/ml or 0.01ng/ml TNFα for 2h or left unstimulated (US) as a control as 
indicated above. Levels of pro-inflammatory transcripts were quantified by real-time PCR 
and normalized by measuring β-actin transcript levels. Mean values were calculated from 
triplicate measurements and are shown with standard deviations.  
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The literature also suggested 10ng/ml TNFα to be a reasonable stimulus for studying EC 
activation before any toxic effects of the cytokine are detected
180, 186
. Thus I decided to use 
TNFα at this concentration far all the subsequent experiments.  
 
Using 10ng/ml TNFα, I set-up a time-course experiment to see what would be the best time-
point to study induction of pro-inflammatory and cytoprotective molecules in EC. I 
stimulated the cultured HUVEC with 10ng/ml TNFα for 2h, 4h or they were untreated as a 
control. Pro-inflammatory molecules E-selectin, VCAM-1 and IL-8 were all induced at 2h 
(Figure 18, A-C). E-selectin levels did not alter significantly between 2h and 4h of 
stimulation. VCAM-1 levels were significantly higher at 4h compared to 2h (Figure 18, B) 
but there was only a slight decrease in IL-8 levels following an additional 2h of TNFα 
stimulation. These data suggested that TNFα treatment for 4h might be an optimal time point 
to use for observing effects on pro-inflammatory transcripts.  
 
I also performed qPCR to study A20 transcript levels (Figure 18, D). A20, a negative 
regulator of NF-κB, reduces pro-inflammatory activation and is considered to be anti-
apoptotic
207
. A20 levels reflected a similar pattern to IL-8 mRNA transcript thus supporting 
the idea that TNFα treatment for 4h would be a reasonable time point to study transcription. 
 
I then went on to analyse cytoprotective transcript levels in these samples and observed that 
GADD45β was only induced by 2-fold at 2h and there was no change in transcript levels at 
4h (Figure 18, E). However the other cytoprotective molecules A1 and MnSOD were both 
induced at 2h (Figure 18, F, and G) and mRNA levels were further enhanced at 4h. 
 
Thus I concluded that stimulation of HUVEC with 10ng/ml TNFα for 2h was enough to elicit 
a pro-inflammatory and cytoprotective response. However after 4h the cytoprotective 
response was more pronounced thus subsequent experiments were performed using 10ng/ml 
TNFα for 4h. 
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Figure 18: TNFα time-course for induction of pro-inflammatory and cytoprotective 
molecules in HUVEC 
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HUVEC cultured under static conditions on fibronectin were stimulated with 10ng/ml TNFα 
for 2h, 4h or left unstimulated (US) as a control as indicated above. Levels of pro-
inflammatory and cytoprotective transcripts were quantified by real-time PCR and 
normalized by measuring β-actin transcript levels. Mean values were calculated from 
triplicate measurements and are shown with standard deviations. 
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Activation of MAP kinases by TNFα in HUVEC 
 
MAP kinases are transiently activated by phosphorylation in response to TNFα and to 
identify the best time point to study the effects of shear stress on MAP kinase activation by 
TNFα, I treated the HUVEC with 10ng/ml TNFα for varying time points over a period of 
60min. Phosphorylated JNK protein levels were then assessed by ELISA and Western 
blotting (Figure 19, A-B) and phosphorylated p38 levels were studied by Western blotting 
only (Figure 20). 
 
After TNFα stimulation for 5min there was no noticeable change in JNK phosphorylation in 
HUVEC as shown by ELISA (see Figure 19, A). Phosphorylated JNK levels increased 
transiently and were maximal after 15min of TNFα stimulation (2-fold) and had reduced by 
30min. These data were verified by Western blotting (Figure 19, B; upper panel) which 
revealed that phosphorylated JNK levels were highest at 15min of TNFα treatment compared 
to total JNK protein levels (Figure 19, B; lower panel). 
 
I also assessed p38 phosphorylation by Western blotting (Figure 20) and observed that p38 
was phosphorylated after just 5min of TNFα stimulation. This activation was still detectable 
at 15min of TNFα stimulation (Figure 20, lane 3) but was reduced after 60min (Figure 20, 
lane 5). Thus I decided to stimulate HUVEC with 10ng/ml TNFα for 15min to study the 
effects of shear stress on JNK and p38 activity, as both MAP kinases were phosphorylated at 
this time point.  
 
Once I had optimised activation of MAP kinases and induction of pro-inflammatory 
mediators in response to TNFα, I proceeded to designing experiments to study the effects of 
shear stress on these processes.  
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Figure 19: TNFα-induced JNK activation in HUVEC 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were stimulated with TNFα 
(10ng/ml) for 5min, 15min, 30min, 60min or left untreated as a control as indicated above. 
Levels of total JNK and phosphorylated JNK were measured by testing cell lysates using A) 
ELISA where data shown are mean levels of phosphorylated JNK normalised for total JNK 
levels with standard deviations or B) Western blotting. Phosphorylated species (arrows) and 
non-specific bands (N.S.) are indicated. Representative of 3 experiments that gave closely 
similar results.  
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Figure 20: TNFα-induced p38 activation in HUVEC 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were stimulated with TNFα 
(10ng/ml) for 5min, 15min, 30min, 60min or left untreated as a control as indicated above. 
Levels of total p38 and phosphorylated p38 were measured by testing cellular lysates by 
Western blotting. Representative of 3 experiments that gave closely similar results. 
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Effects of shear stress on responses of cultured EC to TNFα 
 
Previous studies described that laminar flow (LF), which exerts high shear stress, has 
profound effects on endothelial physiology. Our group has previously shown that LF can 
modulate transcriptional responses to TNFα by suppressing pro-inflammatory transcripts and 
elevating the expression of cytoprotective transcripts (Partridge et al 
186
). I attempted to 
reproduce these observations made by our group and others that high shear can suppress 
activation of cultured EC in response to pro‐inflammatory mediators. Thus I examined the 
effect of applying high shear stress for 24h on subsequent pro-inflammatory activation of 
HUVEC in response to TNFα. I observed that TNFα induced E‐selectin, VCAM‐1 and IL‐8 
transcripts in static cultures of HUVEC but this induction was enhanced in cells 
preconditioned under flow (Figure 21, A-C). 
 
HO-1 was used as a positive marker to assess whether cells had been preconditioned under 
LF. Thus I assessed HO‐1 mRNA levels in these samples and found that they were elevated 
in pre‐sheared HUVEC suggesting that these cells had responded to shear stress (Figure 21, 
D). Thus in my hands preconditioning HUVEC for 24h was not sufficient to suppress 
pro‐inflammatory activation, indeed preconditioning enhanced the production of adhesion 
molecules in response to TNFα (Figure 21, compare bar 2 and 4, A-C). 
 
  
~ 96 ~ 
 
Figure 21: Preconditioning under laminar flow (24h) did not suppress pro-
inflammatory activation of HUVEC by TNFα 
 
 
HUVEC cultured on fibronectin coated glass slides were placed into a vacuum-held parallel 
plate flow chamber and preconditioned under laminar flow (12dynes/cm
2
) or under static 
conditions for 24h. They were subsequently stimulated with TNFα (10ng/ml for 4h) or 
remained untreated as a control. Transcript levels were then quantified by reverse 
transcription, real-time PCR using gene-specific PCR primers. The amount of transcript was 
normalised by measuring β-actin transcript levels. Mean values were calculated from 
triplicate measurements and are shown with standard deviations. Representative of 6 
experiments that gave closely similar results. 
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To understand the effects of shear stress on MAP kinase activation, I went on to apply high 
shear stress for 24h and then stimulated the HUVEC with TNFα for 15min. Western blotting 
and ELISA revealed that JNK and p38 were phosphorylated after 15min of TNFα stimulation 
under static conditions (Figure 22 and 23 compare lanes 1&2). Preconditioning under LF did 
not suppress TNFα mediated MAP kinase activation (Figure 22 and 23 compare lanes 2&4). 
In fact, in some experiments the levels of phosphorylated JNK and p38 were elevated in 
samples that had been preconditioned under LF compared to HUVEC cultured under static 
conditions.  
 
This led to the concern that the medium in the flow apparatus may have been contaminated 
with a low level infection. This may lead to stimulation of EC with microbial products, which 
may overcome the cytoprotective effects of shear stress and enhance the MAP kinase 
activation and the inflammatory response. 
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Figure 22:  Preconditioning under laminar flow (24h) did not suppress JNK 
phosphorylation of HUVEC by TNFα 
 
 
 
 
 
HUVEC were cultured under laminar flow (12dynes/cm
2
) or under static conditions for 24h 
and were subsequently stimulated with 10ng/ml TNFα for 15min or remained untreated as a 
control as indicated above. Levels of total JNK and phosphorylated JNK were measured by 
testing cell lysates using A) ELISA where data shown are mean levels of phosphorylated 
JNK normalised for total JNK levels with standard deviations or B) Western blotting. 
Representative of 3 experiments that gave closely similar results. 
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Figure 23:  Preconditioning under laminar flow (24h) did not suppress p38 
phosphorylation of HUVEC by TNFα  
 
 
 
 
 
HUVEC were cultured under laminar flow (12dynes/cm
2
) or under static conditions for 24h 
and were subsequently stimulated with 10ng/ml TNFα for 15min or remained untreated as a 
control as indicated above. Levels of total p38 and phosphorylated p38 were measured by 
testing cell lysates using A) ELISA where data shown are mean levels of phosphorylated 
JNK normalised for total JNK levels with standard deviations or B) Western blotting. 
Representative of 3 experiments that gave closely similar results. 
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To minimise the potential effects of low level microbial contamination I preconditioned 
HUVEC under high shear for a shorter period of time i.e. 4h. It has been shown by others that 
4h shearing can suppress subsequent responses to pro‐inflammatory mediators180. I observed 
that 4h shear elevated HO‐1 which was a positive control of the physiological response to 
shear stress (Figure 24, B). However 4h preconditioning did not reduce the capacity of TNFα 
to induce E‐selectin in HUVEC (Fig 24, A). 
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Figure 24: Preconditioning under laminar flow (4h) did not suppress pro-inflammatory 
activation of HUVEC by TNFα  
 
 
 
HUVEC cultured on fibronectin coated glass slides were placed into a vacuum-held parallel 
plate flow chamber and preconditioned under laminar flow (12dynes/cm
2
) or under static 
conditions for 4h. They were subsequently stimulated with TNFα (10ng/ml for 4h) or 
remained untreated as a control. Transcript levels were then quantified by reverse 
transcription, real-time PCR using gene-specific PCR primers. The amount of transcript was 
normalised by measuring β-actin transcript levels. Mean values were calculated from 
triplicate measurements and are shown with standard deviations.  
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Edelman et al demonstrated that shear stress has differential effects on EC cultured from 
venous or arterial vascular beds. Thus I reasoned that arterial EC responses to arterial shear 
may be a more appropriate model than venous EC responses to arterial shear. I therefore 
decided to assess the effects of shear on PAEC. 
 
I then went on to culture PAEC onto glass slides and preconditioned them under LF for 4h to 
assess whether EC from an arterial vascular bed respond differently that EC from a venous 
bed. In the first instance, I analysed the HO-1 mRNA levels to establish whether or not the 
EC had responded to the arterial shear (Figure 25, B). I observed a significant increase in 
HO-1 transcript levels in sheared samples suggesting that the PAEC had responded to the 
preconditioning. Further real‐time PCR analysis revealed that TNFα induced E‐selectin 
transcripts in static PAEC (Figure 25, B), but not in cells that were subjected to LF for 4h 
(Figure 25, B, compare bars 2&4). Thus I concluded that shear stress can significantly 
suppress E‐selectin induction in response to TNFα in EC from an arterial vascular bed. 
 
I then examined whether suppression of pro‐inflammatory activation by shear was associated 
with reduced activation of pro‐inflammatory JNK and p38 MAP kinases. Analysis of cell 
lysates revealed that TNFα induced JNK and p38 phosphorylation and that the response was 
enhanced by shear stress (Figure 26, compare lane 2 and 4). Thus exposure of PAEC to shear 
stress did not suppress phosphorylation of JNK or p38 MAP kinase in response to TNFα, 
suggesting that suppression of E‐selectin transcript at 4h is not mediated by downregulation 
of JNK and p38 activities. 
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Figure 25: Preconditioning under laminar flow suppressed TNFα mediated pro-
inflammatory activation of PAEC 
 
 
 
Porcine aortic endothelial cells (PAEC) cultured on fibronectin coated glass slides were 
placed into a vacuum-held parallel plate flow chamber and preconditioned under laminar 
flow (12dynes/cm
2
) or under static conditions for 4h. They were subsequently stimulated 
with TNFα (10ng/ml for 4h) or remained untreated as a control. Transcript levels were then 
quantified by reverse transcription, real-time PCR using gene-specific PCR primers. The 
amount of transcript was normalised by measuring cyclophilinα transcript levels. Mean 
values were calculated from triplicate measurements and are shown with standard deviations.  
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Figure 26: Preconditioning under laminar flow (4h) did not suppress TNFα-mediated 
MAP kinase activation of PAEC 
 
 
 
 
 
PAEC were cultured under laminar flow (12dynes/cm
2
) or under static conditions for 4h. 
Cells were subsequently stimulated with TNFα (10ng/ml for 15min) or remained untreated as 
a control. Cellular lysates were tested by Western blotting using antiphospho-JNK, anti-JNK, 
antiphospho-p38 and anti-p38 antibodies. Phosphorylated species (arrows) and non-specific 
bands (N.S.) are indicated. Representative of 3 experiments that gave closely similar results. 
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Spatial distribution of JNK activation in the murine aortic arch 
 
To examine the relationship between MAP kinases and shear stress in a more physiological 
environment, I assessed the spatial distribution of JNK activation in the aorta of wild type 
C57BL/6 mice. I used a model established by M. Cybulsky‟s lab to study regions of the 
murine aortic endothelium that are known to be exposed to different forms of blood flow.  
 
I specifically used en face immunostaining followed by confocal microscopy to measure the 
levels of phosphorylated JNK in the endothelium of the following two regions of the mouse 
aorta: 
 The inner curvature which has a high probability of atherosclerosis development 
(HP), mainly referred to as the susceptible site and 
 The outer curvature which has a low probability of atherosclerosis development (LP) 
mainly referred to as the protected site.  
Computational fluid dynamics suggest that the outer curvature is exposed to high shear stress 
whereas the inner curvature is exposed to relatively low shear stress
152
.  
 
Before the experiment was conducted to assess JNK phosphorylation levels in EC in the 
mouse aorta, I set-up preliminary experiments to verify the specificity of the antibody 
staining. Initially, aortae were stained with secondary only or isotype matched IgG control 
antibody and Alexa Fluor 568-labelled secondary antibodies and counterstained with Alexa 
Fluor 488-conjugated anti‐CD31 (to identify endothelium) and DRAQ 5 (to identify nuclei) 
and then imaged. Using these tissues, I identified appropriate confocal laser settings for 
imaging Alexa Fluor 488-conjugated anti‐CD31 and DRAQ 5 staining. I did not detect any 
binding of secondary only or isotype matched IgG control antibody in atherosusceptible or 
atheroprotected sites (Figure 27).  
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Figure 27: Specificity of antibody staining  
 
 
 
Aortae were stained with secondary only (1-2) or isotype matched IgG control (3-4) antibody, 
followed by Alexa Fluor 568-labelled secondary antibodies (red) and counterstained with 
Alexa Fluor 488-conjugated anti‐CD31 (green) and DRAQ 5 (purple). Susceptible and 
protected sites were then imaged. 
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I subsequently stained tissues using antibodies that recognize the active, phosphorylated form 
of JNK. Using optimal laser settings, I observed that basal levels of the phosphorylated JNK 
were significantly higher in the susceptible region compared to the protected region of 
untreated animals (Figure 28, A, 1, 2). LPS treatment significantly elevated phosphorylated 
JNK levels in the susceptible region but had only weak effects on JNK activation in the 
protected region (Figure 28, A, 3, 4) and quantification of multiple animals confirm these 
data (Figure 28, B).  In summary, activation of JNK was observed at a constitutive level and 
was elevated in response to LPS in EC in the susceptible region but not in the protected 
region. Thus my data reveal that phosphorylated JNK levels are higher in atherosusceptible, 
low shear stress regions of the mouse aorta compared to atheroprotected, high shear stress 
sites. 
 
I then speculated that this difference could be explained by differential expression of JNK in 
the two regions. However, en face staining using anti‐JNK antibodies revealed that total JNK 
levels were similar in the susceptible and protected regions both with and without LPS 
stimulation (Figure 29). Thus the difference in JNK activation observed between susceptible 
and protected sites cannot be attributed to variation in JNK expression. 
 
In summary, my studies have revealed that activation of JNK occurs predominantly in low 
shear regions that are susceptible to inflammation and atherosclerosis. This activation is 
observed at a constitutive level and can be elevated in response to a pro-inflammatory 
mediator. 
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Figure 28: Phosphorylated JNK is elevated in EC at atherosusceptible sites  
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The levels of phosphorylated JNK were assessed in the susceptible and protected regions of 
the aorta of C57BL/6 mice which were treated with LPS (4mg/kg for 1h; n=4) or remained 
untreated as controls (n=4). Phosphorylated JNK was detected by en face staining using anti-
phosphoJNK antibodies and AlexaFluor568-conjugated secondary antibodies (red) followed 
by confocal microscopy. EC were identified by co-staining with anti-CD31 antibodies 
conjugated to AlexaFluor488 (green). Cell nuclei were identified using Draq5 (purple) (A). 
Representative images are shown (B).  Levels of phosphorylated JNK were quantified by 
measuring fluorescence from multiple cells (>50) in susceptible and protected regions of 
treated or untreated mice. Mean fluorescence intensities are shown with standard deviations. 
Differences between samples were analysed using an unpaired t-test.  
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Figure 29:  Total JNK levels are similar in EC at atherosusceptible and atheroresistant 
sites 
 
 
 
The levels of JNK were assessed in HP and LP regions of the aorta of C57BL/6 mice which 
were treated with LPS (4mg/kg for 1h; n=4) or remained untreated as controls (n=4). Total 
levels of JNK were measured by en face staining using anti-JNK antibodies and 
AlexaFluor568-conjugated secondary antibodies (red) followed by confocal microscopy. EC 
were identified by co-staining with anti-CD31 antibodies conjugated to AlexaFluor488 
(green). Cell nuclei were identified using Draq5 (purple). Representative images are shown.  
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CONCLUSIONS 
 
 TNFα treatment led to the induction of pro-inflammatory and cytoprotective 
molecules in cultured HUVEC 
 Stimulation of HUVEC with TNFα  resulted in transient activation of JNK and p38 
MAP kinases in vitro  
 Anti-inflammatory effects of steady laminar flow were observed using cultured PAEC 
but not using HUVEC 
 Activation of JNK by phosphorylation was greatly enhanced in the atherosusceptible 
site compared to the atheroprotected site of the murine aortic arch 
 JNK phosphorylation was suppressed in aortic EC exposed to high shear in vivo  
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DISCUSSION 
 
Previous studies demonstrated that the application of shear stress for 4h‐24h reduced EC 
activation in response to TNFα165, 173, 180, 186. Therefore my observation that high shear stress 
enhanced the capacity of TNFα to induce pro‐inflammatory transcripts in EC does not 
support the literature. I was concerned that the medium used in the flow experiments may 
have a low level of infection which may accumulate over 24h and prime EC for enhanced 
induction of pro‐inflammatory molecules via the TNFα pathway. To address this potential 
complication I exposed EC to LF for 4h, a time point where microbial build‐up would be 
relatively low. However my data reveal that preshearing HUVEC for 4h did not inhibit 
TNFα‐inducible pro‐inflammatory mediators. It is difficult to explain why pre-shearing did 
not suppress HUVEC activation in my hands. It is plausible however that the responses of 
HUVEC to flow are influenced by confluency, passage number, batch-to-batch variations in 
serum/medium components or other seemingly minor technical factors. 
 
EC from different vascular beds are known to respond differently to flow. For example, 
Methe et al reported flow to differentially influence adhesion molecule and transcription 
factor expression in human saphenous vein (HSVEC) and coronary artery endothelial cells 
(HCAEC). I therefore repeated the experiment using arterial EC (PAEC). I observed that 
subjecting PAEC cultured on fibronectin to high shear stress for 4h suppressed the capacity 
of TNFα to induce pro‐inflammatory transcripts. 
 
Using a perfusion organ culture system, Yamawaki et al revealed that the application of high 
shear to arteries perfused ex vivo suppressed subsequent activation of JNK and p38 MAP 
kinase and induction of adhesion molecules by TNFα. In contrast my study demonstrated that 
suppression of E‐selectin by shear stress in cultured PAEC does not rely on inhibition of JNK 
or p38, which were strongly activated by TNFα in cells cultured under flow. Thus shear stress 
inhibited activation of MAP kinases in EC in rabbit aortae perfused ex vivo but not in 
cultured PAEC. There are several experimental differences between the studies that could 
explain this discrepancy including species, composition of matrix, duration of preshearing, 
composition of culture medium, concentration of TNFα used and the basal conditions used to 
make a comparison (listed in Table 6). 
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Table 6: Factors that may influence the effects of shear stress on EC activation in ex 
vivo and in vitro experiments 
 
 Cultured cells (Fig 25, 26) Perfused artery
165
 
Species Porcine Rabbit 
Matrix Fibronectin Physiological basement 
membrane matrix 
Duration of flow 4h 24h 
Culture Medium Medium M199 with ECGF 
+ 20% FCS 
Medium with 5% dextran to 
achieve physiological fluid 
viscosity + 10% FCS 
TNFα 
concentration 
10ng/ml TNFα 50ng/ml TNFα 
Basal conditions Compared to static cultures Compared to low shear stress 
0.4dynes/cm
2
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For example, a previous study revealed that the subendothelial matrix plays a part in 
regulating shear stress mediated pro‐inflammatory signaling. Indeed LF activated NF‐κB in 
EC plated on matrix proteins such as fibronectin and fibrinogen but not in EC plated on 
endogenous collagen basement membrane
208
. Thus differences in matrix proteins could 
potentially influence EC response to shear stress and contribute to the different observations 
made by Yamawaki et al and myself. 
 
Because of these conditions and the limitations of the in vitro system, I decided to change my 
model to assess JNK activation in regions of the murine aorta exposed to high shear (outer 
curvature) or low shear (inner curvature). I observed that phosphorylated JNK levels were 
higher in regions exposed to low shear that are predisposed to atherosclerosis compared to a 
region exposed to high shear that is protected. My data suggest that JNK is phosphorylated 
constitutively in atherosusceptible regions. In addition, LPS treatment, which is known to 
induce acute systemic activation, resulted in a significant increase in phosphorylated JNK 
levels at this site. This suggests that the EC in the susceptible region of the murine aortic arch 
undergo further activation following exposure to a pro‐inflammatory stimulus. 
 
These observations reveal a correlation between phosphorylated JNK levels in EC and sites 
in the aorta that experience low shear stress. The study does not reveal a causal relationship; 
however it is plausible that shear stress reduces JNK activation in the atheroprotected site 
because: 
1. High shear stress induces MKP-1 (a negative regulator of JNK) in cultured EC189 
2. High shear stress reduced JNK activation in perfused rabbit arteries165  
3. High shear stress suppressed JNK activation in culture EC by altering the activity of 
PKCδ205, 209 and also abrogated the activity of the upstream MAPK kinase ASK1210.  
In addition to these, generation of low shear stress may influence EC physiology through 
shear independent mechanisms such as alterations in mass transport
211
. The spatial 
distribution of JNK activation in the aorta may contribute to the localization of inflammation 
and atherosclerosis in atherosusceptible regions.  
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My data on JNK phosphorylation follows a pattern similar to p65 activation shown by Hajra 
et al. They observed high levels of p65 in the susceptible region which translocated to the 
nucleus upon stimulation with LPS leading to high levels of VCAM-1. In contrast, p65 
expression levels in EC were relatively low in the protected region. The relative contribution 
of enhanced JNK activation and raised NF‐κB levels to increased inflammation at 
atheroprone sites remains uncertain. 
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CHAPTER 4: GENOME-WIDE TRANSCRIPT 
ANALYSIS TO ASSESS THE FUNCTION OF JNK AND 
p38 MAP KINASE IN VASCULAR ENDOTHELIAL 
CELLS 
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INTRODUCTION 
 
My previous studies and others in this laboratory
189
 revealed that JNK and p38 are activated 
preferentially in EC at susceptible regions of the arterial tree. It is well established that JNK 
and p38 regulate transcription by influencing the activity of AP-1 family transcription factors 
(e.g. c-jun, ATF2); however JNK-dependent and p38-dependent transcription had not been 
studied in detail at a genomic level in EC. 
 
Therefore, to identify the functional significance of JNK and p38 activity at atherosusceptible 
sites and to improve our understanding of the role of MAP kinases in endothelial physiology, 
I examined the effects of pharmacological inhibition of JNK and p38 on transcriptional 
programmes in cultured EC. Various groups have previously suggested that JNK inhibition 
may protect against cartilage and bone erosion
 
and can also be beneficial for treating patients 
with rheumatoid arthritis
212
. However the role of JNK in EC activation has not been looked at 
closely. p38 activation has been observed in a number of inflammatory responses in various 
cell types including macrophages, neutrophils, EC and chondrocytes
32
.  
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Hypothesis and Aims 
 
I hypothesised that JNK and p38 regulate specific transcriptional programmes in EC. To 
assess this idea the following aims were addressed: 
1. Optimise suppression of JNK and p38 activation in cultured EC using 
pharmacological inhibitors. 
2. Examine the function of JNK and p38 on transcriptional programmes regulated 
constitutively and by TNFα by conducting a genome-wide microarray study in the 
presence or absence of specific pharmacological inhibitors.   
3. Validate microarray findings by quantitative RT-PCR in independent experiments 
using pharmacological inhibitors of JNK and p38 and small interfering RNAs to 
suppress JNK and c-jun. 
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RESULTS 
 
Validation of inhibitors of JNK and p38 
 
1. Effects on downstream targets 
 
The small molecule inhibitors CT 536706 and CT8730 were identified by UCB Celltech by 
screening libraries of small molecules. They are claimed to be more selective and specific 
than commercially available ATP-competitive pharmacological inhibitors
201
 (see Table 7 
below). 
 
Table 7: JNK and p38 inhibitors, in vitro kinase assay 
 
JNK inhibitors p38 inhibitors 
 
 CT536706 SP600125 
IC50 JNK1 28nM 39nM 
IC50 CDK2 55nM 20nM 
Kinome assay data provided by J. Davis (UCB Celltech, personal communication). 
 
Initially, I assessed the potency of the small molecule inhibitors by measuring their ability to 
suppress phosphorylation of downstream substrates in the MAP kinase pathway to ensure that 
the inhibitors were functional in my hands in cultured EC. 
 
I observed by ELISA that the JNK inhibitor CT536706 suppressed phosphorylation of c‐Jun 
(a downstream target of JNK) in response to TNFα whereas vehicle alone or a p38 inhibitor 
(CT8730) had little or no effect (Figure 30). Conversely, Western blotting revealed that 
CT8730 completely blocked the phosphorylation of HSP27 (a downstream target of p38) in 
response to TNFα whereas vehicle alone or the JNK inhibitor (CT536706) did not (Figure 
31). These validation studies were conducted at 10μM and no off‐target effects were observed 
implying that CT536706 and CT8730 inhibitors are specific for JNK and p38 respectively at 
these concentrations. Thus my validation studies are consistent with the suggestion by UCB 
that these inhibitors are specific for their respective targets when used at 10μM. 
  
 CT8730 SB202190 
IC50 p38 Very good Good 
Off-target effects Very little Some 
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Figure 30: CT536706 has specific inhibitory effects on JNK 
 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with a p38 inhibitor 
CT8730 (10μM for 1h), a JNK inhibitor CT536706 (10μM for 1h), vehicle (DMSO) or 
remained untreated as a control. Cultures were subsequently stimulated with TNFα (10ng/ml 
for 15min) or left untreated as a control as indicated above. Levels of total c-Jun and 
phosphorylated c-Jun were measured by testing cell lysates using ELISA. Data shown are 
mean levels of phosphorylated c-Jun normalised for total c-Jun levels with standard 
deviations. 
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Figure 31: CT8730 inhibits HSP27 phosphorylation by TNFα in HUVEC 
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with a p38 inhibitor 
CT8730 (10μM for 1h), a JNK inhibitor CT536706 (10μM for 1h), vehicle (DMSO) or 
remained untreated as a control. Cultures were subsequently stimulated with TNFα (10ng/ml 
for 15min) or left untreated as a control as indicated above. Cellular lysates were tested by 
Western blotting using anti-phosphoHSP27 and anti-HSP27 antibodies.  
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2. Effects on transcripts 
 
To further validate the use of the UCB small molecule inhibitors in a genome-wide 
microarray study, I compared them with commercially available ATP-competitive 
pharmacological inhibitors of JNK and p38 for modulation of pro-inflammatory transcripts. 
 
Using the commercially available ATP-competitive inhibitors at the recommended 
concentrations (SP600125 at 50μM and SB202190 at 25μM), I observed that suppression of 
JNK or p38 led to a decrease in E-selectin mRNA levels relative to vehicle (Figure 32, B, D). 
I then tested the small molecule inhibitors and observed a similar trend (Figure 32, A, C). 
Thus my data suggests that activation of both JNK and p38 is necessary for E-selectin 
induction by TNFα. However E-selectin mRNA was suppressed to a greater degree with the 
small molecule inhibitors.  
 
I then went on to look at the effects of the inhibitors on VCAM-1 (Figure 33) and IL-8 
(Figure 34). The small molecule inhibitor of JNK, CT536706, suppressed the TNFα-
induction of VCAM-1 and IL-8 whereas the commercially available inhibitor, SP600125 did 
not influence these molecules. The reason for this discrepancy is not certain but it is possible 
that this molecule is not as potent and therefore less effective at blocking JNK activity 
compared to the small molecule inhibitor. Both inhibitors of p38 (CT8730 and SB202190) 
suppressed VCAM-1 and IL-8 induction by TNFα equally well.  
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Figure 32: Suppression of E-selectin transcript levels by small molecule inhibitors 
similar to commercially available ATP-competitive inhibitors 
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with either a JNK 
inhibitor (A) CT536706 (10μM for 1h) or (B) SP600125 (50μM for 1h) or a p38 inhibitor (C) 
CT8730 (10μM for 1h) or (D) SB202190 (25μM for 1h). EC were treated with vehicle 
(DMSO) or remained untreated as a control. Cultures were subsequently stimulated with 
TNFα (10ng/ml for 4h) or left untreated as a control as indicated above. Levels of E-selectin 
transcript were quantified by quantitative RT-PCR and normalized by measuring β-actin 
transcript levels. Mean values were calculated from triplicate measurements and are shown 
with standard deviations. 
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Figure 33: Suppression of VCAM-1 transcript levels by small molecule inhibitors and 
commercially available ATP-competitive inhibitors  
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with either a JNK 
inhibitor (A) CT536706 (10μM for 1h) or (B) SP600125 (50μM for 1h) or a p38 inhibitor (C) 
CT8730 (10μM for 1h) or (D) SB202190 (25μM for 1h). EC were treated with vehicle 
(DMSO) or remained untreated as a control. Cultures were subsequently stimulated with 
TNFα (10ng/ml for 4h) or left untreated as a control as indicated above. Levels of VCAM-1 
transcript were quantified by quantitative RT-PCR and normalized by measuring β-actin 
transcript levels. Mean values were calculated from triplicate measurements and are shown 
with standard deviations. 
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Figure 34: Suppression of IL-8 transcript levels by small molecule inhibitors and 
commercially available ATP-competitive inhibitors   
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with either a JNK 
inhibitor (A) CT536706 (10μM for 1h) or (B) SP600125 (50μM for 1h) or a p38 inhibitor (C) 
CT8730 (10μM for 1h) or (D) SB202190 (25μM for 1h). EC were treated with vehicle 
(DMSO) or remained untreated as a control. Cultures were subsequently stimulated with 
TNFα (10ng/ml for 4h) or left untreated as a control as indicated above. Levels of E-selectin 
transcript were quantified by quantitative RT-PCR and normalized by measuring β-actin 
transcript levels. Mean values were calculated from triplicate measurements and are shown 
with standard deviations. 
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Once the validity of the small molecule inhibitors was established, I went on to look at the 
effects of varying doses of CT536706 and CT8730 on VCAM-1 transcript levels. I observed 
suppression of TNFα-induced VCAM-1 transcript whereas vehicle alone had little or no 
effect (Figure 35).  At 1μM there was a similar pattern with marked suppression in VCAM-1 
transcript levels. Thus CT536706 and CT8730 inhibited VCAM-1 levels in response to TNFα 
in a dose dependent manner. Consequently I decided to use both these inhibitors at 1μM 
concentration to examine their effects on other TNFα induced transcripts with the added 
advantage of reduced DMSO-related off target effects. 
 
Subsequent quantitative RT-PCR analysis revealed that the small molecule inhibitors of JNK; 
CT536706 and p38; CT8730 at 1μM did not alter the TNFα-induced protective gene, A1 
transcript levels as shown in Figure 36. 
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Figure 35: Small molecule inhibitors suppressed VCAM-1 expression in a dose 
dependent manner 
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with either a JNK 
inhibitor CT536706 or a p38 inhibitor CT8730 at 10μM, 1μM, 0.1μM or 0.01μM for 1h as 
indicated. Alternatively cells were treated with vehicle (DMSO) or remained untreated as a 
control. Cultures were then stimulated with TNFα (10ng/ml for 4hr) or left untreated as a 
control as indicated. VCAM-1 transcript levels were then quantified by quantitative RT-PCR 
using gene-specific PCR primers. The amount of transcript was normalised by measuring β-
actin transcript levels. Mean values were calculated from triplicate measurements and are 
shown with standard deviations.    
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Figure 36: Small molecule inhibitors of JNK and p38 did not alter cytoprotective 
molecule A1 in HUVEC in response to TNFα  
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with a JNK inhibitor 
CT536706 (1μM for 1h) or a p38 inhibitor CT8730 (1μM for 1h). Vehicle (DMSO) or 
untreated cells were used as a control. Cultures were subsequently stimulated with TNFα 
(10ng/ml for 4h) or left untreated as a control as indicated above. A1 transcript levels were 
quantified by quantitative RT-PCR using gene-specific primers. The amount of transcript was 
normalised by measuring β-actin transcript levels. Mean values were calculated from 
triplicate measurements and are shown with standard deviations. Data are representative of 
three independent experiments.  
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Microarray to identify JNK- and p38-dependent transcriptional programmes 
 
To further understand of the role of JNK and p38 MAP kinases in EC responses to TNFα, I 
conducted a microarray study using Affymetrix® arrays which contain more than 28,000 
human genes. The experiment was performed using HUVEC treated with or without 
CT536706 (1μM, 1h) or CT8730 (1μM, 1h) prior to application of TNFα (10ng/ml, 4h) as 
illustrated in Table 8. Each condition was performed in triplicate and total RNA was 
generated as explained in the materials and methods section. During the various steps of the 
whole transcript labelling process, I performed numerous quality control tests using the 
Nanodrop and Bioanalyzer (Appendix 5&6).  
 
Quality Assessment of total RNA  
 
The whole transcript labelling assay had previously been optimised for 100ng total RNA in a 
maximum volume of 3μl. Thus the RNA concentration of the samples generated was 
measured using the nanodrop (see Appendix 5 for RNA quantities) and were then adjusted by 
dilution with RNase free water to achieve the desired concentration of approximately 
34ng/μl. I then went on to analyse the quality of the RNA by running the samples on a 
bioanalyser. Features present in good quality total RNA are highlighted in Figure 37 and the 
traces generated from the experimental samples are shown in Appendix 5.  
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Figure 37: Key features of good quality total RNA 
 
 
 
Electropherogram of a total RNA sample highlighting the features included in good quality 
total RNA. (1) A nanodrop A260/A280 ratio between 1.9-2.1, (2) Clear 18S and 28S 
ribosomal RNA peaks, (3) A low small RNAs (5S, transfer RNA and miRNA) presence 
relative to the ribosomal  RNA peaks, (4) A flat base line in the fast-migrating region, before 
the 18S peak, (5) A flat baseline between the 18S and 28S ribosomal RNA peaks, (6) A 
return to the baseline after the ribosomal RNA peaks and (7) These features are used to 
calculate a RNA index number (RIN) which is proportional to RNA quality. Trace adapted 
from Agilent. 
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I observed that all the test RNA samples had an A260/A280 ratio between the desired 1.9-2.1 
ranges and that the amount of RNA generated per sample was more than sufficient to 
continue with the whole transcript labelling assay. The Bioanalyzer generates a RIN score 
based on several parameters (see Figure 37) that indicates RNA quality. A RIN score 
between 7 to 10 is sufficient for microarray. Analysis of samples by Bioanalyzer revealed 
traces and RIN scores that were indicative of high quality RNA. (RIN score: 10 for all test 
samples; see Appendix 5 for traces).  
 
Once these house-keeping checks had been performed, I set-up a quantitative RT-PCR 
experiment to analyse VCAM-1, which I had previously shown to be regulated by JNK and 
p38. This was to ensure that the samples generated for the microarray analysis conformed to 
the previous data I had obtained with the small molecule inhibitors, thus eliminating outliers 
from being labelled and hybridised for analysis. I observed that TNFα induced VCAM-1 
transcript levels were reduced by both CT536706 and CT8730 compared to vehicle alone 
(Figure 38). Hence I continued to proceed with the whole transcript labelling assay to assess 
the function of JNK and p38 on transcriptional programmes. The samples were further 
analyzed on the bioanalyser before and after cDNA fragmentation to ensure consistently good 
quality product at the end of each stage (see Appendix 6 for traces). 
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Figure 38: Inhibition of JNK or p38 leads to suppression of VCAM-1 transcript levels 
 
 
 
HUVEC cultured under static conditions on fibronectin were pretreated with a JNK inhibitor 
CT536706 (1μM for 1h) or a p38 inhibitor CT8730 (1μM for 1h). Vehicle (DMSO) or 
untreated cells were used as a control. Cultures were subsequently stimulated with TNFα 
(10ng/ml for 4h) or left untreated as a control as indicated above. VCAM-1 transcript levels 
were quantified by quantitative RT-PCR using gene-specific primers. The amount of 
transcript was normalised by measuring β-actin transcript levels. Mean values were 
calculated from triplicate measurements and are shown with standard deviations. Data are 
representative of three independent experiments.  
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Experimental design 
 
To assess the functional role of JNK and p38 in EC in basal condition or following TNFα 
treatment, I set-up the following microarray experiment: 
 
Table 8: Microarray set-up to assess the effects of JNK and p38 on transcriptional 
responses regulated constitutively and in response to TNFα in HUVEC 
 
Conditions Pretreatment TNFα (4h) 
Sample 1 None - 
Sample 2 None + 
Sample 3 Vehicle - 
Sample 4 Vehicle + 
Sample 5 CT536706 (JNKi) - 
Sample 6 CT536706 (JNKi) + 
Sample 7 CT8730 (p38i) - 
Sample 8 CT8730 (p38i) + 
 
 
Once the samples were hybridized and the microchips scanned (by the MRC, Clinical 
Science Centre, Genomics laboratory), I went on to analyse the data using Rosetta Resolver 
software and DAVID to identify genes that are regulated by JNK or p38 at a constitutive 
level and in response to TNFα and then to annotate the various groups of genes in to 
functional categories.  
 
Each experimental condition was prepared in triplicate using three different isolates. As a 
first step in the analysis, data from triplicates were grouped together thus generating a mean ± 
SD intensity for each gene which allows subsequent statistical tests to be performed.  
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Identification of TNFα-induced genes 
 
To identify TNFα-induced genes, I compared data sets from samples that were either 
untreated or treated with TNFα (Table 8, samples 1 and 2). Using Rosetta Resolver, I 
observed that 384 transcripts were expressed at significantly different levels between 
samples. The expression levels of each of these so-called signature genes in untreated vs. 
TNFα-treated HUVEC is plotted in Figure 39. 
 
This revealed that 183 transcripts were significantly upregulated by TNFα, whereas 76 genes 
were downregulated. 
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Figure 39: Genome wide assessment of TNFα-induced transcript levels 
 
 
 
An intensity plot of untreated sample 1 against TNFα treated sample 2. HUVEC were treated 
with TNFα (10ng/ml) for 4h. Each experimental condition was performed in triplicate. 
Transcript levels in each sample were assessed at a genomic level using Affymetrix® 
microarrays and analysed using Rosetta-resolver® software. The plot represents the entire 
array data, blue crosses represent unchanged transcripts, red indicates upregulated transcripts, 
and downregulated transcripts are represented in green. 
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The function of TNFα-induced transcripts was identified using the DAVID database. Of the 
183 transcripts, 151 had a putative function (Appendix 7) whereas 32 were unannotated. A 
summary of the functional categories of TNFα-induced genes is given in Table 9 below.  
 
Table 9: Functional annotation of TNFα-induced transcripts 
 
Functional groups Enrichment (%) age 
Immune process 46 30 
Apoptosis 47 31 
Inflammatory response 31 21 
Signal transduction 48 32 
NF-κB signaling 24 16 
Transcription factor 13 9 
Cytoskeleton 12 8 
 
I found that TNFα induced genes fell in to various functional categories with enrichment in 
the immune, apoptotic and inflammatory groups which supports previous studies
41
.  
 
The inhibitors used in this study were dissolved in DMSO. Therefore it was important to 
assess whether DMSO would influence gene transcription in HUVEC. I did this by 
comparing transcripts induced by TNFα in the presence (Table 8, sample 3 and 4) or absence 
(Table 8, sample 1 and 2) of DMSO. 
 
Comparison of samples 3 and 4 (Figure 40) revealed that 356 transcripts were differentially 
expressed in TNFα-treated compared to untreated HUVEC in the presence of DMSO. Of 
these, 165 transcripts were positively regulated by TNFα. A heat map (Figure 41) revealed 
that TNFα-induced very similar sets of genes in the presence or absence of DMSO. I 
therefore concluded that the concentration of DMSO used in this study has modest effects on 
transcriptional changes in cultured EC. 
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Figure 40 Genome wide assessment of transcript levels in DMSO pretreated, TNFα-
induced samples 
 
 
 
An intensity plot of vehicle (DMSO) pretreated samples in the presence (sample 4) and 
absence (sample 3) of TNFα. HUVEC were treated with vehicle (DMSO) for 5h or remained 
untreated. Cultures were co-stimulated with TNFα (10ng/ml) for the final 4 hours or 
remained untreated. Each experimental condition was performed in triplicate. Transcript 
levels in each sample were assessed at a genomic level using Affymetrix® microarrays and 
analysed using Rosetta-resolver® software. The plot represents the entire array data, blue 
crosses represent unchanged transcripts, red indicates upregulated transcripts, and 
downregulated transcripts are represented in green. 
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Figure 41 Comparison of TNFα treatments in the presence or absence of DMSO 
 
 
Heat maps depicting the effects of DMSO alone (panel 2), CT8730 (panel 3) or CT536706 
(panel 4) on the TNFα-induced endothelial transcriptome to allow comparison of TNFα 
treated vs. untreated samples. HUVEC were treated with vehicle (DMSO) alone, CT8730 or 
CT536706 for 5h or remained untreated. Cultures were co-stimulated with TNFα (10ng/ml) 
for the final 4 hours. Each experimental condition was performed in triplicate. Transcript 
levels in each sample were assessed at a genomic level using Affymetrix® microarrays and 
analysed using Rosetta-resolver® software. Transcripts represented in green are suppressed 
and red indicate induced transcripts.  
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The heat map (Figure 41) also gave a global overview of the effects of the JNK and p38 
inhibitor in the TNFα treated samples. I subsequently assessed the role of JNK and p38 MAP 
kinase regulated basal and TNFα-induced transcripts.  
 
Identification of JNK regulated genes in TNFα-treated and quiescent EC 
 
1. Identification of TNFα-induced JNK regulated genes 
 
To address the role of JNK in TNFα induced transcripts at a global level; I compared cells 
treated with TNFα in the presence of CT536706 with cells treated with TNFα plus vehicle 
alone (Table 8, samples 6 and 4). Using Rosetta Resolver, I observed that 96 transcripts were 
expressed at significantly different levels between samples. The expression levels of each of 
these so-called signature genes in untreated vs. TNFα-treated HUVEC is plotted in Figure 42. 
 
This revealed that 56 transcripts were significantly upregulated by JNK inhibition in TNFα-
induced EC, whereas 3 genes were downregulated. 
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Figure 42: Genome wide assessment of JNK regulated, TNFα-induced transcript levels 
 
 
 
An intensity plot of JNK inhibitor (CT536706) pretreated samples in the presence (sample 6) 
and absence (sample 5) of TNFα. HUVEC were treated with the JNK inhibitor (CT536706; 
1μM for 5h) or vehicle (DMSO) alone. Cultures were co-stimulated with TNFα (10ng/ml) for 
the final 4 hours or remained untreated. Transcript levels in each sample were assessed at a 
genomic level using Affymetrix® microarrays and analysed using Rosetta-resolver® 
software. The plot represents the entire array data, blue crosses represent unchanged 
transcripts, red indicates upregulated transcripts, and downregulated transcripts are 
represented in green. 
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Of the 183 TNFα-induced transcripts (Figure 39), JNK was not required for the induction of 
56 transcripts, as these where up regulated in the presence of the JNK inhibitor, CT536706. 
The function of JNK regulated, TNFα-induced transcripts was identified using the DAVID 
database.  
 
Of the 137 transcripts, 120 had a putative function (Appendix 8) whereas 17 were 
unannotated. A summary of the functional categories of the JNK regulated, TNFα-induced 
genes is given in Table 10 below.  
 
Table 10: Functional annotation of JNK regulated, TNFα-induced transcripts 
 
Functional groups 
TNFα 
induced 
Enrichment 
JNK dependent 
JNK 
independent 
(%) age 
Transcription factor 17 14 3 82 
Apoptosis 27 17 10 63 
Inflammatory response 34 29 5 85 
Signal transduction 21 18 3 86 
NF-κB signaling 4 3 1 75 
 
I found that JNK regulated, TNFα-induced genes fell in to various functional categories with 
enrichment in the apoptotic, inflammatory and transcription factor groups which support 
previous studies
212
.  
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2. Constitutive JNK regulated transcripts  
 
To identify JNK regulated genes, I compared data sets from samples that were either 
untreated or treated with CT536506 (Table 8, samples 5 and 6). Using Rosetta Resolver, I 
observed that 1,570 transcripts were expressed at significantly different levels between 
samples. The expression levels of each of these so-called signature genes in untreated vs. 
TNFα-treated HUVEC is plotted in Figure 43. 
 
This revealed that 1,007 transcripts were significantly downregulated by JNK inhibition, 
whereas 116 genes were upregulated.  
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Figure 43: Genome wide assessment of JNK regulated transcript levels 
 
 
 
An intensity plot of JNK inhibitor (CT536706) treated samples (sample 5) compared to 
vehicle (DMSO) treated (sample 3). HUVEC were treated with the JNK inhibitor 
(CT536706; 1μM for 5h) or vehicle (DMSO) alone. Each experimental condition was 
performed in triplicate. Transcript levels in each sample were assessed at a genomic level 
using Affymetrix® microarrays and analysed using Rosetta-resolver® software. The plot 
represents the entire array data, blue crosses represent unchanged transcripts, red indicates 
upregulated transcripts, and downregulated transcripts are represented in green. 
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The function of positively JNK regulated transcripts was identified using the DAVID 
database. Of the 1,007 transcripts, 916 had a putative function (Appendix 9) whereas 91 were 
unannotated. A summary of the functional categories of JNK dependent genes is given in 
Table 11 below.  
 
Table 11: Functional annotation of constitutive JNK regulated transcripts 
 
Functional groups 
Number 
on array 
Enrichment 
JNK 
dependent 
JNK 
independent 
(%) age 
Immune process 1007 39 986 4 
Apoptosis 483 79 404 16 
Inflammatory response 1428 40 1388 3 
Signal transduction 2459 217 2242 9 
NF-κB signaling 119 34 85 29 
Transcription factor 791 207 584 26 
Cytoskeleton 1755 165 1590 9 
Proliferation 1299 95 1204 7 
Oxidative mechanism 1769 45 1724 3 
Post-translational 
modification 
713 132 581 19 
DNA binding 1611 142 1469 9 
 
In summary, these findings suggest that JNK regulates pro-inflammatory, pro-apoptotic and 
other physiological processes in quiescent EC. 
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Identification of p38 regulated genes in TNFα-treated and quiescent EC 
 
1. Identification of TNFα-induced p38 regulated genes 
 
To address the role of p38 in TNFα induced transcripts at a global level; I compared cells 
treated with TNFα in the presence of CT8730 with cells treated with TNFα plus vehicle alone 
(Table 8, samples 8 and 4). Using Rosetta Resolver, I observed that 433 transcripts were 
expressed at significantly different levels between samples. The expression levels of each of 
these so-called signature genes in untreated vs. TNFα-treated HUVEC is plotted in Figure 44. 
 
This revealed that 308 transcripts were significantly upregulated by p38 inhibition in TNFα-
induced EC, whereas 29 genes were downregulated. 
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Figure 44: Genome wide assessment of p38 regulated, TNFα-induced transcript levels 
 
 
 
An intensity plot of p38 inhibitor (CT8730) pretreated samples in the presence (sample 8) and 
absence (sample 7) of TNFα. HUVEC were treated with the p38 inhibitor (CT8730; 1μM for 
5h) or vehicle (DMSO) alone. Cultures were co-stimulated with TNFα (10ng/ml) for the final 
4 hours or remained untreated. Transcript levels in each sample were assessed at a genomic 
level using Affymetrix® microarrays and analysed using Rosetta-resolver® software. The 
plot represents the entire array data, blue crosses represent unchanged transcripts, red 
indicates upregulated transcripts, and downregulated transcripts are represented in green. 
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p38 was not required for the induction of 308 transcripts, as these where up regulated in the 
presence of the p38 inhibitor, CT8730. Of the 183 TNFα-induced transcripts (Figure 39), the 
function of p38 regulated, TNFα-induced transcripts (28 transcripts) was identified using the 
DAVID database.  
 
Of the 28 transcripts, all had a putative function (Appendix 10). A summary of the functional 
categories of the p38 regulated, TNFα-induced genes is given in Table 12 below.  
 
Table 12: Functional annotation of p38 regulated, TNFα-induced transcripts 
 
Functional groups 
TNFα 
induced 
Enrichment 
p38 dependent 
p38 
independent 
(%) age 
Transcription factor 17 13 4 76.5 
Apoptosis 27 8 19 29.6 
Inflammatory response 34 0 34 0.0 
Signal transduction 21 4 17 19.0 
NF-κB signaling 4 0 4 0.0 
 
I found that p38 regulated, TNFα-induced genes fell in to various functional categories with 
enrichment in the transcription factor, apoptotic and signal transduction groups.  
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2. Constitutive p38 regulated transcripts  
 
To identify p38 regulated genes, I compared data sets from samples that were either untreated 
or treated with CT8730 (Table 8, samples 7 and 8). Using Rosetta Resolver, I observed that 
13 transcripts were expressed at significantly different levels between samples. The 
expression levels of each of these so-called signature genes in untreated vs. TNFα-treated 
HUVEC is plotted in Figure 45. 
 
This revealed that 2 transcripts were significantly downregulated by p38 inhibition, and 2 
genes were upregulated.  
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Figure 45: Genome wide assessment of p38 regulated transcript levels 
 
 
 
An intensity plot of p38 inhibitor (CT8730) treated samples (sample 7) compared to vehicle 
(DMSO) treated (sample 3). HUVEC were treated with the p38 inhibitor (CT8730; 1μM for 
5h) or vehicle (DMSO) alone. Each experimental condition was performed in triplicate. 
Transcript levels in each sample were assessed at a genomic level using Affymetrix® 
microarrays and analysed using Rosetta-resolver® software. The plot represents the entire 
array data, blue crosses represent unchanged transcripts, red indicates upregulated transcripts, 
and downregulated transcripts are represented in green. 
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The function of positively p38 regulated transcripts could not be identified as they were both 
unannoted transcripts. These transcripts were identified using a 2-fold increase threshold. 
Thus I decided to reduce the threshold to 1.5-fold to analyse the role of constitutive p38 
regulated genes. I found that of the 35 transcripts regulated by p38, 13 had a putative function 
(Appendix 11).  A summary of the functional categories of the p38 regulated genes is given 
in Table 13 below. 
 
Table 13: Functional annotation of constitutive p38 regulated transcripts  
 
Functional groups 
Number 
on array 
Enrichment 
p38 
dependent 
p38 
independent 
(%) age 
Immune process 1007 4 1003 0.4 
Apoptosis 483 5 478 1.0 
Inflammatory response 1428 3 1425 0.2 
Signal transduction 2459 6 2453 0.2 
Proliferation 1299 3 1296 0.2 
 
In summary, these findings suggest that p38 plays a role in regulation of apoptosis, 
inflammation, proliferation and other physiological processes in both quiescent and TNFα-
treated EC as well as influencing transcription factors in activated EC. 
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From here on I only assessed the JNK side of the story only and tried to validate the 
microarray data using the small molecule inhibitor CT536706 as well as a gene silencing 
approach.  
 
Independent validation of microarray data using the JNK inhibitor, CT536706 
 
The next step was to use quantitative RT-PCR to independently verify that selected pro-
inflammatory and pro-apoptotic transcripts identified by the array were genuinely regulated 
by JNK. Independent quantitative RT-PCR experiments confirmed that pharmacological 
inhibition of JNK leads to reduced basal expression of molecules that positively regulate 
apoptosis e.g. caspase-3, PP2A, DPF2, JAZ (Table 14 and Figure 46A), pro-inflammatory 
activation e.g. VCAM-1, E-selectin, (Table 14 and Figure 46B), or both of these processes 
e.g. TLR4, CARD6, RIP1, BMP2, BMP4, DKK1 (Table 14 and Figure 46 C).  
 
I also looked at several TNFα-induced genes such as, VCAM-1, E-selectin and IL-8 by 
quantitative RT-PCR (Table 14, red boxes) and found that this induction is regulated by JNK, 
supporting the array data (Table 14, red boxes) and my previous results. However I did not 
observe TNFα-induced upregulation by quantitative RT-PCR analysis in most of the other 
molecules of interest as mentioned in Table 14. 
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Table 14: Comparison of Microarray data with quantitative RT-PCR for selected genes 
 
 
 
HUVEC were treated with JNK inhibitor, CT536706 (1μM for 1h), with vehicle alone, or 
remained untreated. Cultures were then stimulated with TNFα (10ng/ml for 4h) or remained 
untreated. Each experimental condition was performed in triplicate. Transcript levels in each 
sample were assessed at a genomic level using Affymetrix® microarrays. Pro-inflammatory 
and pro-apoptotic transcripts that were positively regulated by JNK in all 3 isolates, either in 
the basal state or in response to TNFα treatment, were identified using Rosetta-resolver and 
DAVID software. The effects of the JNK inhibitor or TNFα on the expression levels of 
selected transcripts were subsequently validated by quantitative RT-PCR in 3 additional 
independent experiments. A summary of array and quantitative RT-PCR results are shown 
for selected genes that regulate inflammation, apoptosis, or cell survival. NA indicates not 
applicable; NT, not tested. 
 
  
Genes
Basal state TNFα-treated
Effects of JNK 
inhibitor Induction
Effects of JNK 
inhibitor
Array q-PCR Array q-PCR
Vascular cell adhesion molecule 1 (VCAM-1) Yes
E-selectin Yes
Interleukin 8 (IL-8) Yes
Toll-like receptor 4 (TLR4) No n.a. n.a .
Caspase recruitment domain family 6 (CARD6) No n.a. n.a .
Receptor interacting protein 1 (RIP1) No n.a. n.a .
Bone morphogenetic protein 2 (BMP2) Yes n.t.
Bone morphogenetic protein 4 (BMP4) No n.a. n.a .
Dickkopf1 (DKK1) No n.a. n.a .
Caspase 3 Yes n.t.
Serine threonine kinase (Mst-1) No n.a. n.a .
Protein phosphatise 2A (PP2A) Yes
D4, zinc and double PHD fingers family 2 (DPF2) No n.a. n.a .
Zinc finger protein 346 (JAZ) No n.a. n.a .
Growth arrest and DNA damage-inducible (GADD45β) Yes n.t.
Bcl-2 related protein A1 Yes
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Figure 46: JNK positively regulates pro-apoptotic and pro-inflammatory molecules 
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HUVEC cultured under static condition on fibronectin were exposed to the JNK inhibitor 
(CT536706; 1μM for 5h), with vehicle (DMSO) alone or remained untreated (A-B). Cultures 
were co-stimulated with TNFα (10ng/ml) for the final 4h or remained untreated (C). Levels 
of pro-apoptotic and pro-inflammatory transcripts were then quantified by quantitative RT-
PCR using gene-specific PCR primers. The amount of transcript was normalised by 
measuring β-actin transcript levels. Mean values were calculated from triplicate 
measurements and are shown with standard deviations.   
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JNK regulates pro-caspase-3 and RIP1 protein levels in resting EC 
 
I examined the effects of the JNK inhibitor on protein levels of a subset of molecules that 
were shown to be regulated by JNK at the mRNA level. Caspase-3 protein levels were 
studied because of its major role in the apoptotic pathway. I also investigated RIP1 levels 
because it also has an important role in TNF receptor 1-mediated cell death. 
 
I demonstrated by Western blotting that pharmacological inhibition of JNK reduced the 
expression of pro-caspase-3 and RIP1 proteins in HUVEC in a time-dependent manner 
(Figure 47). The mRNA data described above (Figure 46) was obtained post 5hr CT536706 
treatment. However that time point was not sufficient to see a reduction in protein levels. So I 
continued the CT536706 treatment for two additional time points of 12h and 24h and 
observed reduction in protein level at 12h which were more pronounced at 24h relative to 
tubulin levels (Figure 47, lower panel) used as a house-keeping control. The p38 inhibitor, 
CT8730 was used as a negative control which did not alter protein levels. Thus JNK is 
required for the basal levels of RIP1 and pro-caspase-3 in EC.  
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Figure 47: JNK regulates the constitutive expression of pro-apoptotic molecules in EC 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were treated with CT536706 (1μM), 
CT8730 (1μM) or were treated with vehicle alone (DMSO) or remained untreated for 5h, 12h 
or 24h. Cellular lysates were tested by Western blotting using anti-pro-caspase-3, anti-RIP1, 
and anti-tubulin antibodies. Data representative of 2 independent experiments. 
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JNK1-specific siRNA suppresses RIP1 and caspase-3 mRNA through the JNK-c-jun 
pathway 
 
I examined the specificity of 2 different JNK1-specific siRNA sequences (JNK1a, JNK1b) 
and observed that only JNK1 mRNA and protein was significantly suppressed with no effect 
on JNK2 protein levels (Figure 48, A; upper panel compare lanes 2 and 3). I then examined 
the effects of JNK1 suppression on RIP1 and caspase-3 mRNA levels which were both 
reduced by approximately 50% compared to a scrambled, non-targeting control that had no 
effect (Figure 48, B).  
 
The next step was to examine whether these pro-apoptotic molecules were regulated through 
the JNK-c-jun axis. Silencing of the downstream transcription factor c-jun also led to a 
significant reduction in RIP1 and caspase-3 levels (Figure 49). Thus I concluded that JNK-c-
jun signaling positively regulates the expression of pro-apoptotic molecules in cultured EC.  
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Figure 48: JNK1 regulates RIP1 and pro-caspase-3 in resting EC 
 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were treated with JNK1-specific 
siRNA (JNK1a or JNK1b) or with a scrambled non-targeting sequence (Scramble) and were 
incubated for 24 hours. (A) Cellular lysates were tested by Western blotting using anti-JNK 
and anti-tubulin antibodies. Representative of 2 independent experiments. (B) Transcript 
levels were quantified by quantitative RT-PCR and normalized by measuring β-actin 
transcript levels. Mean values were calculated from triplicate measurements and are shown 
with standard deviations.  
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Figure 49: c-jun regulates RIP1 and pro-caspase-3 in resting EC 
 
 
 
 
 
HUVEC cultured under static conditions on fibronectin were treated with c-jun-specific 
siRNA or with a scrambled non-targeting sequence (Scramble) and were incubated for 24 
hours. (A) Cellular lysates were tested by Western blotting using anti-c-jun and anti-tubulin 
antibodies. Representative of 2 independent experiments. (B) Transcript levels were 
quantified by quantitative RT-PCR and normalized by measuring β-actin transcript levels. 
Mean values were calculated from triplicate measurements and are shown with standard 
deviations.  
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CONCLUSIONS 
 
 TNFα-induced transcripts are involved in diverse cellular functions 
 JNK and p38 both positively regulate the constitutive and TNFα-induced pro-
apoptotic and pro-inflammatory transcripts 
 Microarray and quantitative RT-PCR analyses reveal that JNK positively regulates the 
basal expression of pro-apoptotic molecules (e.g. RIP1, caspase-3, TLR4, CARD6, 
BMP4, etc) 
 JNK1 is necessary for transcription of pro-apoptotic molecules 
 Basal expression of RIP1 and caspase-3 is regulated through the JNK-c-jun pathway 
in cultured EC 
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DISCUSSION 
 
DMSO has a variety of biological actions that can affect cell physiology
213
. The JNK and p38 
inhibitors were dissolved in DMSO which needed to be accounted for, so I controlled for 
these potential effects by treating cells with vehicle alone. After testing a range of 
concentrations I concluded that 1μM CT536706 or CT8730 could exert potent 
anti‐inflammatory effects on EC and that pre‐treatment of cells with a corresponding 
concentration of vehicle alone had little or no effect. I therefore chose to use 1μM of MAP 
kinase inhibitors in subsequent experiments.  
 
EC responded in a similar manner to the small molecule inhibitors as well as the 
commercially available inhibitors. However the small molecule inhibitors were effective at 
much lower concentrations, thus I decided to use UCB small molecule inhibitors because 
they may have less off-target effects compared to conventional inhibitors.  
 
Exposure of EC to cytokines or endotoxins leads to the induction of numerous transcripts that 
regulate inflammation, apoptosis and other processes. TNFα, one of the most important 
promoters
 
of inflammation, induces activation of two major signaling
 
pathways involved in 
endothelial activation i.e. the NF-κB pathway and JNK and p38 MAP kinase cascade9.  The 
microarray study revealed that TNFα positively regulates diverse physiological functions 
including inflammation, apoptosis and cell adhesion in EC. TNFα also appeared to be 
involved in regulating transcription factors and signal transduction in EC which is consistent 
with previous studies
41, 214
.  
 
Active forms of JNK and p38 phosphorylate AP-1 transcription factors
32, 212
 such as c-jun, 
ATF2, c-fos; which subsequently form complexes with NF-κB and bind to various promoters 
to modulate gene transcription and translation of pro-inflammatory proteins such as adhesion 
molecules, chemokines and cytokines. Several studies revealed that induction of E-selectin, 
VCAM-1, IL-8 and other pro-inflammatory molecules relies on simultaneous activation of 
NF-κB and MAP kinase pathways4, 47, 215, 216. The function of JNK was investigated in 
cultured EC in the presence or absence of a specific pharmacological inhibitor using a 
genomics platform followed by functional annotation. Consistent with the literature, my data 
show that pre‐treatment of EC with the small molecule inhibitors of JNK or p38 can suppress 
induction of E‐selectin, VCAM‐1 and IL‐8 by TNFα.  
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Initially the experiments with the small molecule inhibitors were set-up to study the balance 
between pro-inflammatory and cytoprotective mRNA induction by JNK and p38 MAP 
kinases in response to TNFα by quantitative RT-PCR. I assessed the role of JNK and p38 in 
the regulation of cytoprotective molecules A20 and A1; both of which are anti-apoptotic 
molecules
207, 217
. Quantitative RT-PCR data suggests JNK and p38 are needed for the 
induction of A20 transcript levels. However, A1 levels were unaltered by both JNK and p38 
inhibition. Although JNK and p38 play a key role in pro-inflammatory activation they may be 
dispensable for the induction of cytoprotective genes. For example, Zhang N et al have 
shown that induction of the anti-apoptotic molecule GADD45β by pro-inflammatory 
mediators relies on NF-κB but not MAPK signaling. Secondly some cytoprotective genes 
(e.g. A1, Bcl-2, GADD45β, and MnSOD) can be activated by NF-κB in the absence of MAP 
kinase signaling in EC cultured under prolonged flow (Partridge et al 
186
). Thus JNK and p38 
may act as 'molecular switches' to regulate diverse transcriptional programmes induced by 
TNFα. 
 
In 2004, using a relatively small gene array Viemann et al 
41
 have reported that induction of 
pro‐inflammatory mediators including VCAM-1, IL‐8 and COX‐2 is p38 MAP kinase 
dependent. However, my study was the first genome wide analysis on the role of JNK and 
p38 in quiescent and TNFα-treated EC. Furthermore JNK and p38 also regulate apoptotic 
transcripts in resting EC e.g. JNK is involved in the positive regulation of TLR4, CARD6, 
BMP2, BMP4, RIP1 and pro-caspase-3 transcription, as well as RIP1 and pro-caspase-3 
protein expression. These data supports the idea that JNK positively regulates the induction 
of pro-inflammatory transcripts
4, 218
 which influence atherosclerosis by regulating the 
recruitment of leukocytes to the vessel wall. 
 
Any form of manipulation is known to have off-target effects, as is the case with 
pharmacological inhibitors. Therefore I subsequently validated a subset of JNK regulated 
molecules using a separate gene silencing approach. With two different siRNA sequences for 
JNK1 silencing and another c-jun siRNA sequence, I found that JNK1 positively regulates 
apoptotic RIP1 and caspase-3 mRNA through the JNK-c-jun axis in EC. Sabbagh et al have 
also shown regulation of caspase-3 mRNA by T cell receptor (TCR) signaling in T- 
lymphocytes
219
. 
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Endothelial apoptosis has a very low rate of expression in cultured EC but it can be induced 
by stress signals, such as H2O2. H2O2-induced oxidative stress leads to activation of JNK and 
is known to be involved in regulating apoptosis in many cell types. Aoki et al demonstrated 
that the molecular mechanism of JNK-mediated apoptosis in adult rat cardiac myocytes in 
vitro is sensitive to oxidative stress. Oxidative stress led to JNK activation, cytochrome c 
release, and subsequent apoptosis without new protein synthesis. This response was 
abrogated by dominant negative stress-activated protein kinase/extracellular signal-regulated 
kinase kinase-1 (SEK1)-mediated inhibition of the JNK pathway, whereas activation of the 
JNK pathway by constitutively active SEK1 was sufficient to cause apoptosis. Inhibition of 
caspase-9 suppressed oxidative stress-induced apoptosis, whereas inhibition of caspase-8 had 
no effect, indicating that both the JNK pathway and the mitochondrial apoptosis machinery 
are central to oxidative stress-induced apoptosis. Both JNK and SEK1 localized on 
mitochondria where JNK was activated by oxidative stress. Furthermore, active JNK caused 
the release of apoptogenic factors such as cytochrome c from isolated mitochondria in a cell-
free assay
220
. These findings indicate that the JNK pathway is a direct activator of 
mitochondrial death machinery without other cellular components and provides a molecular 
linkage between oxidative stress and the mitochondrial apoptosis machinery. Cytochrome c 
activates caspase-9 to initiate the activation and amplification of death signaling. 
 
The JNK pathway was also reported to activate receptor-mediated apoptosis by induction of 
the Fas ligand in T lymphocyte
221
. It has also been proposed that the JNK pathway is 
necessary for UV irradiation-induced activation of mitochondrial death machinery in 
embryonic fibroblast
222
. However, the molecular linkage between the JNK pathway and 
apoptosis pathway is still under investigation. The molecular mechanism underlying the 
spatial distribution of vascular inflammation and atherosclerosis are also uncertain. Here I 
have demonstrated the role of JNK in positively regulating a basal micro-environment that is 
more prone to apoptosis and inflammation. Thus based on my data JNK may prime EC for 
apoptosis by enhancing the expression of pro-apoptotic molecules. 
 
Data generated from cell culture experiments will be validated in vivo by en face staining of 
murine aortae using specific antibodies. Thus I will examine whether expression levels of a 
sub‐set of JNK dependent molecules are reduced in atheroresistant sites where MAPK 
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activation is known to be suppressed. I would also assess the role of JNK in regulating those 
molecules by gathering genetic evidence by using JNK1
-/-
 animals.  
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CHAPTER 5: JNK PRIMES ENDOTHELIAL CELLS 
AT ATHEROSUSCEPTIBLE SITES FOR ENHANCED 
APOPTOSIS IN RESPONSE TO LPS  
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INTRODUCTION 
 
My previously studies revealed that JNK is activated in EC at susceptible regions of the 
arterial tree (see Chapter 3). The role of JNK in the death receptor-initiated extrinsic as well 
as mitochondrial intrinsic apoptotic pathways is well documented
101, 102, 105
. Various groups 
have shown a role for JNK in non-transcriptional pro-apoptotic signaling pathways, e.g. JNK 
is known to activate ITCH and Smac/DIABLO both of which inhibit negative regulators of 
apoptosis, thus aiding caspase-3 activation and subsequent apoptosis
108, 109
. JNK 
phosphorylation also results in the activation of the transcription factor c-jun, which is known 
to regulate p53 which drives apoptosis through caspase-3 cleavage
11, 223
 as well as by directly 
modulating the activities of mitochondrial pro- and anti-apoptotic proteins through distinct 
phosphorylation events
95, 106, 107
. 
 
The genome-wide microarray performed on EC suggested that JNK acts as a positive 
regulator of pro-apoptotic molecules in quiescent cultured EC
224
. However JNK activation 
has not been linked with the transcriptional regulation of pro-apoptotic molecules in vivo.  
 
Thus to establish a role for JNK in the regulation of pro-apoptotic molecule expression and 
apoptosis in EC in vivo, I studied the effects of genetic deletion of JNK1 on EC physiology at 
atherosusceptible and atheroprotected regions of the aorta. 
 
RIP1 is known to be involved in the death receptor initiated cell death pathway
81
 and 
caspase-3 cleavage is well documented as the penultimate step in DNA damage and 
subsequent apoptosis
63
. My work provides the first evidence that transcript levels of RIP1 and 
caspase-3 are regulated by JNK. 
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Hypothesis and Aims 
 
I hypothesised that active JNK may regulate EC apoptosis by inducing pro-apoptotic 
molecules at the atherosusceptible site. To address this idea I considered the following aims: 
1. Compare the expression levels of pro-apoptotic molecules in susceptible and 
protected regions of the murine aortic arch. 
2. Examine the role of JNK1 in dictating the expression levels of pro-apoptotic 
molecules at these sites. 
3. Correlate these findings with levels of apoptosis and proliferation occurring at the 
susceptible vs. protected sites. 
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RESULTS 
 
Levels of pro-apoptotic molecules in the susceptible vs. protected sites 
 
To assess whether JNK phosphorylation correlates with enhanced expression of pro-apoptotic 
molecules, I compared the levels of RIP1 and pro-caspase-3 in the susceptible and protected 
region.  
 
Firstly, I optimised the staining technique using anti-RIP1 or anti-pro-caspase-3 antibodies. 
This was done to ensure minimum numbers of animals were sacrificed to assess RIP1 or 
caspase-3 expression. Thus I stained EC in small pieces of the descending aorta with the anti-
RIP1 or anti-pro-caspase-3 antibodies to optimise the working concentration and laser 
settings for en face immunofluorescent staining and confocal microscopy. 
 
Using the optimised protocol, I observed that RIP1 was expressed at higher levels 
constitutively in the susceptible region compared to the protected region (Figure 50A). 
Similarly EC of the susceptible site expressed higher levels of pro-caspase-3 compared to EC 
of the protected site (Figure 50B). I concluded that elevated JNK activity correlated with 
enhanced expression of RIP1 and pro-caspase-3 at the susceptible site. 
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Figure 50: RIP1 and caspase-3 expression in murine aortic arch 
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RIP1 (A) and pro-caspase-3 (B) expression levels were assessed in the susceptible and 
protected regions of the aorta of C57BL/6 mice (n=4). RIP1 and pro-caspase-3 were detected 
by en face staining using anti-RIP1 and anti-pro-caspase-3 antibodies and AlexaFluor568-
conjugated secondary antibodies (red) followed by confocal microscopy. EC were identified 
by co-staining with anti-CD31 antibodies conjugated to AlexaFluor488 (green). Cell nuclei 
were identified using Draq5 (purple). Representative images are shown in the upper panels. 
Levels of RIP1 and pro-caspase-3 were quantified by measuring fluorescence from multiple 
cells (>50) in susceptible and protected regions of mice (lower panels). Mean fluorescence 
intensities are shown with standard deviations. Differences between samples were analysed 
using an unpaired t-test.  
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JNK1 regulated expression of pro-apoptotic molecules in the arterial tree 
 
I then went on to use a genetic deletion model employing JNK1 knockout mice to  test the 
hypothesis that JNK plays a role in apoptosis through regulating expression of pro-apoptotic 
molecules. I examined the levels of RIP1 and pro-caspase-3 in the susceptible site of the 
JNK1 knockouts and compared it to the wild-type mice. Consistent with my hypothesis, en 
face staining revealed that genetic deletion of JNK1 reduced RIP1 (Figure 51, 1-2) and pro-
caspase-3 (Figure 51, 3-4) levels in the susceptible site, indicating that JNK1 is essential for 
their constitutive expression in this region.  
 
However JNK1 deletion did not have any effect on the level of pro-apoptotic molecules in the 
protected site. This is likely to be due to the fact that JNK is predominatly inactive in EC at 
the protected site. In other words, levels of active JNK at the protected site were similar in 
wild-type and JNK1 knockout mice, and this corresponded with similar expression levels of 
pro-apoptotic molecules. 
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Figure 51: Role of JNK1 in RIP1 and caspase-3 expression in murine aortic arch 
 
 
 
RIP1 (1-2) and pro-caspase-3 (3-4) expression levels were assessed in the susceptible and 
protected regions of the aorta of JNK1
-/-
 mice (n=4). RIP1 and pro-caspase-3 were detected 
by en face staining using anti-RIP1 and anti-pro-caspase-3 antibodies and AlexaFluor568-
conjugated secondary antibodies (red) followed by confocal microscopy. EC were identified 
by co-staining with anti-CD31 antibodies conjugated to AlexaFluor488 (green). Cell nuclei 
were identified using Draq5 (purple). Representative images are shown. 
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JNK1 delineated the spatial distribution of caspase-3 activation in the arterial tree 
 
Having established higher levels of pro-caspase-3 in the susceptible site of wild type mice, I 
went on to examine whether JNK1 regulates caspase-3 activation at the susceptible site by 
studying EC in aortae of wild-type, JNK1 knockout and MKP1 knockout mice. MKP-1 is a 
negative regulator of JNK that inactivates it by dephosphorylation. Our group has shown that 
higher levels of MKP-1 in the protected region of the murine arch are responsible for the very 
low levels of phosphorylated JNK at this site
189
. 
 
I observed by en face staining that the cleaved, activated form of caspase-3 was barely 
detectable in untreated wild-type mice (Figure 51, 1). I did however observe that cleavage of 
caspase-3 was induced at the susceptible site when these mice were stimulated with LPS; a 
known pro-inflammatory and pro-apoptotic stimulus (Figure 51, 2, 4). Genetic deletion of 
JNK1 protected EC at the susceptible site from caspase-3 activation (Figure 51, 4, 6), 
indicating that JNK1 is required for caspase-3 activation in EC at this region. 
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Figure 52: Spatial distribution of caspase-3 activation is regulated by JNK1 and MKP-1 
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Cleaved caspase-3 expression levels were assessed in the susceptible and protected regions of 
the aorta of wild type, JNK1
-/-
 and MKP-1
-/-
 mice (n=4). Cleaved caspase-3 were detected by 
en face staining using anti-caspase-3 antibodies and AlexaFluor568-conjugated secondary 
antibodies (red) followed by confocal microscopy. EC were identified by co-staining with 
anti-CD31 antibodies conjugated to AlexaFluor488 (green). Cell nuclei were identified using 
Draq5 (purple). Representative images are shown (A) and levels of cleaved caspase-3 were 
quantified by measuring fluorescence from multiple cells (>50) in susceptible and protected 
regions of treated or untreated mice (B). Mean fluorescence intensities are shown with 
standard deviations. Differences between samples were analysed using an unpaired t-test.  
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MKP-1 suppressed caspase-3 activation in the protected site 
 
I also studied the activation of caspase-3 at the protected region. I found that caspase-3 was 
not activated in EC at that site either in untreated or LPS treated mice (Figure 52, 3). Because 
MKP-1 suppresses JNK activation at this region, I examined whether MKP-1 was required 
for the suppression of caspase-3 activation in EC at this site.  
 
Thus I measured the levels of cleaved activated caspase-3 in the protected region of MKP-1 
knockout and wild-type mice. Genetic deletion of MKP-1 enhanced caspase-3 activation in 
response to LPS at the protected site (Figure 53, 3, 7). My data are consistent with the 
hypothesis that MKP-1 reduces apoptosis at the protected site by inhibiting JNK, supporting a 
cytoprotective role for MKP-1 in the murine aortic arch. 
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JNK1 activity contributed to the spatial distribution of EC apoptosis in the arterial tree 
 
Caspase-3 activation leads to DNA fragmentation and apoptosis. This functional outcome 
was assessed in EC by detecting DNA fragmentation using TUNEL staining. The TUNEL 
reagent used to detect DNA fragmentation was conjugated to FITC. Thus to ensure no 
overlay of excitation and/or emission wavelengths between the fluorescent markers used for 
TUNEL and co-staining of EC, I refrained from using Alexafluor-488 conjugated anti-
CD31antibodies to detect EC. Instead I used Phycoerythrin (better known as PE) conjugated 
anti-CD31 antibodies to detect EC. However a draw-back of using this labelling molecule is 
that it bleaches very quickly. I therefore also used Rhodamine bound Griffonia lectin to stain 
the endothelial layer which is a documented endothelial marker for en face staining
225
. Thus 
to ensure that apoptotic cells were of endothelial origin, I performed 2 series of experiments 
in which EC were co-stained using either Griffonia lectin (Figure 53A) or anti-CD31 
antibodies (Figure 53B). 
 
I observed no TUNEL-positive nuclei in EC at the susceptible site in untreated wild-type 
mice (Figure 53A, 2). However LPS treatment led to detectable levels of apoptosis at this site 
(Figure 53C, compare panels 2 and 4). Thus JNK phosphorylation, enhanced expression of 
pro-apoptotic proteins and caspase-3 activity correlates with EC apoptosis at the susceptible 
site. 
 
Genetic deletion of JNK1 suppressed DNA fragmentation at the susceptible site in response 
to LPS (Figure 53A-B, 4, 6). These data suggest that although JNK1 regulates constitutive 
expression of pro-apoptotic proteins at the susceptible site, it is not sufficient to induce EC 
apoptosis. However, EC in this region are primed for apoptosis in response to LPS through a 
JNK1-dependent mechanism.  
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Figure 53: Spatial distribution of EC apoptosis is regulated by JNK1 and MKP-1 
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DNA fragmentation in EC was measured by TUNEL staining (green) of susceptible and 
protected regions of the aorta in wild-type, JNK1
-/-
, or MKP-1
-/-
 mice that were either treated 
with LPS (intraperitoneal injection; 4 mg/kg for 6 hours) or remained untreated (n=4). EC 
were detected by counterstaining using (A) Griffonia lectin-rhodamine or (B) anti-CD31 
antibodies conjugated to AlexaFluor488 (red), and nuclei were also counterstained (purple). 
Apoptotic EC, characterized by TUNEL staining colocalized with fragmented nuclei, were 
quantified in multiple fields of view. Representative images (A&B) and the proportion of 
TUNEL-positive EC were quantified (mean±SD) as shown (C). Differences between samples 
were analysed using a chi squared test. 
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Role of MKP-1 in apoptosis at the protected region 
 
In wild-type animals, EC at the protected site were resistant to the induction of apoptosis by 
LPS (Figure 53A, panel 3). I examined whether this could be attributed to the higher levels of 
MKP-1 in the protected site compared to the susceptible site
189
.  
 
I observed that genetic deletion of MKP-1 enhanced DNA fragmentation in response to LPS 
in EC at the protected site (Figure 53B, compare panels 3 and 7); indicating MKP-1 is 
required for the maintenance of EC viability in this region. I did not observe any change in 
levels of apoptosis in the susceptible region of the MKP-1 knockout, which is consistent with 
our previous observation that MKP1 is not expressed at this site
189
.  
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Role of JNK1 in EC turnover in the arterial tree 
 
To examine whether apoptosis at the susceptible site is associated with EC proliferation, I 
measured the expression of Ki-67 protein (a marker of proliferation) by en face staining. Ki-
67–positive EC nuclei were detected at a low rate at the susceptible site in untreated mice but 
could be induced at this region by LPS (Figure 54A, compare panels 2 and 4). I then went on 
to assess the protected site which did not express Ki-67 constitutively and was relatively 
resistant to Ki-67 induction by LPS (Figure 54A, compare panels 3 and 4). Genetic deletion 
of JNK1 suppressed Ki-67 expression at the susceptible site (Figure 54A, compare panels 4 
and 6), indicating that JNK1 is required for EC proliferation at this region.  
 
Thus, I conclude that JNK1 activation enhances EC turnover at the susceptible site by 
positively regulating apoptosis and proliferation. 
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Figure 54: Spatial distribution of endothelial proliferation is regulated by JNK1 
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The expression of Ki-67 was detected by en face staining using anti-Ki-67 antibodies and 
AlexaFluor568-conjugated secondary antibodies (red) in the susceptible and protected 
regions of the aorta in wild-type or JNK1
-/-
 mice that were either treated with LPS 
(intraperitoneal injection; 4 mg/kg for 6 hours) or remained untreated (n=3). EC were 
identified by co-staining with anti-CD31 antibodies conjugated to AlexaFluor488 (green). 
Cell nuclei were identified using Draq5 (purple). (A) Representative images are shown. (B) 
Levels of Ki-67 were quantified by measuring fluorescence from multiple cells (>50) in 
susceptible and protected regions of mice. Mean fluorescence intensities are shown with 
standard deviations. Differences between samples were analysed using an unpaired t-test.  
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CONCLUSIONS 
 
 Elevated JNK activity correlated with enhanced expression of RIP1 and pro-caspase-3 
at the susceptible site. 
 JNK1 is essential for the constitutive expression of RIP1 and pro-caspase-3 in the 
susceptible region. 
 JNK1 is required for caspase-3 activation in EC at the susceptible region. 
 MKP-1 reduces caspase-3 activation at the protected site by inhibiting JNK. 
 EC in the susceptible region are primed for apoptosis in response to LPS through a 
JNK1-dependent mechanism. 
 MKP-1 is required for the maintenance of EC viability in the atheroprotected region. 
 JNK1 activation enhances EC turnover at the susceptible site by positively regulating 
apoptosis and proliferation. 
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DISCUSSION 
 
The physiology of EC varies considerably according to their location in the arterial tree. EC 
at atherosusceptible sites are characterized by enhanced pro-inflammatory activation and 
higher rates of injury and turnover compared to EC at atheroprotected sites. Thus, their 
phenotype enhances the accessibility of the vessel wall to leukocytes and lipoproteins, which 
are key drivers of atherogenesis. Injury of the vascular endothelium can arise through several 
processes, including apoptosis. During my studies, I demonstrated for the first time, to my 
knowledge, that EC at atherosusceptible sites are primed for apoptosis in response to a 
noxious stimulus, whereas EC at atheroprotected sites are resistant. This principle was proven 
using a model noxious agent, LPS, and it will be important in future studies to examine 
whether EC at atheroprone sites are primed for apoptosis in response to other proatherogenic 
molecules such as oxidized low-density lipoproteins and during early atherogenesis.  
 
En face staining of the murine aorta revealed that JNK positively regulates the basal 
expression of pro-caspase-3 and RIP1 at an atherosusceptible site but not at a protected site. 
Although pro-apoptotic proteins were expressed at enhanced levels at susceptible sites, EC 
apoptosis was not detected in untreated animals. However, EC apoptosis was induced 
specifically at the susceptible site in wild-type animals by LPS through a JNK1-dependent 
mechanism. Thus JNK1 governs the spatial distribution of EC apoptosis in the arterial tree.  
 
The mechanism of JNK1-dependent apoptosis at the susceptible site remains uncertain. My 
studies using cultured EC revealed that JNK regulates the expression of pro-apoptotic 
transcripts and my studies of the mouse aorta showed that JNK1 enhances expression of RIP1 
and pro-caspase-3. My studies collectively support the concept that JNK1 may prime EC for 
apoptosis through transcriptional activation of pro-apoptotic genes, however, further work is 
necessary to confirm this. Although this is the first evidence to my knowledge that EC can be 
primed for apoptosis by elevated expression of pro-apoptotic proteins, an analogous 
mechanism has been described for the induction of apoptosis in T lymphocytes in response to 
T-cell receptor signaling, which upregulates pro-caspase-3 at a transcriptional level
226
. In 
addition to the induction of pro-apoptotic transcripts, JNK1 can regulate apoptosis by 
alternative mechanisms (see Figure 55), including cleavage of Bid (a member of the Bcl2 
family) into jBid, which alters mitochondrial permeability to release the pro-apoptotic factor 
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Smac/Diablo, which activates the initiator caspase-8
108
, and by activation of the E3 ubiquitin 
ligase Itch, which ubiquitinates the cytoprotective protein c-FLIP, leading to its 
degradation
109
. Therefore, it is plausible that JNK1 regulates EC apoptosis at susceptible sites 
through mechanisms that operate at both transcriptional and non-transcriptional levels. One 
way to distinguish between the transcriptional and non-transcriptional mechanisms, albeit 
indirectly, would be to study the role of downstream transcription factors e.g. c-jun in 
regulating EC apoptosis. Thus it would be interesting to test whether EC apoptosis is 
modulated by genetic deletion of c-jun in mice. 
 
  
~ 189 ~ 
 
Figure 55: Mechanisms for JNK-dependent apoptosis 
 
 
 
Schematic illustrating the literature supporting the role of JNK in apoptosis. Abbreviations: c-
FLIP, cellular FLICE-like inhibitory protein; c-jun, transcription factor downstream of JNK; 
FADD, Fas-associated death domain; FasL, Fas-ligand; IAP-1, inhibitor of apoptosis protein-
1; Itch, E3 ubiquitin protein ligase; p53, transcription factor; Smac/DIABLO, Second 
mitochondria-derived activator of caspase/direct inhibitor
 
of apoptosis-binding protein with 
low pI; TRADD, TNF receptor 1-associated death domain. 
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My study also revealed that EC at atherosusceptible sites were primed for proliferation in 
response to LPS via a JNK1-dependent mechanism. Although it is plausible that JNK1 
influences EC proliferation directly, a previous study suggested that JNK is a negative 
regulator of EC division. Instead, I suggest that JNK1 may influence proliferation indirectly 
by driving EC apoptosis, which in turn causes neighbouring EC to proliferate because of loss 
of EC–EC contact inhibition. Thus, increased EC proliferation may compensate for EC loss 
attributable to apoptosis and provide an important repair mechanism at atherosusceptible 
sites. Nevertheless, EC turnover is likely to influence atherosclerosis by causing transient, 
local loss of EC, which may increase the accessibility of the artery wall to lipoproteins and 
inflammatory cells. 
 
I observed that EC at the atheroprotected site were resistant to the induction of apoptosis and 
proliferation by LPS. The underlying mechanism is likely to involve blood flow, which varies 
in magnitude and direction according to vascular anatomy and alters the physiology of 
endothelial cells. The application of unidirectional laminar flow (mimicking atheroprotective 
conditions) can suppress JNK activity, apoptosis, and proliferation in cultured EC, whereas 
the application of disturbed flow (mimicking atheroprone conditions) can have the opposite 
effects. Here, I demonstrate that suppression of EC apoptosis at the atheroprotected site relies 
on MKP-1, a negative regulator of JNK that is induced by unidirectional laminar flow in 
cultured EC and is preferentially expressed by EC in the atheroprotected region. Thus, my 
novel findings suggest that local hemodynamics maintain EC viability and reduce EC 
turnover at atheroprotected sites by inducing persistent expression of MKP-1, which 
inactivates JNK and suppresses pro-apoptotic signaling pathways.   
 
In summary, differential activation of JNK1 delineates the spatial variation in pro-apoptotic 
gene and protein expression, apoptosis, and turnover in arterial EC, and may govern the 
spatial distribution of atherosclerotic plaques. This study has implications for the therapeutic 
targeting of JNK1 to suppress vascular injury. 
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CHAPTER 6: DISCUSSION 
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MAIN CONCLUSIONS 
 
 JNK is activated in a region of the arterial tree that is exposed to low shear and is 
susceptible to atherosclerosis. 
 qPCR and microarray analyses reveal that JNK positively regulates the basal 
expression of pro-apoptotic molecules (e.g. RIP1, pro-caspase-3, TLR4, CARD6). 
  Enhanced pro-caspase-3 and RIP1 expression correlates with elevated JNK activation 
in the atherosusceptible area. 
  EC at the susceptible site are primed for apoptosis in response to LPS. Knockout 
studies reveal that JNK1 is necessary. 
  EC at the protected site are resistant to apoptosis in response to LPS. Knockout 
studies reveal that MKP-1, a negative regulator of JNK, is necessary for protection. 
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DISCUSSION  
 
Atherosclerosis is characterised by the accumulation of cells, lipids and extracellular matrix 
in artery walls which can result in occlusion of the vessel lumen and cause heart attack or 
stroke. EC play a critical role in vascular homeostasis by regulating the influx of leukocytes 
and lipoproteins from the circulation to the vascular wall and by maintaining an anti-
thrombotic environment. The corollary is that endothelial apoptosis or injury may initiate 
atherosclerosis by elevating the permeability of arteries to lipoproteins and leukocytes
190, 227-
230
 and reviewed in 
231
. In addition, the stability of established lesions is also governed by 
endothelial function. Thus focal endothelial apoptosis/injury in atherosclerotic lesions can in 
turn lead to endothelial denudation and exposure of a pro-coagulant vascular wall, a major 
cause of coronary thrombosis
232
.  
 
Several pro-atherogenic agents are known to trigger EC apoptosis including oxidised low 
density lipoproteins (oxLDL)
233, 234
, reactive oxygen intermediaries (e.g. H2O2)
204, 235
 and 
pro-inflammatory mediators (e.g. LPS
5, 105
, TNFα108, 205). Studies using cultured cells have 
revealed that JNK is involved in the induction of apoptosis by each of these noxious agents
5, 
105, 108, 204, 205, 234, 235
. JNK drives apoptosis through several mechanisms as highlighted in 
Figure 55 (Chapter 5 Discussion). It is involved in the cleavage of Bid (a member of the Bcl-
2 family) into jBid which alters mitochondrial permeability to release the pro-apoptotic factor 
Smac/Diablo which activates caspase-8
108
. JNK activation also regulates the phosphorylation 
of the E3 ubiquitin ligase Itch which ubiquitinates the cytoprotective protein c-FLIP leading 
to its degradation
109
 and activates the transcription factor c-jun, which induces numerous pro-
apoptotic role in apoptosis by activating several downstream effectors that trigger DNA 
fragmentation and other hallmarks of apoptotic cell death
236
. 
 
Transcriptional programmes regulated by JNK in EC 
 
I investigated the function of JNK in cultured EC in the presence or absence of a specific 
pharmacological inhibitor with and without TNFα treatment using a genomics platform 
followed by functional annotation. This approach and subsequent validation by gene 
silencing confirmed previous reports that JNK positively regulates the induction of pro-
inflammatory transcripts
4, 218
 which influence atherosclerosis by regulating the recruitment of 
leukocytes to the vessel wall. I also found that JNK regulates transcriptional programs that 
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belong to several other functional groups, including proliferation, apoptosis, and cell 
signaling.  
 
I demonstrated for the first time to my knowledge that JNK positively regulates endothelial 
expression of TLR4, bone morphogenetic protein (BMP) 4, and RIP1, which are molecules 
known to trigger dual pro-inflammatory and pro-apoptotic/necrotic signaling pathways
237-239
. 
TLR4, a component of the innate immune system, has been implicated in atherosclerosis 
because its expression in EC is enhanced in atherosclerotic lesions
240
, a polymorphism that 
attenuates TLR4 activity is associated with a decreased risk of atherosclerosis in humans
241
 
and TLR4 signaling in EC can be activated by oxidized low-density lipoprotein
242
 which is 
known to accumulate in plaques. BMP4 may also contribute to EC activation and apoptosis 
during atherogenesis because its expression in EC is greatly increased at atherosusceptible 
sites compared to protected sites
237
. In addition, RIP1 may influence numerous physiological 
activities in EC, including proliferation, activation, and viability by signaling downstream 
from TNF receptors
239, 243
. My finding that JNK regulates the expression of numerous pro-
apoptotic molecules in EC is consistent with previous observations that JNK can activate pro-
apoptotic signaling pathways
108, 109
 and induce pro-apoptotic transcripts by activating the 
transcription factor c-jun
244, 245
. 
 
My work suggests that JNK regulates the basal expression of numerous molecules that 
possess diverse physiological functions in both quiescent and TNFα-treated EC. An 
advantage of unbiased approaches such as arrays is that they can generate new ideas and 
hypotheses and can open up new lines of research. My array data suggests that JNK regulated 
diverse functions in EC. Further work needs to be carried out to validate hits in other 
functional groups such as cell signaling, post-translational modification, etc to distinguish 
between true hits and false positive transcripts. Thus quantitative RT-PCR should be used to 
validate putative JNK-dependent mRNAs in independent experiments where JNK in inhibited 
using either pharmacological agents or using siRNA. In addition, the effects of genetic 
deletion of JNK isoforms on the expression of putative JNK-dependent molecules should 
now be studied using knockout mice. 
 
During the microarray analysis, I observed that pro-apoptotic RIP1 and caspase-3 transcript 
levels were regulated by JNK in EC. My studies involving JNK1 specific siRNA which 
suppressed the expression of JNK1 but did not influence JNK2 showed significantly reduced 
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expression of RIP1 and caspase-3 message. To establish whether this was through the JNK1-
c-jun signaling pathway, I used c-jun specific siRNA which also led to significant reduction 
in RIP1 and caspase-3 levels suggesting that JNK1-c-jun signaling positively regulates the 
transcription of these molecules in cultured EC. A next step to test whether these genes are 
controlled by c-jun at a transcriptional level would be to carry out bioinformatics analysis to 
examine whether their promoters contain putative AP-1 binding sites. There is relatively little 
known about the regulatory elements that control RIP1 or caspase-3 promoter activities. Liu 
et al identified a cluster of Sp-1 elements and an Ets-like element on the rat caspase-3 gene 
and also performed homology analysis to reveal a predicted promoter for human caspase-3 
with 61.8% identity with the known rat promoter
246
, however I have also identified several 
putative AP-1 binding sites (unpublished). Future studies should use chromatin 
immunoprecipitation (ChIP) assays to examine whether c-jun can interact with putative AP-1 
sites on the caspase-3 promoter. In addition, to prove that JNK1‒c-jun regulates RIP1 and 
caspase-3at a transcriptional level, reporter gene studies could be carried out to examine 
whether JNK or c-jun influence RIP1 or caspase-3 promoter activities 
 
JNK1 regulates EC turnover at atherosusceptible sites 
 
En face staining of wild-type and JNK1 knockout murine aorta supported my in vitro studies 
by revealing higher levels of pro-apoptotic molecules RIP1 and pro-caspase-3 in the low 
shear,  atherosusceptible site
189
. In my studies, elevated pro-apoptotic protein expression was 
not sufficient to induce apoptosis at the low shear, susceptible site in untreated animals. 
However EC apoptosis was induced at the low shear, susceptible site of wild-type animals in 
response to LPS through a JNK1-dependent mechanism. Also, levels of a proliferative 
marker Ki-67 were increased in the low shear, susceptible region of the wild-types in 
response to LPS but genetic deletion of JNK1 suppressed this LPS induced expression. Thus 
my novel finding is that JNK1 activation by LPS enhances EC turnover at the low shear, 
susceptible region by positively regulating apoptosis and proliferation. 
 
My findings are consistent with a previous study by Wang et al
247
 that correlated JNK 
activity with the expression of pro-apoptotic proteins and apoptosis in vivo. Here, JNK 
activation, expression of Bax (a pro-apoptotic member of the Bcl-2 family) and apoptosis was 
elevated in livers of rats on a high fat diet (HFD) compared to those fed control diet (CD).  
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Based on my data, I propose a model (Figure 56) which suggests that JNK1 elevates RIP1 
and pro-caspase-3 expression at a transcriptional level via c-jun. Thus elevated activity of 
JNK at low shear, atherosusceptible sites leads to elevated expression of pro-apoptotic 
proteins which primes EC for apoptosis in response to noxious agents. I also propose that EC 
apoptosis leads to enhanced proliferation due to the loss of EC-EC contacts. My model also 
suggests that persistent EC expression of MKP-1, a negative regulator of JNK, suppresses 
JNK-c-jun-dependent apoptosis in the high shear, protected site. 
 
To test my model and examine whether pro-apoptotic molecules are regulated through the 
JNK1-c-jun axis it would be necessary to look at the expression levels of RIP1 and pro-
caspase-3 in c-jun knockout mice and compare the data to wild-type and JNK1 knockouts. 
Based on the JNK1 specific and c-jun specific siRNA data, I would predict to see a similar 
pattern of pro-apoptotic protein expression in the c-jun and JNK1 knockouts i.e. reduced 
expression at atheroprone sites. My model also predicts that EC apoptosis in response to 
noxious agents would be reduced in c-jun knockout mice. 
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Figure 56: JNK1 modulates EC turnover by regulating apoptosis and proliferation 
 
 
 
Abbreviations: CARD6, caspase recruitment domain family member 6; FasL, Fas ligand; 
LPS, lipopolysaccharide; MKP-1, MAP kinase phosphatase 1; RIP1, receptor-interacting 
protein-1; VCAM-1, vascular cell adhesion molecule-1.  
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Apoptosis and cell proliferation are linked by cell-cycle regulators and apoptotic stimuli that 
affect both processes. Thus the fate of a cell is likely to be determined by the interplay of 
these signals ensuring a proper cellular response
248
. In my model (Figure 56), I suggest that 
apoptosis leads to compensatory proliferation due to loss of EC and consequently, lack of 
contact inhibition between cells. However, the converse situation is also plausible i.e. that 
elevated proliferation may drive apoptosis through anoikis
249
. To address whether apoptosis 
induces compensatory proliferation it would be useful to look at the effects of inhibiting 
apoptosis on the expression levels of Ki-67 or other proliferative markers such as 
proliferating cell nuclear antigen (PCNA) and mini-chromosome maintenance complex 6 
(MCM6) involved in genome replication
250, 251
. This could be achieved using various caspase 
inhibitors (a pan caspase inhibitor; Z-VAD-FMK, a selective caspase-3 inhibitor; M826
252
) to 
block apoptosis. Genetic approaches to block EC apoptosis are difficult because conditional 
deletion of caspases in EC is lethal
253, 254
, therefore this approach would require the 
development of conditional inducible knockouts so that caspase-3, for example, could be 
deleted from EC in adult mice. 
 
The relationship between shear stress, JNK activation and EC apoptosis 
 
My data correlated JNK-dependent apoptosis with low, oscillatory shear stress but have not 
revealed a causal relationship. It will therefore be important in future studies to use in vitro 
and in vivo models to study the shear-induced molecular mechanisms underlying the spatial 
distribution of EC apoptosis in the arteries. My findings suggest that the balance between 
JNK1 and MKP-1 activities differs between low shear, susceptible and high shear, protected 
sites and that this balance is a critical determinant of the spatial distribution of EC apoptosis 
in the arterial tree. It would be useful to study the effects of oscillatory shear on cultured EC 
and examine whether it has a priming effect on EC leading to apoptosis by activating JNK1 
which induces pro-apoptotic proteins. In contrast, cultured EC subjected to high 
unidirectional shear would be expected to be protected from apoptosis via induction of MKP-
1 which suppresses JNK (Figure 56). Thus it would be useful to determine whether activation 
of JNK1 is required for the induction of apoptosis by low/oscillatory shear stress in cultured 
EC, and conversely whether suppression of JNK1 by MKP-1 is necessary for the anti-
apoptotic effects of laminar shear stress.  
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To directly assess the role of shear stress in this pathway in vivo, it would useful to use a 
carotid cuff model to generate regions of high shear stress, low shear stress and oscillatory 
shear stress within the same stretch of mouse carotid artery
181
. Using such an approach, one 
could study JNK1 activation levels in the three distinct shear stress regions and then identify 
the percentage of EC apoptosis occurring at the different sites along with the expression 
levels of proliferative markers. It would be particularly informative to study the effects of 
shear stress on JNK activation and EC apoptosis in hypercholesterolemia using 
atherosusceptible mice (LDLR
-/-
). 
 
Does JNK1-dependent apoptosis influence EC permeability? 
 
Previous literature
227, 255
 and more recent studies
190
 suggest that higher EC turnover in the 
porcine aorta is associated with enhanced permeability. My observations suggest that EC 
apoptosis and proliferation occurred preferentially at the low shear, atherosusceptible site of 
the murine aorta. It would be interesting in future studies to examine whether this elevated 
EC turnover contributes to vascular permeability, the localization of inflammation and 
subsequent lesion formation at sites of disturbed flow. Thus to link my findings with the 
initiation of atherosclerosis at susceptible sites, it would be informative to examine whether 
TUNEL-positive apoptotic and Ki-67 positive proliferative EC correlate with hot-spots of 
enhanced vascular permeability. This could be tested by modifying an assay of vascular 
permeability to Evans Blue dye that has been established in rabbits and mice by Prof P. 
Weinberg, Department of Bioengineering; Imperial College London. If a correlation is 
established between TUNEL positive EC and enhanced permeability (as proposed in Figure 
57 below), the next question that should be addressed is whether a JNK1 knockout or a 
caspase inhibitor can reduce vascular permeability. The role of JNK1 can be assessed by 
using JNK1 knockout mice, and to understand the role of caspase-3 in generating 
permeability hot-spots it would be advisable to block the enzyme using specific or broad 
spectrum inhibitors.  
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Figure 57: Proposed spatial distribution of vascular permeability 
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The role of JNK in atherosclerosis 
 
My observation that JNK1 regulates EC apoptosis at atherosusceptible sites suggests that this 
molecule may play a role in the initiation of atherosclerosis, possibly by enhancing the 
permeability of the artery wall to lipoproteins and leukocytes. A recent study examined the 
role of JNK1 and JNK2 in atherogenesis using JNK1
-/-
/ApoE
-/-
 and JNK2
-/-
/ApoE
-/-
 double 
knockouts. It revealed that genetic deletion of JNK2, but not JNK1, suppressed uptake of 
modified low-density lipoprotein by macrophages and reduced lesion development after 
exposure of apolipoprotein E knockout mice to a high-fat diet
147
. Absence of JNK1 had little 
or no effect on atheroma formation compared to JNK2 deletion.  
 
Based on my data, JNK1 deletion protects against EC apoptosis in an LPS-treated mouse 
model. It could be that any protective effects of JNK1 genetic deletion may have been 
overwhelmed by the high atherogenic drive in the apolipoprotein E knockout model in the 
study conducted by Ricci et al. Thus, I suggest that further studies are required to examine 
the potential role of JNK1 in endothelial injury, lipid deposition, and vascular inflammation 
during early atherogenesis. However my in vivo experiments involving LPS were 
representative of a severe pro-inflammatory model which might be a better model for 
studying sepsis.  
 
Understanding of the molecular mechanisms in atherogenesis has been revolutionized by 
studies in transgenic and gene-targeted mice as they have allowed in vivo testing of 
hypotheses
113-116, 118, 120, 121, 153, 256
. Another approach could be to treat the mice with the 
pharmacological JNK inhibitor (CT536706) and study its effects on transcription and 
translation of pro-apoptotic molecules, without the drawbacks of using knockouts. Although 
it should be noted that studies in mice are limited by significant species differences compared 
with humans.  
 
As JNK1 acts a positive regulator of apoptosis, it may contribute to the spatial distribution of 
atherosclerosis. Thus I believe that JNK1 inhibitors may be have beneficial therapeutic 
effects by reducing inflammation and apoptosis at atherosusceptible sites. Curcumin is a 
dietary compound known for its antioxidant, anti-inflammatory and anti-carcinogenic 
properties
257
. Studies have reported curcumin to suppress the JNK pathway, possibly through 
AP-1 signaling
258
 and suppress chemotherapy-induced apoptosis in a time and concentration 
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dependent manner by inhibiting the generation
 
of reactive oxygen species (ROS) and the JNK 
pathway
259
. Thus the use of curcumin as a dietary supplement to inhibit apoptosis at 
atherosusceptible sites may be a therapeutic possibility. Another therapeutic strategy might be 
to induce negative regulators of JNK such as MKP-1 or Nrf2. As mentioned previously, 
MKP-1 is preferentially expressed by ECs in a high-shear, protected region of the mouse 
aorta and is required for the anti-inflammatory effects of shear stress. Thus, MKP-1 induction 
at the susceptible site may lead to a reduction in lesion formation
189
. This could be achieved 
by treatment with dexamethasone
260
; however the side-effects of long-term steroid treatment 
preclude its use in this setting. Alternatively, strategies could be aimed at inducing an anti-
oxidant transcription factor called Nrf2. 
 
Nrf2 prevents ECs at the atheroprotected
 
site from exhibiting a pro-inflammatory state via the 
suppression
 
of VCAM-1 expression. Zakkar et al showed that pharmacological activation of
 
Nrf2 using sulforaphane (a compound derived from broccoli and other green vegetables) 
reduces EC activation at atherosusceptible sites by inhibiting ROS
203
. The corollary is that 
diets rich in sulforaphane (or dietary supplementation using this compound) could provide a 
therapeutic strategy to prevent or reduce atherosclerosis by inhibiting EC apoptosis. 
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Appendix 1: Tissue culture medium (A) and buffers (B) 
(A) 
Medium Ingredients 
Growth medium M199, 200mM L-glutamine, 20% FCS, 100U/ml penicillin G, 
100μg/ml streptomycin, 30μg/ml ECGF and 100U/ml heparin 
Basal medium M199, 200mM L-glutamine, 20% FCS, 100U/ml penicillin G, 
100μg/ml streptomycin 
Transfection medium M199, 20% FCS, 200mM L-glutamine, 30μg/ml ECGF and 
100U/ml heparin. 
Transport medium 
(HUVEC) 
gentamycin (1:100) and sodium pyruvate (1:100) dissolved in 
HBSS
with
 
Transport medium 
(PAEC) 
gentamycin (1:100), fungizone (1:100) and sodium pyruvate (1:100) 
dissolved in HBSS
with
 
(B) 
Buffers Ingredients 
HBSS
w/o
  Hanks balanced salt solution without calcium and magnesium 
(Sigma) 
HBSS
with
  Hanks balanced salt solution with calcium and magnesium (Sigma) 
PBS pH 7.0  Phosphate buffered saline (Invitrogen) 
 
Appendix 2: Western blotting buffers and reagents 
Buffer Ingredients  
RIPA lysis buffer 
 
150mM NaCl, 1.0% Igepal CA‐630, 0.5% sodium deoxycholate, 
0.1% SDS, 50mM Tris, pH 8.0 (Sigma). 
Tris Buffered Saline 
(TBS) 
1x 140mM NaCl, 20mM Tris, p.H 7.6 with HCl. (Invitrogen) 
Wash buffer (TBS-T) 1x TBS, 0.1% Tween20   
Dilution buffer (TBS-T) 1x TBS, 0.1% Tween20 
Blocking buffer 1xTBS, 0.1% Tween20, 5% BSA; or 1xTBS, 0.1% Tween20, 5% 
non-fat dry milk. 
Loading buffer Sample Buffer NuPAGE® LDS Sample Buffer 1x (Invitrogen) + 
DTT 100mM (Sigma) 
Transfer Buffer  NuPAGE Transfer Buffer (20x) + NuPAGE Antioxidant 
(Invitrogen) 
Marker  (SeeBlue Plus2®) (Invitrogen) 
Running buffer NuPAGE MOPS SDS Running Buffer (for Bis-Tris Gels only) 
(20x) (Invitrogen) 
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Appendix 3: En face reagents 
 
En face Ingredients 
Fixative 4% Formalin 
Blocking buffer 1x PBS, 0.1% Tween 20, 20% serum (depending on secondary 
antibody 
Dilution buffer 1x PBS, 0.1% Tween 20 
Wash buffer 1x PBS, 0.1% Tween 20 
 
Appendix 4: TUNEL reagents 
 
TUNEL reagents Ingredients 
4% Paraformaldehyde  
(PFA) 
40g PFA in RNase free PBS 
Blocking solution 3% H2O2 in methanol 
Permeabilization buffer 1x PBS, 0.1% triton  
TUNEL solution  TUNEL reagent + label solution (1:10 dilution) (Roche) 
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Appendix 5: Total RNA: Nanodrop readout (A) and Bioanalyzer traces (B) 
A) 
Condition OD260/280 
Concentration 
(ng/μl) 
HUVEC Isolate 1 
Sample 1 2.10 561.6 
Sample 2 2.12 432.7 
Sample 3 2.11 541.9 
Sample 4 2.11 544.4 
Sample 5 2.10 569.4 
Sample 6 2.09 587.8 
Sample 7 2.11 539.3 
Sample 8 2.11 433.4 
HUVEC Isolate 2 
Sample 1 2.09 655.7 
Sample 2 2.09 669.8 
Sample 3 2.09 622.8 
Sample 4 2.22 469.1 
Sample 5 2.13 518.0 
Sample 6 2.12 505.2 
Sample 7 2.19 268.8 
Sample 8 2.15 360.3 
HUVEC Isolate 3 
Sample 1 2.15 547.7 
Sample 2 2.16 503.9 
Sample 3 2.10 457.7 
Sample 4 2.12 341.6 
Sample 5 2.11 427.2 
Sample 6 2.10 439.6 
Sample 7 2.11 399.2 
Sample 8 2.12 375.4 
B)  
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Appendix 6: Unfragmented (A) and fragmented (B) cDNA Bioanalyzer traces 
  
A)
 
 
B) 
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Appendix 7: TNFα-induced transcripts 
p<0.05 
No. 
Primary 
sequence 
name 
Accession no. Sequence description 
Fold 
Change 
1.  FBXL3 NM_012158 F-box and leucine-rich repeat protein 3 1.23 
2.     1.27 
3.  MARCKS NM_002356 myristoylated alanine-rich protein kinase C substrate 1.28 
4.  ZFP36L1 X79067 zinc finger protein 36, C3H type-like 1 1.29 
5.  GOLPH3 AK128510 golgi phosphoprotein 3 (coat-protein) 1.29 
6.  BAZ1A BC020636 bromodomain adjacent to zinc finger domain, 1A 1.32 
7.  COTL1 AK127352 coactosin-like 1 (Dictyostelium) 1.34 
8.  GJC1 AK124339 gap junction protein, gamma 1, 45kDa 1.34 
9.  HLA-B M16102 major histocompatibility complex, class I, B 1.35 
10.  KBTBD2 AB040922 kelch repeat and BTB (POZ) domain containing 2 1.35 
11.  SNTB2 NM_006750 
syntrophin, beta 2 (dystrophin-associated protein A1, 
59kDa, basic component 2) 
1.35 
12.     1.35 
13.  ITSN2 AK091859 intersectin 2 1.35 
14.     1.35 
15.  RELT AK074128 RELT tumor necrosis factor receptor 1.36 
16.  BRPF3 AK123574 bromodomain and PHD finger containing, 3 1.36 
17.  MSX1 NM_002448 msh homeobox 1 1.36 
18.  MT1L BC070351 metallothionein 1L (gene/pseudogene) 1.36 
19.  PPP2R1B NM_002716 
protein phosphatase 2 (formerly 2A), regulatory subunit 
A, beta isoform 
1.37 
20.  EIF2C2 AY077717 eukaryotic translation initiation factor 2C, 2 1.38 
21.  ROBO1 AF040990 
roundabout, axon guidance receptor, homolog 1 
(Drosophila) 
1.38 
22.  WTAP AK127822 Wilms tumor 1 associated protein 1.39 
23.  FAM65A BC041086 family with sequence similarity 65, member A 1.39 
24.  CDV3 BC007338 CDV3 homolog (mouse) 1.40 
25.  HLA-B U88407 major histocompatibility complex, class I, B 1.40 
26.  PPP1R15B NM_032833 
protein phosphatase 1, regulatory (inhibitor) subunit 
15B 
1.40 
27.  PPAP2B AF480883 phosphatidic acid phosphatase type 2B 1.41 
28.  MT2A BC007034 metallothionein 2A 1.41 
29.  MAP2K3 AK093838 mitogen-activated protein kinase kinase 3 1.41 
30.     1.42 
31.  WTAP AK127822 Wilms tumor 1 associated protein 1.42 
32.  HLA-B U88407 major histocompatibility complex, class I, B 1.42 
33.  CITED4 NM_133467 
Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 4 
1.42 
34.  RAP1B NM_015646 RAP1B, member of RAS oncogene family 1.42 
35.     1.42 
36.  C5orf24 AK094881 chromosome 5 open reading frame 24 1.43 
37.  SLFN5 BC021238 schlafen family member 5 1.43 
38.  MT1E BC062734 metallothionein 1E 1.43 
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39.  KLF3 BC051687 Kruppel-like factor 3 (basic) 1.43 
40.  MT1DP AF348999 metallothionein 1D (pseudogene) 1.44 
41.     1.45 
42.  STK4 BC005231 serine/threonine kinase 4 1.45 
43.  LOC401805 XR_017148 hypothetical gene supported by NM_144726 1.45 
44.  WDR51B AK123106 WD repeat domain 51B 1.45 
45.  PRKCD Z22521 protein kinase C, delta 1.46 
46.  SNN NM_003498 stannin 1.46 
47.  CREB3 U88528 cAMP responsive element binding protein 3 1.46 
48.  DNAJA1 AY186741 DnaJ (Hsp40) homolog, subfamily A, member 1 1.46 
49.  ZFPM2 AL389989 zinc finger protein, multitype 2 1.48 
50.     1.48 
51.  RELL1 NM_001085399 RELT-like 1 1.48 
52.     1.49 
53.     1.49 
54.  RHOB NM_004040 ras homolog gene family, member B 1.49 
55.  RAPH1 AB053311 
Ras association (RalGDS/AF-6) and pleckstrin 
homology domains 1 
1.49 
56.  B4GALT5 NM_004776 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 5 
1.50 
57.  MT1X BC053882 metallothionein 1X 1.50 
58.  KIAA0701 BC003391 KIAA0701 protein 1.50 
59.  EFNB1 NM_004429 ephrin-B1 1.51 
60.  CDGAP AK026689 Cdc42 GTPase-activating protein 1.51 
61.  ZBTB5 NM_014872 zinc finger and BTB domain containing 5 1.52 
62.  MT2A NM_005953 metallothionein 2A 1.53 
63.  SERPINB8 NM_002640 
serpin peptidase inhibitor, clade B (ovalbumin), 
member 8 
1.53 
64.     1.55 
65.  MT1G BC035287 metallothionein 1G 1.55 
66.  BTN2A2 BC014021 butyrophilin, subfamily 2, member A2 1.55 
67.  SCYL1BP1 BC064945 SCY1-like 1 binding protein 1 1.56 
68.  SLC31A2 AK131546 
solute carrier family 31 (copper transporters), member 
2 
1.56 
69.  CLEC1A AY358587 C-type lectin domain family 1, member A 1.56 
70.  VPS37A AL834189 vacuolar protein sorting 37 homolog A (S. cerevisiae) 1.56 
71.  SLC25A32 NM_030780 solute carrier family 25, member 32 1.57 
72.  ELL2 BX538289 elongation factor, RNA polymerase II, 2 1.57 
73.  FOSL2 BX647822 FOS-like antigen 2 1.57 
74.  IER5 AJ251089 immediate early response 5 1.57 
75.  NINJ1 AK094530 ninjurin 1 1.57 
76.     1.57 
77.  CD83 NM_004233 CD83 molecule 1.58 
78.  FMNL3 NM_175736 formin-like 3 1.59 
79.  GBP1 NM_002053 
guanylate binding protein 1, interferon-inducible, 
67kDa 
1.59 
80.   AK130041 Homo sapiens cDNA FLJ26531 fis, clone KDN08812. 1.59 
81.     1.59 
82.  PNPLA8 AK024335 patatin-like phospholipase domain containing 8 1.59 
83.  WDR48 NM_020839 WD repeat domain 48 1.60 
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84.  BCL3 NM_005178 B-cell CLL/lymphoma 3 1.60 
85.  MAP3K8 Z14138 mitogen-activated protein kinase kinase kinase 8 1.60 
86.  CLIP2 NM_003388 CAP-GLY domain containing linker protein 2 1.61 
87.  ZC3H7B AK225891 zinc finger CCCH-type containing 7B 1.61 
88.  SEC24A BC019341 SEC24 related gene family, member A (S. cerevisiae) 1.61 
89.  HINT3 AJ420577 histidine triad nucleotide binding protein 3 1.62 
90.  NFKBIB AB209784 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, beta 
1.63 
91.     1.63 
92.  SMAD3 AK026690 SMAD family member 3 1.64 
93.  LRIG1 BC071561 
leucine-rich repeats and immunoglobulin-like domains 
1 
1.65 
94.     1.66 
95.  MTB AF348994 metallothionein B 1.67 
96.  BIRC2 BC028578 baculoviral IAP repeat-containing 2 1.69 
97.  B4GALT1 BC045773 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
1.69 
98.  RAINB1 AB063115 retinoic acid inducible in neuroblastoma 1.70 
99.  IFNGR2 NM_005534 
interferon gamma receptor 2 (interferon gamma 
transducer 1) 
1.70 
100.    1.70 
101. ZSWIM4 NM_023072 zinc finger, SWIM-type containing 4 1.71 
102. FSTL3 NM_005860 follistatin-like 3 (secreted glycoprotein) 1.73 
103. STAT5A NM_003152 signal transducer and activator of transcription 5A 1.74 
104. FAM148A NM_207322 family with sequence similarity 148, member A 1.74 
105. SQRDL AK130140 sulfide quinone reductase-like (yeast) 1.75 
106. BMP2 NM_001200 bone morphogenetic protein 2 1.76 
107. STX11 NM_003764 syntaxin 11 1.77 
108. HIVEP1 NM_002114 
human immunodeficiency virus type I enhancer binding 
protein 1 
1.78 
109. FAM129A AK095547 family with sequence similarity 129, member A 1.79 
110. GBP3 AK001823 guanylate binding protein 3 1.80 
111. KLF7 BX537890 Kruppel-like factor 7 (ubiquitous) 1.80 
112. GOLPH3L NM_018178 golgi phosphoprotein 3-like 1.80 
113. PSTPIP2 AK023100 
proline-serine-threonine phosphatase interacting protein 
2 
1.81 
114.    1.81 
115. S100A3 NM_002960 S100 calcium binding protein A3 1.82 
116. OTUD4 NM_199324 OTU domain containing 4 1.82 
117.    1.82 
118. CDC14A DQ530256 
CDC14 cell division cycle 14 homolog A (S. 
cerevisiae) 
1.82 
119. HERPUD1 BC009739 
homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 
1.84 
120. DNAJB9 AF093824 DnaJ (Hsp40) homolog, subfamily B, member 9 1.88 
121. RAPGEF5 D87467 Rap guanine nucleotide exchange factor (GEF) 5 1.90 
122. LYPD6 BC032836 LY6/PLAUR domain containing 6 1.91 
123. MMD NM_012329 monocyte to macrophage differentiation-associated 1.93 
124. MAP3K7IP2 NM_015093 
mitogen-activated protein kinase kinase kinase 7 
interacting protein 2 
1.98 
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125. HSPB8 AF133207 heat shock 22kDa protein 8 1.99 
126. CCRN4L BC077723 
CCR4 carbon catabolite repression 4-like (S. 
cerevisiae) 
2.01 
127. APOL3 AK025349 apolipoprotein L, 3 2.01 
128. CNKSR3 AY328894 CNKSR family member 3 2.02 
129. FAM148B NM_001007595 family with sequence similarity 148, member B 2.04 
130. IFNGR1 AK127636 interferon gamma receptor 1 2.05 
131. NFKBIE AK130739 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, epsilon 
2.06 
132. CSF2RB BC070085 
colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage) 
2.06 
133.    2.07 
134. NRIP1 NM_003489 nuclear receptor interacting protein 1 2.08 
135. DTX3L BX648267 deltex 3-like (Drosophila) 2.12 
136. ELL2 NM_012081 elongation factor, RNA polymerase II, 2 2.16 
137. SLC12A7 NM_006598 
solute carrier family 12 (potassium/chloride 
transporters), member 7 
2.19 
138. SAV1 AL833378 salvador homolog 1 (Drosophila) 2.19 
139. TNFAIP1 NM_021137 
tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
2.20 
140. SLC2A6 AK096630 
solute carrier family 2 (facilitated glucose transporter), 
member 6 
2.21 
141. CD200 NM_001004196 CD200 molecule 2.21 
142. CYLD AK024212 cylindromatosis (turban tumor syndrome) 2.27 
143. IFIH1 BC046208 interferon induced with helicase C domain 1 2.27 
144. JHDM1D NM_030647 
jumonji C domain-containing histone demethylase 1 
homolog D (S. cerevisiae) 
2.28 
145. TNFAIP8 AF099936 tumor necrosis factor, alpha-induced protein 8 2.32 
146. SDC4 NM_002999 syndecan 4 2.34 
147. PARP14 DQ063585 poly (ADP-ribose) polymerase family, member 14 2.37 
148. ETS1 BX640634 
v-ets erythroblastosis virus E26 oncogene homolog 1 
(avian) 
2.38 
149. CXCR7 BC036661 chemokine (C-X-C motif) receptor 7 2.39 
150. TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
2.43 
151. TNIP1 BC014008 TNFAIP3 interacting protein 1 2.43 
152. TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
2.43 
153. TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
2.43 
154. BCL2A1 BC016281 BCL2-related protein A1 2.45 
155. IL7R NM_002185 interleukin 7 receptor 2.49 
156. JUNB NM_002229 jun B proto-oncogene 2.51 
157. RELB NM_006509 
v-rel reticuloendotheliosis viral oncogene homolog B, 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 3 (avian) 
2.51 
158. EFNA1 BC095432 ephrin-A1 2.64 
159. RIPK2 NM_003821 receptor-interacting serine-threonine kinase 2 2.66 
160. NUAK2 BX537564 NUAK family, SNF1-like kinase, 2 2.70 
161. CSF1 M37435 colony stimulating factor 1 (macrophage) 2.79 
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162. CLEC2D BC019883 C-type lectin domain family 2, member D 2.80 
163. NFKB1 AK122850 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1 (p105) 
2.83 
164. ICOSLG AF199028 inducible T-cell co-stimulator ligand 2.84 
165. F3 BC011029 coagulation factor III (thromboplastin, tissue factor) 2.86 
166. NFKB2 X61499 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2 (p49/p100) 
2.90 
167. IRF1 AB103081 interferon regulatory factor 1 2.92 
168. IRAK2 NM_001570 interleukin-1 receptor-associated kinase 2 2.96 
169. CCL2 M26683 chemokine (C-C motif) ligand 2 3.02 
170. NFKBIA NM_020529 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, alpha 
3.20 
171. HIVEP2 NM_006734 
human immunodeficiency virus type I enhancer binding 
protein 2 
3.49 
172. TIFA NM_052864 
TRAF-interacting protein with a forkhead-associated 
domain 
3.87 
173. BIC NR_001458 Homo sapiens BIC transcript (BIC) on chromosome 21. 4.52 
174. SELE NM_000450 selectin E (endothelial adhesion molecule 1) 4.63 
175. CCL20 NM_004591 chemokine (C-C motif) ligand 20 5.03 
176. TNFAIP3 NM_006290 tumor necrosis factor, alpha-induced protein 3 5.47 
177. TNFAIP2 BC017818 tumor necrosis factor, alpha-induced protein 2 5.48 
178. IL18R1 AY192162 interleukin 18 receptor 1 5.55 
179. TRAF1 NM_005658 TNF receptor-associated factor 1 5.94 
180. CX3CL1 AB209037 chemokine (C-X3-C motif) ligand 1 6.01 
181. ICAM1 NM_000201 
intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor 
7.47 
182. VCAM1 NM_001078 vascular cell adhesion molecule 1 7.51 
183. BIRC3 NM_001165 baculoviral IAP repeat-containing 3 13.06 
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Appendix 8: JNK dependent TNFα-induced transcripts 
p<0.05 
No. 
Primary 
Sequence 
Name 
Accession no. Sequence Description 
Fold 
Change 
1.  DTX3L BX648267 deltex 3-like (Drosophila) -1.4 
2.  SLFN5 BC021238 schlafen family member 5 -1.3 
3.  DDX58 AK125989 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 -1.2 
4.  GBP1 NM_002053 guanylate binding protein 1, interferon-inducible, 67kDa -1.2 
5.  PARP14 DQ063585 poly (ADP-ribose) polymerase family, member 14 -1.2 
6.  LYSMD3 BC058027 
LysM, putative peptidoglycan-binding, domain 
containing 3 
-1.2 
7.  CDGAP AK026689 Cdc42 GTPase-activating protein -1.2 
8.  APOL3 AK025349 apolipoprotein L, 3 -1.2 
9.  STAT5A NM_003152 signal transducer and activator of transcription 5A -1.2 
10.  GOLPH3L NM_018178 golgi phosphoprotein 3-like -1.2 
11.  IRAK2 NM_001570 interleukin-1 receptor-associated kinase 2 -1.1 
12.  ZSWIM4 NM_023072 zinc finger, SWIM-type containing 4 -1.1 
13.  HYOU1 NM_006389 hypoxia up-regulated 1 -1.1 
14.     -1.1 
15.  APOL2 NM_030882 apolipoprotein L, 2 -1.1 
16.  FMNL3 NM_175736 formin-like 3 -1.1 
17.  IRGQ NM_001007561 immunity-related GTPase family, Q -1.1 
18.  CLEC2D BC019883 C-type lectin domain family 2, member D -1.1 
19.  GBP3 AK001823 guanylate binding protein 3 -1.1 
20.  UGDH NM_003359 UDP-glucose dehydrogenase -1.1 
21.  CREB3 U88528 cAMP responsive element binding protein 3 -1.1 
22.  ABCF1 BC016772 ATP-binding cassette, sub-family F (GCN20), member 1 -1.1 
23.  ZC3H7B AK225891 zinc finger CCCH-type containing 7B -1.1 
24.  ABCF1 BC016772 ATP-binding cassette, sub-family F (GCN20), member 1 -1.1 
25.  BTN2A2 BC014021 butyrophilin, subfamily 2, member A2 -1.1 
26.  ABCF1 BC016772 ATP-binding cassette, sub-family F (GCN20), member 1 -1.1 
27.  GFPT1 AF334737 glutamine-fructose-6-phosphate transaminase 1 -1.1 
28.  STAT6 AY615283 
signal transducer and activator of transcription 6, 
interleukin-4 induced 
-1.1 
29.  IFIH1 BC046208 interferon induced with helicase C domain 1 -1.1 
30.  ZC3H12C AK095101 zinc finger CCCH-type containing 12C -1.1 
31.  NDEL1 AK123802 
nudE nuclear distribution gene E homolog (A. nidulans)-
like 1 
-1.0 
32.  B4GALT5 NM_004776 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 5 
-1.0 
33.  SNN NM_003498 stannin -1.0 
34.  LYPD6 BC032836 LY6/PLAUR domain containing 6 -1.0 
35.  ROBO1 AF040990 
roundabout, axon guidance receptor, homolog 1 
(Drosophila) 
-1.0 
36.  RELA NM_021975 
v-rel reticuloendotheliosis viral oncogene homolog A, 
nuclear factor of kappa light polypeptide gene enhancer 
-1.0 
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in B-cells 3, p65 (avian) 
37.  KIAA0692 AK093451 KIAA0692 -1.0 
38.  ICOSLG AF199028 inducible T-cell co-stimulator ligand -1.0 
39.  RNF145 BX537635 ring finger protein 145 -1.0 
40.  TNFAIP1 NM_021137 
tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
-1.0 
41.  STX5 NM_003164 syntaxin 5 -1.0 
42.  CSF2RB BC070085 
colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage) 
-1.0 
43.  RANGAP1 BC041396 Ran GTPase activating protein 1 -1.0 
44.  RELL1 NM_001085399 RELT-like 1 -1.0 
45.  C5orf24 AK094881 chromosome 5 open reading frame 24 1.0 
46.  SLC31A2 AK131546 solute carrier family 31 (copper transporters), member 2 1.0 
47.  PPP2R1B NM_002716 
protein phosphatase 2 (formerly 2A), regulatory subunit 
A, beta isoform 
1.0 
48.  SLC7A1 NM_003045 
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 1 
1.0 
49.  EIF2C2 AY077717 eukaryotic translation initiation factor 2C, 2 1.0 
50.  OGFRL1 NM_024576 opioid growth factor receptor-like 1 1.0 
51.  SDCBP AK128645 syndecan binding protein (syntenin) 1.0 
52.  SDC4 NM_002999 syndecan 4 1.0 
53.  STK4 BC005231 serine/threonine kinase 4 1.0 
54.  CX3CL1 AB209037 chemokine (C-X3-C motif) ligand 1 1.0 
55.  TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
1.0 
56.  PITPNB NM_012399 phosphatidylinositol transfer protein, beta 1.0 
57.  XBP1 AK093842 X-box binding protein 1 1.0 
58.  TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
1.0 
59.  TAP1 AK123494 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
1.0 
60.   U12597 
Human tumor necrosis factor type 2 receptor associated 
protein (TRAP3) mRNA, complete cds. 
1.0 
61.  NFKBIB AB209784 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, beta 
1.1 
62.  INF2 NM_022489 inverted formin, FH2 and WH2 domain containing 1.1 
63.  CCDC93 NM_019044 coiled-coil domain containing 93 1.1 
64.  MT2A NM_005953 metallothionein 2A 1.1 
65.     1.1 
66.  SLC12A7 NM_006598 
solute carrier family 12 (potassium/chloride 
transporters), member 7 
1.1 
67.  SLC2A6 AK096630 
solute carrier family 2 (facilitated glucose transporter), 
member 6 
1.1 
68.  SLC41A2 NM_032148 solute carrier family 41, member 2 1.1 
69.  MARCKS NM_002356 myristoylated alanine-rich protein kinase C substrate 1.1 
70.  TRIP10 BC013002 thyroid hormone receptor interactor 10 1.1 
71.     1.1 
72.  CDV3 BC007338 CDV3 homolog (mouse) 1.1 
73.  C2CD2 BC062323 C2 calcium-dependent domain containing 2 1.1 
74.  SERPINB8 NM_002640 serpin peptidase inhibitor, clade B (ovalbumin), member 1.1 
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75.  SQLE NM_003129 squalene epoxidase 1.1 
76.   AK123998 
Homo sapiens cDNA FLJ42004 fis, clone 
SPLEN2030736. 
1.1 
77.   X75315 H.sapiens seb4B mRNA. 1.1 
78.  WASF2 BC012329 WAS protein family, member 2 1.1 
79.  MFHAS1 NM_004225 malignant fibrous histiocytoma amplified sequence 1 1.1 
80.     1.1 
81.  TRAF1 NM_005658 TNF receptor-associated factor 1 1.1 
82.  SQRDL AK130140 sulfide quinone reductase-like (yeast) 1.1 
83.  SLC25A32 NM_030780 solute carrier family 25, member 32 1.2 
84.  SCYL1BP1 BC064945 SCY1-like 1 binding protein 1 1.2 
85.  BTG3 NM_006806 BTG family, member 3 1.2 
86.  VPS37A AL834189 vacuolar protein sorting 37 homolog A (S. cerevisiae) 1.2 
87.  NOTCH2 BC071562 Notch homolog 2 (Drosophila) 1.2 
88.  MT2A BC007034 metallothionein 2A 1.2 
89.  NFKB2 X61499 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 2 (p49/p100) 
1.2 
90.  NFKBIE AK130739 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells inhibitor, epsilon 
1.2 
91.     1.2 
92.  MT1G BC035287 metallothionein 1G 1.2 
93.  WTAP AK127822 Wilms tumor 1 associated protein 1.2 
94.  SRGAP1 AK023899 SLIT-ROBO Rho GTPase activating protein 1 1.2 
95.  EHD1 AF099011 EH-domain containing 1 1.2 
96.  RELB NM_006509 
v-rel reticuloendotheliosis viral oncogene homolog B, 
nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 3 (avian) 
1.2 
97.  MAP3K8 Z14138 mitogen-activated protein kinase kinase kinase 8 1.2 
98.  STX6 BC039118 syntaxin 6 1.2 
99.     1.2 
100. GRAMD3 NM_023927 GRAM domain containing 3 1.3 
101. CLEC1A AY358587 C-type lectin domain family 1, member A 1.3 
102. RAINB1 AB063115 retinoic acid inducible in neuroblastoma 1.3 
103. IL18R1 AY192162 interleukin 18 receptor 1 1.3 
104. BIC NR_001458 Homo sapiens BIC transcript (BIC) on chromosome 21. 1.3 
105. ZFPM2 AL389989 zinc finger protein, multitype 2 1.3 
106. SAV1 AL833378 salvador homolog 1 (Drosophila) 1.3 
107. IFNGR1 AK127636 interferon gamma receptor 1 1.3 
108. MTE AF348997 metallothionein E 1.3 
109. IFNGR2 NM_005534 
interferon gamma receptor 2 (interferon gamma 
transducer 1) 
1.3 
110. HERPUD1 BC009739 
homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 
1.3 
111. ALCAM AK054632 activated leukocyte cell adhesion molecule 1.3 
112. ICAM1 NM_000201 
intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor 
1.3 
113. ZNF71 NM_021216 zinc finger protein 71 1.3 
114. BMP2 NM_001200 bone morphogenetic protein 2 1.4 
115. FOSL2 BX647822 FOS-like antigen 2 1.4 
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116. BCL3 NM_005178 B-cell CLL/lymphoma 3 1.4 
117. FSTL3 NM_005860 follistatin-like 3 (secreted glycoprotein) 1.4 
118. SGK AK055077 serum/glucocorticoid regulated kinase 1.4 
119. B4GALT1 BC045773 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 1 
1.4 
120. ITSN2 AK091859 intersectin 2 1.4 
121. CYLD AK024212 cylindromatosis (turban tumor syndrome) 1.4 
122. NRIP1 NM_003489 nuclear receptor interacting protein 1 1.5 
123. RNF19B BC020595 ring finger protein 19B 1.5 
124. JHDM1D NM_030647 
jumonji C domain-containing histone demethylase 1 
homolog D (S. cerevisiae) 
1.5 
125. CD83 NM_004233 CD83 molecule 1.5 
126. PPAP2B AF480883 phosphatidic acid phosphatase type 2B 1.6 
127. RAPGEF5 D87467 Rap guanine nucleotide exchange factor (GEF) 5 1.6 
128. SIN3A BC066364 SIN3 homolog A, transcription regulator (yeast) 1.6 
129. MAP3K7IP2 NM_015093 
mitogen-activated protein kinase kinase kinase 7 
interacting protein 2 
1.6 
130. TANK BC067779 TRAF family member-associated NFKB activator 1.7 
131. HSPB8 AF133207 heat shock 22kDa protein 8 1.7 
132. HIVEP1 NM_002114 
human immunodeficiency virus type I enhancer binding 
protein 1 
1.7 
133. KLF7 BX537890 Kruppel-like factor 7 (ubiquitous) 1.7 
134. CDC14A DQ530256 CDC14 cell division cycle 14 homolog A (S. cerevisiae) 1.7 
135. KLF3 BC051687 Kruppel-like factor 3 (basic) 1.8 
136. IRF1 AB103081 interferon regulatory factor 1 2.0 
137.    2.2 
 
 
  
~ 217 ~ 
 
Appendix 9: Constitutively JNK regulated transcripts 
p<0.05 
No. 
Primary sequence 
name 
Accession no. Sequence description 
Fold 
change 
1.  GIMAP8 NM_175571 GTPase, IMAP family member 8 -8.7 
2.  PPP1R10 NM_002714 
protein phosphatase 1, regulatory (inhibitor) 
subunit 10 
-6.4 
3.  PPP1R10 NM_002714 
protein phosphatase 1, regulatory (inhibitor) 
subunit 10 
-6.4 
4.  PPP1R10 NM_002714 
protein phosphatase 1, regulatory (inhibitor) 
subunit 10 
-6.4 
5.  ZFP62 AK091376 zinc finger protein 62 homolog (mouse) -5.7 
6.  HERPUD1 BC009739 
homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like 
domain member 1 
-5.2 
7.     -5.1 
8.  C1orf103 AK001826 chromosome 1 open reading frame 103 -5.1 
9.  C10orf26 NM_017787 chromosome 10 open reading frame 26 -5.0 
10.  HEY2 NM_012259 
hairy/enhancer-of-split related with YRPW 
motif 2 
-4.8 
11.  GIMAP2 NM_015660 GTPase, IMAP family member 2 -4.7 
12.  KIAA1729 BC040874 KIAA1729 protein -4.6 
13.  ZNF551 BC041615 zinc finger protein 551 -4.6 
14.  KRCC1 NM_016618 lysine-rich coiled-coil 1 -4.5 
15.     -4.5 
16.  PRICKLE1 AK122881 prickle homolog 1 (Drosophila) -4.4 
17.  ART4 AY829437 
ADP-ribosyltransferase 4 (Dombrock blood 
group) 
-4.3 
18.  NUFIP2 NM_020772 
nuclear fragile X mental retardation protein 
interacting protein 2 
-4.1 
19.  C10orf10 NM_007021 chromosome 10 open reading frame 10 -4.0 
20.  ZNF627 BX537936 Zinc finger protein 627 -4.0 
21.   AB007865 Homo sapiens KIAA0405 mRNA, partial cds. -3.9 
22.     -3.7 
23.  ZNF146 NM_007145 zinc finger protein 146 -3.7 
24.  ZNF623 NM_014789 zinc finger protein 623 -3.7 
25.  ZNF302 AF265236 zinc finger protein 302 -3.6 
26.  SSH2 AB072358 slingshot homolog 2 (Drosophila) -3.6 
27.  ZNF175 BC007778 zinc finger protein 175 -3.5 
28.  TTC4 AK090964 tetratricopeptide repeat domain 4 -3.5 
29.     -3.5 
30.  RNF19A BC062676 ring finger protein 19A -3.5 
31.  FAM130A1 NM_030809 
family with sequence similarity 130, member 
A1 
-3.5 
32.  ESCO1 NM_052911 
establishment of cohesion 1 homolog 1 (S. 
cerevisiae) 
-3.5 
33.  NFX1 U15306 nuclear transcription factor, X-box binding 1 -3.4 
34.  FLJ38359 AK095678 hypothetical protein FLJ38359 -3.4 
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35.  RNF111 AK131304 ring finger protein 111 -3.4 
36.     -3.4 
37.  EFNB2 NM_004093 ephrin-B2 -3.3 
38.  TRIM27 BC066924 tripartite motif-containing 27 -3.3 
39.  PNRC2 NM_017761 proline-rich nuclear receptor coactivator 2 -3.3 
40.  PNRC2 NM_017761 proline-rich nuclear receptor coactivator 2 -3.3 
41.  TRIM27 BC066924 tripartite motif-containing 27 -3.3 
42.  GJA5 NM_005266 gap junction protein, alpha 5, 40kDa -3.2 
43.  KIAA0040 AL049799 KIAA0040 -3.2 
44.  LYSMD3 BC058027 
LysM, putative peptidoglycan-binding, 
domain containing 3 
-3.2 
45.     -3.2 
46.  FANCF NM_022725 Fanconi anemia, complementation group F -3.1 
47.  ORC5L NM_002553 
origin recognition complex, subunit 5-like 
(yeast) 
-3.1 
48.  C1orf25 AK131460 chromosome 1 open reading frame 25 -3.1 
49.  IL1A NM_000575 interleukin 1, alpha -3.1 
50.  ZNF542 NR_003127 
Homo sapiens zinc finger protein 542 
(ZNF542) on chromosome 19. 
-3.1 
51.  RAD17 BX537441 RAD17 homolog (S. pombe) -3.0 
52.  CCNF NM_001761 cyclin F -3.0 
53.  ERCC4 BC142631 
excision repair cross-complementing rodent 
repair deficiency, complementation group 4 
-3.0 
54.  ZNF525 AK098804 zinc finger protein 525 -3.0 
55.  ZNF587 AF294842 zinc finger protein 587 -3.0 
56.     -3.0 
57.  MEIS1 BC036511 Meis homeobox 1 -2.9 
58.  CARD6 AY196783 caspase recruitment domain family, member 6 -2.9 
59.  ZBED5 BC038508 zinc finger, BED-type containing 5 -2.9 
60.  C7orf49 AK026103 chromosome 7 open reading frame 49 -2.9 
61.  JMJD2A NM_014663 jumonji domain containing 2A -2.9 
62.  PIK3R1 BC094795 
phosphoinositide-3-kinase, regulatory subunit 
1 (p85 alpha) 
-2.9 
63.  TLR4 U88880 toll-like receptor 4 -2.9 
64.     -2.9 
65.  NAPE-PLD NM_198990 
N-acyl-phosphatidylethanolamine-hydrolyzing 
phospholipase D 
-2.8 
66.  BMP4 D30751 bone morphogenetic protein 4 -2.8 
67.  RASGRP3 BX647990 
RAS guanyl releasing protein 3 (calcium and 
DAG-regulated) 
-2.8 
68.  C1orf163 BC015313 chromosome 1 open reading frame 163 -2.8 
69.  CREB1 X55545 cAMP responsive element binding protein 1 -2.8 
70.  TRIM68 NM_018073 tripartite motif-containing 68 -2.8 
71.  ZNF383 AK122892 zinc finger protein 383 -2.8 
72.  DHX32 BC068471 DEAH (Asp-Glu-Ala-His) box polypeptide 32 -2.8 
73.  C17orf39 BC000636 chromosome 17 open reading frame 39 -2.8 
74.  ZNF322A NM_024639 zinc finger protein 322A -2.7 
75.  ZNF234 AF228417 zinc finger protein 234 -2.7 
76.  PALMD AF262379 palmdelphin -2.7 
77.  CXCR4 NM_001008540 chemokine (C-X-C motif) receptor 4 -2.7 
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78.  ZNF561 AK122974 zinc finger protein 561 -2.7 
79.  PTPRE BC050062 protein tyrosine phosphatase, receptor type, E -2.7 
80.  WDR82 AK123860 WD repeat domain 82 -2.7 
81.  RIPK1 AJ420482 
receptor (TNFRSF)-interacting serine-
threonine kinase 1 
-2.7 
82.     -2.7 
83.     -2.7 
84.  RNF146 AJ420549 ring finger protein 146 -2.7 
85.     -2.7 
86.  KLHL9 AY172949 kelch-like 9 (Drosophila) -2.6 
87.  C22orf30 CT841517 chromosome 22 open reading frame 30 -2.6 
88.  DCP1B NM_152640 
DCP1 decapping enzyme homolog B (S. 
cerevisiae) 
-2.6 
89.  C17orf80 AY239293 chromosome 17 open reading frame 80 -2.6 
90.  ZNF187 NM_007151 Zinc finger protein 187 -2.6 
91.  SETX AK125448 senataxin -2.6 
92.  CDGAP AK026689 Cdc42 GTPase-activating protein -2.6 
93.  KIAA1826 NM_032424 KIAA1826 -2.6 
94.  ROS1 X51619 
v-ros UR2 sarcoma virus oncogene homolog 1 
(avian) 
-2.6 
95.   AK131567 
Homo sapiens cDNA FLJ16820 fis, clone 
TRACH3019290, moderately similar to Zinc 
finger protein 93. 
-2.6 
96.  RBAK NM_021163 RB-associated KRAB zinc finger -2.6 
97.  SCYL1BP1 BC064945 SCY1-like 1 binding protein 1 -2.5 
98.  FBXO28 AB007952 F-box protein 28 -2.5 
99.  ARHGEF2 BC020567 
rho/rac guanine nucleotide exchange factor 
(GEF) 2 
-2.5 
100. SMAD6 U59914 SMAD family member 6 -2.5 
101. ZMYM1 AK125741 zinc finger, MYM-type 1 -2.5 
102. RAPGEF5 D87467 
Rap guanine nucleotide exchange factor 
(GEF) 5 
-2.5 
103. MED8 NM_201542 mediator complex subunit 8 -2.5 
104. GPATCH1 AK091835 G patch domain containing 1 -2.5 
105. FLJ20696 AB046771 hypothetical protein FLJ20696 -2.5 
106. DIXDC1 BC128600 DIX domain containing 1 -2.5 
107. PDGFB BC077725 
platelet-derived growth factor beta 
polypeptide (simian sarcoma viral (v-sis) 
oncogene homolog) 
-2.5 
108. ZNF28 BC070146 zinc finger protein 28 -2.5 
109. ZNF480 BC065503 zinc finger protein 480 -2.5 
110. AASDH BC142709 aminoadipate-semialdehyde dehydrogenase -2.5 
111. CCDC55 BC016313 coiled-coil domain containing 55 -2.5 
112. XPC NM_004628 
xeroderma pigmentosum, complementation 
group C 
-2.5 
113. NSUN4 AK128066 NOL1/NOP2/Sun domain family, member 4 -2.5 
114. RAD17 BX537441 RAD17 homolog (S. pombe) -2.5 
115. GTPBP2 NM_019096 GTP binding protein 2 -2.4 
116.    -2.4 
117. ZKSCAN2 AK131342 zinc finger with KRAB and SCAN domains 2 -2.4 
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118. LARP5 NM_015155 
La ribonucleoprotein domain family, member 
5 
-2.4 
119. STARD13 AY082592 
StAR-related lipid transfer (START) domain 
containing 13 
-2.4 
120. DKK1 AF127563 dickkopf homolog 1 (Xenopus laevis) -2.4 
121.  AL834146 
Homo sapiens mRNA; cDNA 
DKFZp761F06121 (from clone 
DKFZp761F06121). 
-2.4 
122. TRAF6 NM_145803 TNF receptor-associated factor 6 -2.4 
123. BCL6B NM_181844 
B-cell CLL/lymphoma 6, member B (zinc 
finger protein) 
-2.4 
124.    -2.4 
125.    -2.4 
126. MEF2C AL833268 myocyte enhancer factor 2C -2.4 
127. RAB43 NM_198490 RAB43, member RAS oncogene family -2.4 
128. KRIT1 AF296765 KRIT1, ankyrin repeat containing -2.4 
129. ZNF518 BC030967 zinc finger protein 518 -2.4 
130. QRICH1 AK124205 glutamine-rich 1 -2.4 
131. EIF2C4 NM_017629 eukaryotic translation initiation factor 2C, 4 -2.4 
132. ETAA1 NM_019002 Ewing tumor-associated antigen 1 -2.4 
133. ZNF583 NM_152478 zinc finger protein 583 -2.4 
134. OTUD7B BX641079 OTU domain containing 7B -2.4 
135. C6orf203 AK091564 chromosome 6 open reading frame 203 -2.4 
136. GTPBP10 BC021573 GTP-binding protein 10 (putative) -2.4 
137. GON4L BC117557 gon-4-like (C. elegans) -2.4 
138. DNAJC14 AK057354 
DnaJ (Hsp40) homolog, subfamily C, member 
14 
-2.3 
139. FAM72A DQ786198 
Family with sequence similarity 72, member 
A 
-2.3 
140. FLJ11171 BX648660 hypothetical protein FLJ11171 -2.3 
141. CSTF1 NM_001033522 
cleavage stimulation factor, 3' pre-RNA, 
subunit 1, 50kDa 
-2.3 
142. RWDD2A NM_033411 RWD domain containing 2A -2.3 
143.    -2.3 
144. RND1 AK124288 Rho family GTPase 1 -2.3 
145. AP4B1 AK001045 
adaptor-related protein complex 4, beta 1 
subunit 
-2.3 
146. SMARCAD1 BC045534 
SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, subfamily 
a, containing DEAD/H box 1 
-2.3 
147. POGK AK093951 
pogo transposable element with KRAB 
domain 
-2.3 
148. GIMAP4 NM_018326 GTPase, IMAP family member 4 -2.3 
149. C5orf37 BC065750 chromosome 5 open reading frame 37 -2.3 
150. ZNF322A NM_024639 zinc finger protein 322A -2.3 
151. ZNF224 BC002889 zinc finger protein 224 -2.3 
152. ACTR8 BC032744 ARP8 actin-related protein 8 homolog (yeast) -2.3 
153. ARL6IP2 BC053508 
ADP-ribosylation factor-like 6 interacting 
protein 2 
-2.3 
154. ZNF780A AK131328 zinc finger protein 780A -2.3 
~ 221 ~ 
 
155. PHF23 AK122901 PHD finger protein 23 -2.3 
156. LOC285636 NM_175921 hypothetical protein LOC285636 -2.3 
157. SCYL3 NM_181093 SCY1-like 3 (S. cerevisiae) -2.3 
158. VPS18 NM_020857 
vacuolar protein sorting 18 homolog (S. 
cerevisiae) 
-2.3 
159. CDC42SE1 AF286592 CDC42 small effector 1 -2.3 
160. MIS12 AK056072 
MIS12, MIND kinetochore complex 
component, homolog (yeast) 
-2.3 
161. AKAP10 NM_007202 A kinase (PRKA) anchor protein 10 -2.3 
162. AP1GBP1 AK126988 AP1 gamma subunit binding protein 1 -2.3 
163. AHCTF1 AY157619 AT hook containing transcription factor 1 -2.3 
164. ZNF594 NM_032530 zinc finger protein 594 -2.3 
165. CSRP2BP AK023634 CSRP2 binding protein -2.2 
166. CCDC131 BC073843 coiled-coil domain containing 131 -2.2 
167. ST3GAL1 NM_003033 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 1 
-2.2 
168. PTPMT1 BC018974 protein tyrosine phosphatase, mitochondrial 1 -2.2 
169. FLJ10739 AL355736 hypothetical protein FLJ10739 -2.2 
170. RHOBTB1 BC032848 Rho-related BTB domain containing 1 -2.2 
171. BCAR1 AK124815 breast cancer anti-estrogen resistance 1 -2.2 
172. ZNF792 BC106043 zinc finger protein 792 -2.2 
173. ZNF713 BC094796 zinc finger protein 713 -2.2 
174. ZKSCAN5 BC030790 zinc finger with KRAB and SCAN domains 5 -2.2 
175. ZNF221 NM_013359 zinc finger protein 221 -2.2 
176. ZNF143 BC020219 zinc finger protein 143 -2.2 
177. MASTL AK123004 
microtubule associated serine/threonine 
kinase-like 
-2.2 
178. ZNF140 BC022291 zinc finger protein 140 -2.2 
179. BIN3 AK124486 bridging integrator 3 -2.2 
180. FLJ16287 BC011784 FLJ16287 protein -2.2 
181. RNF34 AK096994 ring finger protein 34 -2.2 
182. NAV3 BC017667 neuron navigator 3 -2.2 
183. ZNF791 NM_153358 zinc finger protein 791 -2.2 
184. ASXL2 NM_018263 additional sex combs like 2 (Drosophila) -2.2 
185. ZSCAN16 NM_025231 zinc finger and SCAN domain containing 16 -2.2 
186. BBS12 NM_152618 Bardet-Biedl syndrome 12 -2.2 
187. LCMT2 NM_014793 leucine carboxyl methyltransferase 2 -2.2 
188. UMPS NM_000373 
uridine monophosphate synthetase (orotate 
phosphoribosyl transferase and orotidine-5'-
decarboxylase) 
-2.2 
189. GRAP NM_006613 GRB2-related adaptor protein -2.2 
190. ARMCX1 NM_016608 armadillo repeat containing, X-linked 1 -2.2 
191.    -2.2 
192. FLJ31529 AK093979 hypothetical protein FLJ31529 -2.2 
193.  AK057718 
Homo sapiens cDNA FLJ33156 fis, clone 
UTERU2000377, weakly similar to 
PROBABLE PEPTIDYL-PROLYL CIS-
TRANS ISOMERASE C57A10.03 (EC 
5.2.1.8). 
-2.2 
194.  DQ658414 Homo sapiens microRNA miR-146a primary -2.2 
~ 222 ~ 
 
transcript, complete sequence. 
195. FAM122A NM_138333 family with sequence similarity 122A -2.2 
196. ZNF585B AK094989 zinc finger protein 585B -2.2 
197.    -2.2 
198. ASPM AY971957 
asp (abnormal spindle) homolog, 
microcephaly associated (Drosophila) 
-2.2 
199. IRF6 NM_006147 interferon regulatory factor 6 -2.1 
200. TRIP11 BC069008 thyroid hormone receptor interactor 11 -2.1 
201. BMP2 NM_001200 bone morphogenetic protein 2 -2.1 
202. ZNF521 NM_015461 zinc finger protein 521 -2.1 
203. GBA2 AF258662 glucosidase, beta (bile acid) 2 -2.1 
204. DCLRE1A NM_014881 
DNA cross-link repair 1A (PSO2 homolog, S. 
cerevisiae) 
-2.1 
205. NDC80 BC005239 
NDC80 homolog, kinetochore complex 
component (S. cerevisiae) 
-2.1 
206. ZNF486 BC027608 zinc finger protein 486 -2.1 
207.    -2.1 
208. TSPYL5 NM_033512 TSPY-like 5 -2.1 
209. MMAA NM_172250 
methylmalonic aciduria (cobalamin 
deficiency) cblA type 
-2.1 
210. C11orf46 BC047775 chromosome 11 open reading frame 46 -2.1 
211. TIGD2 NM_145715 tigger transposable element derived 2 -2.1 
212. C17orf42 BC024328 chromosome 17 open reading frame 42 -2.1 
213. SLC40A1 AF231121 
solute carrier family 40 (iron-regulated 
transporter), member 1 
-2.1 
214.    -2.1 
215. EXOSC3 AF229833 exosome component 3 -2.1 
216. ZBTB38 NM_001080412 zinc finger and BTB domain containing 38 -2.1 
217.  AK127794 
Homo sapiens cDNA FLJ45895 fis, clone 
OCBBF3023993. 
-2.1 
218.  AK126563 
Homo sapiens cDNA FLJ44600 fis, clone 
BLADE2007744. 
-2.1 
219. LOC642778 XR_016512 
similar to nuclear pore complex interacting 
protein 
-2.1 
220. GDF6 NM_001001557 growth differentiation factor 6 -2.1 
221. ZNF160 BC000807 zinc finger protein 160 -2.1 
222. ZNF770 BC035308 zinc finger protein 770 -2.1 
223. FAM39DP DQ786211 
Family with sequence similarity 39, member 
D pseudogene 
-2.1 
224. FAM72A DQ786198 
Family with sequence similarity 72, member 
A 
-2.1 
225. ZFP161 Y12726 zinc finger protein 161 homolog (mouse) -2.1 
226. CCDC77 NM_032358 coiled-coil domain containing 77 -2.1 
227. MEPCE AK055964 methylphosphate capping enzyme -2.1 
228. ERG M21535 
v-ets erythroblastosis virus E26 oncogene 
homolog (avian) 
-2.1 
229. C13orf7 AK098640 chromosome 13 open reading frame 7 -2.1 
230. PAPOLG AB209304 poly(A) polymerase gamma -2.1 
231. ZBTB40 AK095273 zinc finger and BTB domain containing 40 -2.1 
232. PRKD1 NM_002742 protein kinase D1 -2.1 
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233. GOSR1 BC012620 golgi SNAP receptor complex member 1 -2.1 
234.    -2.1 
235.  AK126511 
Homo sapiens cDNA FLJ44547 fis, clone 
UTERU3006228. 
-2.1 
236. NDST2 AB208870 
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 2 
-2.1 
237. ELK3 NM_005230 
ELK3, ETS-domain protein (SRF accessory 
protein 2) 
-2.1 
238. ARHGAP28 BC065274 Rho GTPase activating protein 28 -2.1 
239. MYNN AK092022 myoneurin -2.1 
240. ZNF766 BC109201 zinc finger protein 766 -2.1 
241.  AK021961 
Homo sapiens cDNA FLJ11899 fis, clone 
HEMBA1007327. 
-2.1 
242. DCBLD1 AK095973 
discoidin, CUB and LCCL domain containing 
1 
-2.1 
243. ZHX2 NM_014943 zinc fingers and homeoboxes 2 -2.1 
244. ANKRD46 BC050396 ankyrin repeat domain 46 -2.1 
245. RPP38 NM_183005 ribonuclease P/MRP 38kDa subunit -2.1 
246.    -2.1 
247. PSCD2 AK091443 
pleckstrin homology, Sec7 and coiled-coil 
domains 2 (cytohesin-2) 
-2.1 
248. C7orf38 AK024526 chromosome 7 open reading frame 38 -2.1 
249.    -2.1 
250. NCOA7 BC071782 nuclear receptor coactivator 7 -2.1 
251.  AK026936 
Homo sapiens cDNA: FLJ23283 fis, clone 
HEP08729, highly similar to AF006005 Homo 
sapiens zinc finger protein PLAGL2 mRNA. 
-2.1 
252. TNFRSF11B NM_002546 
tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
-2.1 
253. ZC3HC1 NM_016478 zinc finger, C3HC-type containing 1 -2.0 
254. ZNF3 AK091984 zinc finger protein 3 -2.0 
255. ABT1 NM_013375 activator of basal transcription 1 -2.0 
256. ZFP90 AK122847 zinc finger protein 90 homolog (mouse) -2.0 
257. TOP3B AK096695 topoisomerase (DNA) III beta -2.0 
258.    -2.0 
259. PALB2 NM_024675 partner and localizer of BRCA2 -2.0 
260. PDPK2 AJ785968 PDPK2 protein -2.0 
261. OFD1 BC099659 oral-facial-digital syndrome 1 -2.0 
262. KIF2A NM_004520 kinesin heavy chain member 2A -2.0 
263. TRIM24 NM_015905 tripartite motif-containing 24 -2.0 
264. DOPEY1 AK094766 dopey family member 1 -2.0 
265. ZNF346 AK026627 zinc finger protein 346 -2.0 
266. DUS2L AK000406 
dihydrouridine synthase 2-like, SMM1 
homolog (S. cerevisiae) 
-2.0 
267. METT5D1 NM_152636 methyltransferase 5 domain containing 1 -2.0 
268. RBM12B NM_203390 RNA binding motif protein 12B -2.0 
269. RSF1 AF227948 remodeling and spacing factor 1 -2.0 
270. LOC284371 AK131409 hypothetical protein LOC284371 -2.0 
271. FAM35A AK025471 family with sequence similarity 35, member A -2.0 
272. CRK NM_016823 v-crk sarcoma virus CT10 oncogene homolog -2.0 
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(avian) 
273. C11orf57 BC072455 chromosome 11 open reading frame 57 -2.0 
274. BBS10 AK027213 Bardet-Biedl syndrome 10 -2.0 
275. POLH AK122807 polymerase (DNA directed), eta -2.0 
276. ZNF295 AB190374 zinc finger protein 295 -2.0 
277.  AK023843 
Homo sapiens cDNA FLJ13781 fis, clone 
PLACE4000465. 
-2.0 
278.    -2.0 
279. PTPN9 NM_002833 
protein tyrosine phosphatase, non-receptor 
type 9 
-2.0 
280. CTF8 NM_001039690 
chromosome transmission fidelity factor 8 
homolog (S. cerevisiae) 
-2.0 
281. LIMD1 M80651 LIM domains containing 1 -2.0 
282. GNE NM_005476 
glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
-2.0 
283. KIF13A BC062673 kinesin family member 13A -2.0 
284. ZNF740 BC053557 zinc finger protein 740 -2.0 
285. IRAK1BP1 AK098678 
interleukin-1 receptor-associated kinase 1 
binding protein 1 
-2.0 
286. C11orf30 BC033404 chromosome 11 open reading frame 30 -2.0 
287.    -2.0 
288. NUDT12 NM_031438 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 12 
-2.0 
289. NEIL3 NM_018248 nei endonuclease VIII-like 3 (E. coli) -2.0 
290. COIL NM_004645 coilin -2.0 
291. TULP3 AF045583 tubby like protein 3 -2.0 
292. SSFA2 BC037334 sperm specific antigen 2 -2.0 
293. ZCCHC14 AL117532 zinc finger, CCHC domain containing 14 -2.0 
294.    -2.0 
295. BET1L AF234160 
blocked early in transport 1 homolog (S. 
cerevisiae)-like 
-2.0 
296.    -2.0 
297. MGC35361 BC029175 hypothetical MGC35361 -2.0 
298. SP1 NM_138473 Sp1 transcription factor -2.0 
299. ZKSCAN3 AK091225 zinc finger with KRAB and SCAN domains 3 -2.0 
300. FLJ36031 NM_175884 hypothetical protein FLJ36031 -2.0 
301. CHD8 AB046784 
chromodomain helicase DNA binding protein 
8 
-2.0 
302. FRMD8 BC033851 FERM domain containing 8 -2.0 
303. C19orf61 AK022948 chromosome 19 open reading frame 61 -2.0 
304. PRDM4 BC068562 PR domain containing 4 -2.0 
305. RSBN1L NM_198467 round spermatid basic protein 1-like -2.0 
306. STXBP3 NM_007269 syntaxin binding protein 3 -2.0 
307. THAP1 NM_018105 
THAP domain containing, apoptosis 
associated protein 1 
-2.0 
308. ZNF254 BC044906 zinc finger protein 254 -2.0 
309. S100PBP AK090711 S100P binding protein -2.0 
310.    -2.0 
311. C17orf71 BC031604 chromosome 17 open reading frame 71 -2.0 
312. ZNF382 BC038358 zinc finger protein 382 -2.0 
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313. GAB1 AK022142 GRB2-associated binding protein 1 -2.0 
314. PMM2 AB209659 phosphomannomutase 2 -2.0 
315. OXSM NM_017897 3-oxoacyl-ACP synthase, mitochondrial -2.0 
316. INTS2 NM_020748 integrator complex subunit 2 -2.0 
317. PHLDB1 AK125783 
pleckstrin homology-like domain, family B, 
member 1 
-2.0 
318. FAM118B NM_024556 
family with sequence similarity 118, member 
B 
-2.0 
319. ATAD5 NM_024857 ATPase family, AAA domain containing 5 -2.0 
320. BAZ1A BC020636 
bromodomain adjacent to zinc finger domain, 
1A 
-2.0 
321.  AK091026 
Homo sapiens cDNA FLJ33707 fis, clone 
BRAWH2007825. 
-2.0 
322. TRMT12 NM_017956 
tRNA methyltransferase 12 homolog (S. 
cerevisiae) 
-2.0 
323.    -2.0 
324. HARS2 NM_012208 
histidyl-tRNA synthetase 2, mitochondrial 
(putative) 
-2.0 
325. SH3BP4 BX648877 SH3-domain binding protein 4 -2.0 
326.    -2.0 
327. RNF214 NM_001077239 ring finger protein 214 -2.0 
328.    -2.0 
329. NCOA5 AF470686 nuclear receptor coactivator 5 -2.0 
330. VPS4B NM_004869 
vacuolar protein sorting 4 homolog B (S. 
cerevisiae) 
-1.9 
331. TMEM55B AL137727 transmembrane protein 55B -1.9 
332. PAFAH1B1 BX538346 
platelet-activating factor acetylhydrolase, 
isoform Ib, alpha subunit 45kDa 
-1.9 
333. PEX12 BC015751 peroxisomal biogenesis factor 12 -1.9 
334. TLR1 NM_003263 toll-like receptor 1 -1.9 
335. ETV6 NM_001987 ets variant gene 6 (TEL oncogene) -1.9 
336. POLR3A BC014399 
polymerase (RNA) III (DNA directed) 
polypeptide A, 155kDa 
-1.9 
337. URLC9 NM_018410 up-regulated in lung cancer 9 -1.9 
338. CSNK1D U29171 casein kinase 1, delta -1.9 
339. ZF6 U71363 zinc finger protein zfp6 -1.9 
340. TRIM32 NM_012210 tripartite motif-containing 32 -1.9 
341. INTS7 NM_015434 integrator complex subunit 7 -1.9 
342. SMAD1 U59912 SMAD family member 1 -1.9 
343. TMEM60 BC065930 transmembrane protein 60 -1.9 
344.    -1.9 
345. SLC7A11 NM_014331 
solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11 
-1.9 
346. NSUN3 BC018432 NOL1/NOP2/Sun domain family, member 3 -1.9 
347. DDX58 AK125989 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
58 
-1.9 
348. LOC399491 AK131085 LOC399491 protein -1.9 
349. CLEC14A AY606132 C-type lectin domain family 14, member A -1.9 
350. ZSCAN29 BC043612 zinc finger and SCAN domain containing 29 -1.9 
351. ZMYND8 BC146802 zinc finger, MYND-type containing 8 -1.9 
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352. UPF2 AF318574 
UPF2 regulator of nonsense transcripts 
homolog (yeast) 
-1.9 
353. SKIL X15217 SKI-like oncogene -1.9 
354. DKFZP564O0523 BC020919 hypothetical protein DKFZp564O0523 -1.9 
355.    -1.9 
356. HYLS1 AK127394 hydrolethalus syndrome 1 -1.9 
357. TFB1M NM_016020 transcription factor B1, mitochondrial -1.9 
358. SLFN5 BC021238 schlafen family member 5 -1.9 
359. DEPDC5 BX640828 DEP domain containing 5 -1.9 
360.    -1.9 
361. UBXD8 BC015791 UBX domain containing 8 -1.9 
362. SAP30BP AF450482 SAP30 binding protein -1.9 
363. LRRC8A NM_019594 
leucine rich repeat containing 8 family, 
member A 
-1.9 
364. ZNF813 BC071639 Zinc finger protein 813 -1.9 
365.    -1.9 
366. ELAC1 NM_018696 elaC homolog 1 (E. coli) -1.9 
367. TMEM186 BC015912 transmembrane protein 186 -1.9 
368. ZFYVE1 AF311602 zinc finger, FYVE domain containing 1 -1.9 
369. PATZ1 AY028384 
POZ (BTB) and AT hook containing zinc 
finger 1 
-1.9 
370. LOC402055 U63541 similar to SRR1-like protein -1.9 
371.    -1.9 
372. ZNF611 NM_030972 zinc finger protein 611 -1.9 
373. TRMT5 NM_020810 
TRM5 tRNA methyltransferase 5 homolog (S. 
cerevisiae) 
-1.9 
374. ZNFX1 BC110888 zinc finger, NFX1-type containing 1 -1.9 
375. BRWD1 BC031545 
bromodomain and WD repeat domain 
containing 1 
-1.9 
376. C13orf15 AK095079 chromosome 13 open reading frame 15 -1.9 
377. RBM34 D38491 RNA binding motif protein 34 -1.9 
378. DCUN1D5 NM_032299 
DCN1, defective in cullin neddylation 1, 
domain containing 5 (S. cerevisiae) 
-1.9 
379. BTRC BC027994 beta-transducin repeat containing -1.9 
380. TMEM115 NM_007024 transmembrane protein 115 -1.9 
381. TFCP2 U03494 transcription factor CP2 -1.9 
382. ZNF229 NM_014518 zinc finger protein 229 -1.9 
383. ZNF193 AY261373 zinc finger protein 193 -1.9 
384. PIK3R4 NM_014602 
phosphoinositide-3-kinase, regulatory subunit 
4, p150 
-1.9 
385. PPAPDC2 NM_203453 
phosphatidic acid phosphatase type 2 domain 
containing 2 
-1.9 
386. ZNF217 NM_006526 zinc finger protein 217 -1.9 
387. REXO4 NM_020385 
REX4, RNA exonuclease 4 homolog (S. 
cerevisiae) 
-1.9 
388. IREB2 BC017880 iron-responsive element binding protein 2 -1.9 
389. CDCA8 NM_018101 cell division cycle associated 8 -1.9 
390. SH3PXD2B BC038561 SH3 and PX domains 2B -1.9 
391. PTCD2 BC018720 pentatricopeptide repeat domain 2 -1.9 
392. EML1 AK023861 echinoderm microtubule associated protein -1.9 
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like 1 
393. BET1 BC012595 
blocked early in transport 1 homolog (S. 
cerevisiae) 
-1.9 
394. LDOC1L NM_032287 
leucine zipper, down-regulated in cancer 1-
like 
-1.9 
395. ZNF786 NM_152411 zinc finger protein 786 -1.9 
396.  S82362 
hRAR- beta 2=retinoic-acid-receptor 
beta/suspected tumor suppressor (5' region, 
transcription control region) [human, mRNA 
Partial, 1730 nt]. 
-1.9 
397. FAM26E NM_153711 family with sequence similarity 26, member E -1.9 
398. APEX2 NM_014481 
APEX nuclease (apurinic/apyrimidinic 
endonuclease) 2 
-1.9 
399. USP53 AK025301 ubiquitin specific peptidase 53 -1.9 
400.  BC063597 
Homo sapiens cDNA clone IMAGE:4754960, 
partial cds. 
-1.9 
401. KIAA0241 BC027724 KIAA0241 -1.9 
402. MORC2 NM_014941 MORC family CW-type zinc finger 2 -1.9 
403. ZNF619 NM_173656 zinc finger protein 619 -1.9 
404. TIMM9 AF150100 
translocase of inner mitochondrial membrane 
9 homolog (yeast) 
-1.9 
405. AFTPH AB073356 aftiphilin -1.9 
406. SETDB1 BC009362 SET domain, bifurcated 1 -1.9 
407. NPIP AK160377 nuclear pore complex interacting protein -1.9 
408. LOC63920 NM_022090 transposon-derived Buster3 transposase-like -1.9 
409. STK10 AK092814 serine/threonine kinase 10 -1.9 
410. KCTD7 BC042482 
potassium channel tetramerisation domain 
containing 7 
-1.9 
411. ARFGEF1 AK127799 
ADP-ribosylation factor guanine nucleotide-
exchange factor 1(brefeldin A-inhibited) 
-1.9 
412. TTC23 AK023001 tetratricopeptide repeat domain 23 -1.9 
413.    -1.9 
414. NPIP NM_006985 nuclear pore complex interacting protein -1.9 
415. DNMBP BC041628 dynamin binding protein -1.9 
416. FZR1 BC013413 
fizzy/cell division cycle 20 related 1 
(Drosophila) 
-1.9 
417. PRUNE NM_021222 prune homolog (Drosophila) -1.9 
418. OBFC2A AK023686 
oligonucleotide/oligosaccharide-binding fold 
containing 2A 
-1.9 
419. SETD4 BC036556 SET domain containing 4 -1.9 
420. JAGN1 NM_032492 jagunal homolog 1 (Drosophila) -1.9 
421. ZNF91 NM_003430 zinc finger protein 91 -1.9 
422.    -1.9 
423. ZNF223 AF187989 zinc finger protein 223 -1.9 
424. TNNI3K BC032865 TNNI3 interacting kinase -1.9 
425. SEMA6D BC150253 
sema domain, transmembrane domain (TM), 
and cytoplasmic domain, (semaphorin) 6D 
-1.9 
426.  AK091245 
Homo sapiens cDNA FLJ33926 fis, clone 
CTONG2017409. 
-1.9 
427. ZNF282 BC009542 zinc finger protein 282 -1.8 
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428. ZADH2 BC033780 
zinc binding alcohol dehydrogenase, domain 
containing 2 
-1.8 
429. C8orf41 BC066935 chromosome 8 open reading frame 41 -1.8 
430. IPPK AK123694 inositol 1,3,4,5,6-pentakisphosphate 2-kinase -1.8 
431. TOB2 BC028919 transducer of ERBB2, 2 -1.8 
432. C7orf26 BC005121 chromosome 7 open reading frame 26 -1.8 
433. HSZFP36 NM_001080493 ZFP-36 for a zinc finger protein -1.8 
434. DUSP18 BC028724 dual specificity phosphatase 18 -1.8 
435. FADD NM_003824 Fas (TNFRSF6)-associated via death domain -1.8 
436. NOX4 BC051371 NADPH oxidase 4 -1.8 
437. ZNF543 NM_213598 zinc finger protein 543 -1.8 
438.    -1.8 
439. ANGEL2 BC016966 angel homolog 2 (Drosophila) -1.8 
440. TP53INP1 NM_033285 tumor protein p53 inducible nuclear protein 1 -1.8 
441. ZNF287 BC041159 zinc finger protein 287 -1.8 
442. GABRE BC026337 
gamma-aminobutyric acid (GABA) A 
receptor, epsilon 
-1.8 
443. SPEN NM_015001 
spen homolog, transcriptional regulator 
(Drosophila) 
-1.8 
444. RASA1 BC020761 
RAS p21 protein activator (GTPase activating 
protein) 1 
-1.8 
445.  X55313 
H.sapiens TNF-R mRNA for tumor necrosis 
factor receptor type 1. 
-1.8 
446. DACH1 NM_080759 dachshund homolog 1 (Drosophila) -1.8 
447. LOC400581 BC060883 GRB2-related adaptor protein-like -1.8 
448. RBM23 NM_001077351 RNA binding motif protein 23 -1.8 
449. ANKRD27 NM_032139 ankyrin repeat domain 27 (VPS9 domain) -1.8 
450.  BC021961 
Homo sapiens cDNA clone IMAGE:3908832, 
complete cds. 
-1.8 
451. ZNF566 BX649070 zinc finger protein 566 -1.8 
452.  U09825 
Human acid finger protein mRNA, complete 
cds. 
-1.8 
453. ZIK1 BC103959 
zinc finger protein interacting with K protein 1 
homolog (mouse) 
-1.8 
454. LCA5 NM_181714 Leber congenital amaurosis 5 -1.8 
455. TBC1D10A AK127939 TBC1 domain family, member 10A -1.8 
456. ZNF436 NM_001077195 zinc finger protein 436 -1.8 
457. GEMIN4 AF177341 gem (nuclear organelle) associated protein 4 -1.8 
458. MKI67IP AB044971 
MKI67 (FHA domain) interacting nucleolar 
phosphoprotein 
-1.8 
459. ERCC6 AB209504 
excision repair cross-complementing rodent 
repair deficiency, complementation group 6 
-1.8 
460. SLC26A2 NM_000112 
solute carrier family 26 (sulfate transporter), 
member 2 
-1.8 
461. PDXDC2 BX647358 
Pyridoxal-dependent decarboxylase domain 
containing 2 
-1.8 
462. UNK NM_001080419 unkempt homolog (Drosophila) -1.8 
463. ZNF141 AK123078 Zinc finger protein 141 -1.8 
464.  U09825 
Human acid finger protein mRNA, complete 
cds. 
-1.8 
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465. ZBTB41 NM_194314 zinc finger and BTB domain containing 41 -1.8 
466. C20orf121 AK125126 chromosome 20 open reading frame 121 -1.8 
467. MOCS3 NM_014484 molybdenum cofactor synthesis 3 -1.8 
468. SETDB2 AB209349 SET domain, bifurcated 2 -1.8 
469. KEAP1 NM_203500 kelch-like ECH-associated protein 1 -1.8 
470. C10orf28 BC098268 chromosome 10 open reading frame 28 -1.8 
471. FAM101A BC042102 
family with sequence similarity 101, member 
A 
-1.8 
472.  AK092919 
Homo sapiens cDNA FLJ35600 fis, clone 
SPLEN2008737. 
-1.8 
473. MRPL46 AK074053 mitochondrial ribosomal protein L46 -1.8 
474. ZNF45 L75847 zinc finger protein 45 -1.8 
475. SLC16A13 NM_201566 
solute carrier family 16, member 13 
(monocarboxylic acid transporter 13) 
-1.8 
476. DUSP16 AB051487 dual specificity phosphatase 16 -1.8 
477. CHSY-2 AJ862728 chondroitin synthase-2 -1.8 
478. DET1 BC073867 de-etiolated homolog 1 (Arabidopsis) -1.8 
479.  AK123300 
Homo sapiens cDNA FLJ41306 fis, clone 
BRAMY2042549. 
-1.8 
480. C1orf107 AK096118 chromosome 1 open reading frame 107 -1.8 
481. ZCCHC8 AL157433 zinc finger, CCHC domain containing 8 -1.8 
482. CRKRS NM_016507 Cdc2-related kinase, arginine/serine-rich -1.8 
483. ZNF552 NM_024762 zinc finger protein 552 -1.8 
484. SH2D3C AK056068 SH2 domain containing 3C -1.8 
485. STK38L NM_015000 serine/threonine kinase 38 like -1.8 
486. LOC649115 XR_019031 
similar to Zinc finger protein 73 (Zinc finger 
protein 186) (hZNF2) 
-1.8 
487. MBD1 AJ564845 methyl-CpG binding domain protein 1 -1.8 
488. ZC3H8 BC032001 zinc finger CCCH-type containing 8 -1.8 
489. ZNF440 AK092559 zinc finger protein 440 -1.8 
490.  AK096150 
Homo sapiens cDNA FLJ38831 fis, clone 
MESAN1000126, weakly similar to 
Drosophila melanogaster Crossveinless 2 
(CV-2) mRNA. 
-1.8 
491. DNAJC16 AK091848 
DnaJ (Hsp40) homolog, subfamily C, member 
16 
-1.8 
492. LOC162073 NM_001034841 hypothetical protein LOC162073 -1.8 
493. ZNF553 NM_152652 zinc finger protein 553 -1.8 
494. RPAP2 BC039014 RNA polymerase II associated protein 2 -1.8 
495. SUOX L31573 sulfite oxidase -1.8 
496. GOLPH3 AK128510 golgi phosphoprotein 3 (coat-protein) -1.8 
497. NPIP AK160377 nuclear pore complex interacting protein -1.8 
498.  AK091373 
Homo sapiens cDNA FLJ34054 fis, clone 
FCBBF3000228, moderately similar to 
THIOREDOXIN PEROXIDASE 2. 
-1.8 
499. KIAA0892 BC063863 KIAA0892 -1.8 
500. SLRN AK123022 Synleurin -1.8 
501. WBP4 AK000979 
WW domain binding protein 4 (formin 
binding protein 21) 
-1.8 
502. GOLGA5 NM_005113 golgi autoantigen, golgin subfamily a, 5 -1.8 
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503. ZBTB24 BC036731 zinc finger and BTB domain containing 24 -1.8 
504. KLHL8 BX640744 kelch-like 8 (Drosophila) -1.8 
505. POLD3 BC108909 
polymerase (DNA-directed), delta 3, 
accessory subunit 
-1.8 
506. ZDHHC5 BX647707 zinc finger, DHHC-type containing 5 -1.8 
507. MGC12966 NM_001037163 hypothetical protein LOC84792 -1.8 
508. GGA3 AK124541 
golgi associated, gamma adaptin ear 
containing, ARF binding protein 3 
-1.8 
509. TBP CR456776 TATA box binding protein -1.8 
510. ZNF398 BC043295 zinc finger protein 398 -1.8 
511. CBFB NM_001755 core-binding factor, beta subunit -1.8 
512. SH3BP5L AK091164 SH3-binding domain protein 5-like -1.8 
513. PPP2R2D BC072402 
protein phosphatase 2, regulatory subunit B, 
delta isoform 
-1.8 
514. GRB10 BX649028 growth factor receptor-bound protein 10 -1.8 
515. ZFYVE20 NM_022340 zinc finger, FYVE domain containing 20 -1.8 
516. JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase) -1.8 
517. TNFAIP1 NM_021137 
tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
-1.8 
518.  AK093866 
Homo sapiens cDNA FLJ36547 fis, clone 
TRACH2007577. 
-1.8 
519. ZNF283 BC045755 Zinc finger protein 283 -1.8 
520.    -1.8 
521. PLEKHM1 NM_014798 
pleckstrin homology domain containing, 
family M (with RUN domain) member 1 
-1.8 
522. NOL8 BC146810 nucleolar protein 8 -1.8 
523. CREBZF NM_001039618 CREB/ATF bZIP transcription factor -1.8 
524. WDR37 BC018044 WD repeat domain 37 -1.8 
525. LDLR S70123 
low density lipoprotein receptor (familial 
hypercholesterolemia) 
-1.8 
526. PARG NM_003631 poly (ADP-ribose) glycohydrolase -1.8 
527.  AF086333 
Homo sapiens full length insert cDNA clone 
ZD55A11. 
-1.8 
528. TRIM21 NM_003141 tripartite motif-containing 21 -1.8 
529. MTERF AL832861 mitochondrial transcription termination factor -1.8 
530. HEL308 BC015428 DNA helicase HEL308 -1.8 
531. ALG11 AK128503 
asparagine-linked glycosylation 11 homolog 
(S. cerevisiae, alpha-1,2-mannosyltransferase) 
-1.8 
532. ZMIZ1 AK025812 zinc finger, MIZ-type containing 1 -1.8 
533. IGF2BP3 NM_006547 
insulin-like growth factor 2 mRNA binding 
protein 3 
-1.8 
534. TIAM2 AF120323 T-cell lymphoma invasion and metastasis 2 -1.7 
535. POLR3C BC004424 
polymerase (RNA) III (DNA directed) 
polypeptide C (62kD) 
-1.7 
536. IRAK2 NM_001570 interleukin-1 receptor-associated kinase 2 -1.7 
537. FLJ32065 AK056627 hypothetical protein FLJ32065 -1.7 
538. HIST1H2BF NM_003522 histone cluster 1, H2bf -1.7 
539. HKR1 BC053845 GLI-Kruppel family member HKR1 -1.7 
540. ATP8B1 NM_005603 ATPase, class I, type 8B, member 1 -1.7 
541. FLJ40913 AK098232 FLJ40913 protein -1.7 
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542. MLX AF203978 MAX-like bHLHZIP protein -1.7 
543. IBTK DQ005634 
inhibitor of Bruton agammaglobulinemia 
tyrosine kinase 
-1.7 
544.    -1.7 
545. WDR53 NM_182627 WD repeat domain 53 -1.7 
546. DDX59 NM_031306 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
59 
-1.7 
547. MTUS1 BC117564 mitochondrial tumor suppressor 1 -1.7 
548. RNF14 AK129515 ring finger protein 14 -1.7 
549. CEP110 AF083322 centrosomal protein 110kDa -1.7 
550. TIMM22 NM_013337 
translocase of inner mitochondrial membrane 
22 homolog (yeast) 
-1.7 
551. SAP130 AK055979 Sin3A-associated protein, 130kDa -1.7 
552.    -1.7 
553. ST8SIA4 NM_005668 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 
-1.7 
554. MCM9 AK000177 
minichromosome maintenance complex 
component 9 
-1.7 
555. ASTE1 AF113539 asteroid homolog 1 (Drosophila) -1.7 
556. TNRC15 BX647172 trinucleotide repeat containing 15 -1.7 
557. ZCCHC9 BC014841 zinc finger, CCHC domain containing 9 -1.7 
558. RAI1 AJ271790 retinoic acid induced 1 -1.7 
559. MRPL2 BC013685 mitochondrial ribosomal protein L2 -1.7 
560. MDS1 AF164154 myelodysplasia syndrome 1 -1.7 
561. ADAMTS4 BC030812 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 4 
-1.7 
562. ZNF816A NM_001031665 zinc finger protein 816A -1.7 
563. WDR5B NM_019069 WD repeat domain 5B -1.7 
564. PHF20L1 AF151830 PHD finger protein 20-like 1 -1.7 
565.    -1.7 
566. SRCAP AK023808 Snf2-related CREBBP activator protein -1.7 
567. CERK BC008382 ceramide kinase -1.7 
568. EZH1 AB004818 enhancer of zeste homolog 1 (Drosophila) -1.7 
569. ZNF468 NM_199132 zinc finger protein 468 -1.7 
570. MGC13198 BC040698 hypothetical protein MGC13198 -1.7 
571. ZNF510 BC036676 zinc finger protein 510 -1.7 
572. E2F3 BC099908 E2F transcription factor 3 -1.7 
573. CEBPZ NM_005760 CCAAT/enhancer binding protein zeta -1.7 
574. MLLT3 BC036089 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated 
to, 3 
-1.7 
575. PTPRB BC051329 protein tyrosine phosphatase, receptor type, B -1.7 
576. ZSCAN12 AB007886 zinc finger and SCAN domain containing 12 -1.7 
577. TERF2 BC024890 telomeric repeat binding factor 2 -1.7 
578. TMUB2 BC063489 
transmembrane and ubiquitin-like domain 
containing 2 
-1.7 
579. CD274 DQ836393 CD274 molecule -1.7 
580. ZNF589 AF114817 zinc finger protein 589 -1.7 
581. PHACTR4 BC068508 phosphatase and actin regulator 4 -1.7 
582.    -1.7 
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583.    -1.7 
584.    -1.7 
585. CCDC142 AK027303 coiled-coil domain containing 142 -1.7 
586. SNORD114-2 NR_003194 
Homo sapiens small nucleolar RNA, C/D box 
114-2 (SNORD114-2) on chromosome 14. 
-1.7 
587. ZNF30 NM_194325 zinc finger protein 30 -1.7 
588. KIAA0226 BC033615 KIAA0226 -1.7 
589. ST5 AK127763 suppression of tumorigenicity 5 -1.7 
590. KIN AJ005273 
KIN, antigenic determinant of recA protein 
homolog (mouse) 
-1.7 
591.  U79252 Human clone 23679 mRNA, complete cds. -1.7 
592. VISA BC044952 virus-induced signaling adapter -1.7 
593. ANKRD1 BC005191 ankyrin repeat domain 1 (cardiac muscle) -1.7 
594. SYNJ2 AY152396 synaptojanin 2 -1.7 
595. ZNF451 BC098382 zinc finger protein 451 -1.7 
596. IGF2BP1 NM_006546 
insulin-like growth factor 2 mRNA binding 
protein 1 
-1.7 
597.    -1.7 
598. ZNF248 BC110869 zinc finger protein 248 -1.7 
599. MIER2 NM_017550 
mesoderm induction early response 1, family 
member 2 
-1.7 
600. ZNF763 NM_001012753 zinc finger protein 763 -1.7 
601. AMOTL2 AK091040 angiomotin like 2 -1.7 
602. NOL11 AK025390 nucleolar protein 11 -1.7 
603. GIT2 AK125441 G protein-coupled receptor kinase interactor 2 -1.7 
604. STIL AK128406 SCL/TAL1 interrupting locus -1.7 
605.  AK092838 
Homo sapiens cDNA FLJ35519 fis, clone 
SPLEN2001176. 
-1.7 
606. TTRAP AJ420495 TRAF and TNF receptor associated protein -1.7 
607. SPIRE1 NM_020148 spire homolog 1 (Drosophila) -1.7 
608. RALA NM_005402 
v-ral simian leukemia viral oncogene homolog 
A (ras related) 
-1.7 
609. ZNF507 AB029007 zinc finger protein 507 -1.7 
610. C20orf177 BC020771 chromosome 20 open reading frame 177 -1.7 
611. DKFZp547E087 AK128772 hypothetical gene LOC283846 -1.7 
612. PLEKHA5 AK056054 
pleckstrin homology domain containing, 
family A member 5 
-1.7 
613. TDG DQ786320 thymine-DNA glycosylase -1.7 
614. COG2 AL832190 component of oligomeric golgi complex 2 -1.7 
615.  BC069286 Homo sapiens cDNA clone IMAGE:7262680. -1.7 
616. DIDO1 NM_033081 death inducer-obliterator 1 -1.7 
617. MGC10334 BC072454 hypothetical protein MGC10334 -1.7 
618.    -1.7 
619. ZNF767 BC047675 zinc finger family member 767 -1.7 
620. TAL1 X51990 T-cell acute lymphocytic leukemia 1 -1.7 
621. MORC3 BC058002 MORC family CW-type zinc finger 3 -1.7 
622. ZNF765 BC017357 zinc finger protein 765 -1.7 
623. FTSJ2 NM_013393 FtsJ homolog 2 (E. coli) -1.7 
624. ZNF32 NM_006973 zinc finger protein 32 -1.7 
625. ZCCHC6 BC032456 zinc finger, CCHC domain containing 6 -1.7 
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626. HEATR5B BX648805 HEAT repeat containing 5B -1.7 
627. RNF216 AY177398 ring finger protein 216 -1.7 
628. MLLT10 BC080577 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated 
to, 10 
-1.7 
629. MLYCD AK094095 malonyl-CoA decarboxylase -1.7 
630. CSTF3 BC059948 
cleavage stimulation factor, 3' pre-RNA, 
subunit 3, 77kDa 
-1.7 
631. CCDC16 NM_052857 coiled-coil domain containing 16 -1.7 
632. FAM53C BC052993 family with sequence similarity 53, member C -1.7 
633. CACHD1 BC039301 cache domain containing 1 -1.7 
634. DNAJA3 AK127660 
DnaJ (Hsp40) homolog, subfamily A, member 
3 
-1.7 
635. ZNF174 AF542096 zinc finger protein 174 -1.7 
636. IFNAR2 NM_000874 interferon (alpha, beta and omega) receptor 2 -1.7 
637. TRIM4 NM_033017 tripartite motif-containing 4 -1.7 
638. ELF4 BC017194 
E74-like factor 4 (ets domain transcription 
factor) 
-1.7 
639.    -1.7 
640. NOD1 AY128686 
nucleotide-binding oligomerization domain 
containing 1 
-1.7 
641. GRWD1 AB075822 glutamate-rich WD repeat containing 1 -1.7 
642. RIC8A BX538115 
resistance to inhibitors of cholinesterase 8 
homolog A (C. elegans) 
-1.7 
643. LOC728888 XR_015889 similar to Protein KIAA0220 -1.7 
644.    -1.7 
645. PDXDC2 BX647358 
Pyridoxal-dependent decarboxylase domain 
containing 2 
-1.7 
646. TBCEL AK024239 tubulin folding cofactor E-like -1.7 
647. GIMAP7 BC006010 GTPase, IMAP family member 7 -1.7 
648. CCDC76 AK001149 coiled-coil domain containing 76 -1.7 
649. ZNF788 AK128700 zinc finger family member 788 -1.7 
650. RNF122 NM_024787 ring finger protein 122 -1.7 
651. LOC643015 XR_016273 similar to nucleolar protein 11 -1.7 
652. PRPF4 NM_004697 
PRP4 pre-mRNA processing factor 4 homolog 
(yeast) 
-1.7 
653. BNC1 NM_001717 basonuclin 1 -1.7 
654.    -1.7 
655. PHLPPL AK001854 
PH domain and leucine rich repeat protein 
phosphatase-like 
-1.7 
656. C13orf3 NM_145061 chromosome 13 open reading frame 3 -1.7 
657. C12orf4 AK074479 chromosome 12 open reading frame 4 -1.7 
658. ARNTL BC041129 
aryl hydrocarbon receptor nuclear 
translocator-like 
-1.7 
659. ESF1 BC039706 
ESF1, nucleolar pre-rRNA processing protein, 
homolog (S. cerevisiae) 
-1.7 
660. CDCA4 NM_017955 cell division cycle associated 4 -1.7 
661. TRIP4 NM_016213 thyroid hormone receptor interactor 4 -1.7 
662. RNF185 BX648019 ring finger protein 185 -1.7 
663. ARHGEF15 AK023853 Rho guanine nucleotide exchange factor -1.7 
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(GEF) 15 
664. TM2D2 NM_031940 TM2 domain containing 2 -1.7 
665. IL7R NM_002185 interleukin 7 receptor -1.7 
666. NPIP AK126798 nuclear pore complex interacting protein -1.7 
667. BFAR NM_016561 bifunctional apoptosis regulator -1.7 
668. BMPR2 U25110 
bone morphogenetic protein receptor, type II 
(serine/threonine kinase) 
-1.7 
669. PDP2 NM_020786 
pyruvate dehydrogenase phosphatase 
isoenzyme 2 
-1.7 
670.    -1.7 
671.    -1.7 
672.  X83973 H.sapiens mRNA for TTF-I. -1.7 
673. BTBD10 BC017072 BTB (POZ) domain containing 10 -1.7 
674.    -1.7 
675. Mar-03 AF055007 membrane-associated ring finger (C3HC4) 3 -1.7 
676. EPM2AIP1 NM_014805 EPM2A (laforin) interacting protein 1 -1.7 
677. TXLNA AK096939 taxilin alpha -1.7 
678. BAZ2B AB032255 
bromodomain adjacent to zinc finger domain, 
2B 
-1.7 
679. ZNF426 AK095759 zinc finger protein 426 -1.7 
680. NR3C2 NM_000901 
nuclear receptor subfamily 3, group C, 
member 2 
-1.7 
681. RUNDC1 NM_173079 RUN domain containing 1 -1.7 
682. PIGA NM_002641 
phosphatidylinositol glycan anchor 
biosynthesis, class A (paroxysmal nocturnal 
hemoglobinuria) 
-1.7 
683.    -1.7 
684.    -1.7 
685. TTC9C NM_173810 tetratricopeptide repeat domain 9C -1.7 
686. LOC730153 XM_001132675 
similar to similar to nuclear pore complex 
interacting protein 
-1.7 
687. BPTF U05237 bromodomain PHD finger transcription factor -1.7 
688. ARID5B BC015120 AT rich interactive domain 5B (MRF1-like) -1.7 
689. AURKA NM_198433 aurora kinase A -1.7 
690. C18orf21 BC025950 chromosome 18 open reading frame 21 -1.6 
691. ZKSCAN1 AY260738 zinc finger with KRAB and SCAN domains 1 -1.6 
692. CCDC32 AL832032 coiled-coil domain containing 32 -1.6 
693. ORAOV1 AK126490 oral cancer overexpressed 1 -1.6 
694. LRIG3 AY358295 
leucine-rich repeats and immunoglobulin-like 
domains 3 
-1.6 
695. TMEM41A BX647928 transmembrane protein 41A -1.6 
696.    -1.6 
697. QRSL1 AK022251 
glutaminyl-tRNA synthase (glutamine-
hydrolyzing)-like 1 
-1.6 
698. ZBTB33 NM_006777 zinc finger and BTB domain containing 33 -1.6 
699. GTF2A1 NM_015859 general transcription factor IIA, 1, 19/37kDa -1.6 
700. EGFR K03193 
epidermal growth factor receptor 
(erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
-1.6 
701. TBCCD1 AK124362 TBCC domain containing 1 -1.6 
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702. PIM3 NM_001001852 pim-3 oncogene -1.6 
703. ZFYVE26 BC008927 zinc finger, FYVE domain containing 26 -1.6 
704. C3orf19 BC005199 chromosome 3 open reading frame 19 -1.6 
705. NUP37 NM_024057 nucleoporin 37kDa -1.6 
706. RTN4IP1 AF336861 reticulon 4 interacting protein 1 -1.6 
707. ALX1 NM_006982 ALX homeobox 1 -1.6 
708. DNTTIP1 NM_052951 
deoxynucleotidyltransferase, terminal, 
interacting protein 1 
-1.6 
709. DDX31 AF335567 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
31 
-1.6 
710. MTM1 AL832715 myotubularin 1 -1.6 
711. TGIF2 NM_021809 TGFB-induced factor homeobox 2 -1.6 
712. EPHB4 AB209644 EPH receptor B4 -1.6 
713. SLC25A30 AL832206 solute carrier family 25, member 30 -1.6 
714. METTL4 BX647373 methyltransferase like 4 -1.6 
715.  M87339 
Human replication factor C, 37-kDa subunit 
mRNA, complete cds. 
-1.6 
716. DNAJB1 NM_006145 
DnaJ (Hsp40) homolog, subfamily B, member 
1 
-1.6 
717. WDR73 AK055578 WD repeat domain 73 -1.6 
718. C16orf53 NM_024516 chromosome 16 open reading frame 53 -1.6 
719. CTTNBP2 AL137685 cortactin binding protein 2 -1.6 
720. ZC3H11A BC038513 zinc finger CCCH-type containing 11A -1.6 
721.  AK127197 
Homo sapiens cDNA FLJ45262 fis, clone 
BRHIP2022298, highly  similar to Homo 
sapiens Rab geranylgeranyltransferase, beta 
subunit (RABGGTB). 
-1.6 
722. FLJ45055 BC052779 60S ribosomal pseudogene -1.6 
723. MAPK7 NM_139033 mitogen-activated protein kinase 7 -1.6 
724. FAM74A4 BC121813 
family with sequence similarity 74, member 
A4 
-1.6 
725. SFRS4 AK223444 splicing factor, arginine/serine-rich 4 -1.6 
726. TBX18 BC040697 T-box 18 -1.6 
727. PFAAP5 U50529 
phosphonoformate immuno-associated protein 
5 
-1.6 
728. ADPRHL2 NM_017825 ADP-ribosylhydrolase like 2 -1.6 
729. TOX4 NM_014828 
TOX high mobility group box family member 
4 
-1.6 
730. GABPB2 D13316 
GA binding protein transcription factor, beta 
subunit 2 
-1.6 
731. SH3D19 AK128493 SH3 domain protein D19 -1.6 
732. TNRC6C AK056421 trinucleotide repeat containing 6C -1.6 
733. GBP4 NM_052941 guanylate binding protein 4 -1.6 
734. ARMCX6 AK097018 armadillo repeat containing, X-linked 6 -1.6 
735.    -1.6 
736. RGS4 BC000737 regulator of G-protein signaling 4 -1.6 
737. SYDE1 AK128870 
synapse defective 1, Rho GTPase, homolog 1 
(C. elegans) 
-1.6 
738. KLHL6 BX648370 kelch-like 6 (Drosophila) -1.6 
739. DSCR3 AK126461 Down syndrome critical region gene 3 -1.6 
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740. PPFIA1 AK124621 
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 1 
-1.6 
741. FLJ23861 AK056911 hypothetical protein FLJ23861 -1.6 
742.    -1.6 
743. C16orf30 BC004932 chromosome 16 open reading frame 30 -1.6 
744. LOC347509 XR_018238 similar to ribosomal protein L7-like 1 -1.6 
745. GUCY1A3 BC028384 guanylate cyclase 1, soluble, alpha 3 -1.6 
746. CAB39 AF134480 calcium binding protein 39 -1.6 
747. ZNF20 AK096560 zinc finger protein 20 -1.6 
748. ZNF675 AB209601 zinc finger protein 675 -1.6 
749. LRCH3 AK055819 
leucine-rich repeats and calponin homology 
(CH) domain containing 3 
-1.6 
750. HDX AK055240 highly divergent homeobox -1.6 
751. FGD4 AY367054 FYVE, RhoGEF and PH domain containing 4 -1.6 
752. FAM135A BC131782 
family with sequence similarity 135, member 
A 
-1.6 
753.    -1.6 
754. SHE NM_001010846 Src homology 2 domain containing E -1.6 
755. GRPEL2 NM_152407 GrpE-like 2, mitochondrial (E. coli) -1.6 
756.    -1.6 
757. MTFMT NM_139242 
mitochondrial methionyl-tRNA 
formyltransferase 
-1.6 
758. MTIF2 NM_001005369 mitochondrial translational initiation factor 2 -1.6 
759.    -1.6 
760. ZNF528 AL832630 zinc finger protein 528 -1.6 
761. PLEKHJ1 AK092742 
pleckstrin homology domain containing, 
family J member 1 
-1.6 
762. NY-SAR-48 BC040564 sarcoma antigen NY-SAR-48 -1.6 
763. RAB35 AK125543 RAB35, member RAS oncogene family -1.6 
764. METTL3 AK093509 methyltransferase like 3 -1.6 
765. THNSL1 BC016697 threonine synthase-like 1 (S. cerevisiae) -1.6 
766. BTN2A1 AK093886 butyrophilin, subfamily 2, member A1 -1.6 
767. RELA NM_021975 
v-rel reticuloendotheliosis viral oncogene 
homolog A, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3, p65 
(avian) 
-1.6 
768. SURF6 NM_006753 surfeit 6 -1.6 
769. C6orf47 NM_021184 chromosome 6 open reading frame 47 -1.6 
770. ZNF691 BC000157 zinc finger protein 691 -1.6 
771. CLK2P NR_002711 
Homo sapiens CDC-like kinase 2, pseudogene 
(CLK2P) on chromosome 7. 
-1.6 
772. DISP1 BC107762 dispatched homolog 1 (Drosophila) -1.6 
773. ZNF610 BC105967 zinc finger protein 610 -1.6 
774. GCNT1 NM_001490 
glucosaminyl (N-acetyl) transferase 1, core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 
-1.6 
775. FBXO34 BX648092 F-box protein 34 -1.6 
776. ZNF570 NM_144694 zinc finger protein 570 -1.6 
777. ZNF638 AF273049 zinc finger protein 638 -1.6 
778. ZNF252 BC019922 zinc finger protein 252 -1.6 
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779. RUSC2 BX647690 RUN and SH3 domain containing 2 -1.6 
780. EHMT1 BC047504 
euchromatic histone-lysine N-
methyltransferase 1 
-1.6 
781. PCID2 BC008975 PCI domain containing 2 -1.6 
782. CDC42EP1 NM_152243 
CDC42 effector protein (Rho GTPase 
binding) 1 
-1.6 
783. CYP1A1 AM233520 
cytochrome P450, family 1, subfamily A, 
polypeptide 1 
-1.6 
784. LOC728323 BC131690 Similar to F-box only protein 25 isoform 2 -1.6 
785. DDX56 NM_019082 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
56 
-1.6 
786. C9orf97 BC022958 chromosome 9 open reading frame 97 -1.6 
787. IL17RA NM_014339 interleukin 17 receptor A -1.6 
788. C14orf79 BC011537 chromosome 14 open reading frame 79 -1.6 
789.    -1.6 
790. EAPP NM_018453 E2F-associated phosphoprotein -1.6 
791. FAM124A BC051771 family with sequence similarity 124A -1.6 
792. MSL-1 NM_001012241 male-specific lethal-1 homolog -1.6 
793. SPECC1L NM_015330 SPECC1-like -1.6 
794. CCDC66 AK096754 coiled-coil domain containing 66 -1.6 
795. KLF3 BC051687 Kruppel-like factor 3 (basic) -1.6 
796. TRIM23 NM_001656 tripartite motif-containing 23 -1.6 
797. DIABLO AK001399 diablo homolog (Drosophila) -1.6 
798. PLEKHG1 AJ420468 
pleckstrin homology domain containing, 
family G (with RhoGef domain) member 1 
-1.6 
799. PCTP AF151638 phosphatidylcholine transfer protein -1.6 
800. ZNF319 NM_020807 zinc finger protein 319 -1.6 
801. PGBD1 BC032507 piggyBac transposable element derived 1 -1.6 
802. SLC3A2 AF055031 
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
-1.6 
803. C1orf131 AK055124 chromosome 1 open reading frame 131 -1.6 
804. ERF AB209271 Ets2 repressor factor -1.6 
805.    -1.6 
806. INTS9 NM_018250 integrator complex subunit 9 -1.6 
807. ZNF569 NM_152484 zinc finger protein 569 -1.6 
808. SUPT7L AF224759 suppressor of Ty 7 (S. cerevisiae)-like -1.6 
809.    -1.6 
810. VPRBP BC022792 Vpr (HIV-1) binding protein -1.6 
811. SEMA4C AK126512 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4C 
-1.6 
812. TAF6L NM_006473 
TAF6-like RNA polymerase II, p300/CBP-
associated factor (PCAF)-associated factor, 
65kDa 
-1.6 
813. DAGLB AK127440 diacylglycerol lipase, beta -1.6 
814. LOC728323 BC131690 Similar to F-box only protein 25 isoform 2 -1.6 
815. ZNF614 NM_025040 zinc finger protein 614 -1.6 
816. C21orf63 AK125013 chromosome 21 open reading frame 63 -1.6 
817. ZNF142 AK095027 zinc finger protein 142 -1.6 
818. CKAP2L NM_152515 cytoskeleton associated protein 2-like -1.6 
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819. C19orf48 BC051842 chromosome 19 open reading frame 48 -1.6 
820. SGOL1 AB193060 shugoshin-like 1 (S. pombe) -1.6 
821. UBR2 BC024217 
ubiquitin protein ligase E3 component n-
recognin 2 
-1.6 
822. ZMYM4 NM_005095 zinc finger, MYM-type 4 -1.6 
823. CCDC101 NM_138414 coiled-coil domain containing 101 -1.6 
824. STON1 NM_006873 stonin 1 -1.6 
825. TAOK3 AF135158 TAO kinase 3 -1.6 
826. MYSM1 BX648168 myb-like, SWIRM and MPN domains 1 -1.6 
827. PTPN1 NM_002827 
protein tyrosine phosphatase, non-receptor 
type 1 
-1.6 
828. TRAF3IP2 NM_147686 TRAF3 interacting protein 2 -1.6 
829. ZNF192 BC096282 zinc finger protein 192 -1.6 
830. SOS1 AL833457 son of sevenless homolog 1 (Drosophila) -1.6 
831. ZNF18 NM_144680 zinc finger protein 18 -1.6 
832. ZBTB5 NM_014872 zinc finger and BTB domain containing 5 -1.6 
833. FAM148B NM_001007595 
family with sequence similarity 148, member 
B 
-1.6 
834. MTRF1 BC042196 mitochondrial translational release factor 1 -1.6 
835. ZC3H4 NM_015168 zinc finger CCCH-type containing 4 -1.6 
836. MOSPD2 AK093075 motile sperm domain containing 2 -1.6 
837.    -1.6 
838. ZNF702 NR_003578 
Homo sapiens zinc finger protein 702 
(ZNF702) on chromosome 19. 
-1.6 
839. SNUPN AF039029 snurportin 1 -1.6 
840. SNORD45B NR_002748 
Homo sapiens small nucleolar RNA, C/D box 
45B (SNORD45B) on chromosome 1. 
-1.6 
841. FAM76A AK098318 family with sequence similarity 76, member A -1.6 
842. MAPKAPK5 NM_003668 
mitogen-activated protein kinase-activated 
protein kinase 5 
-1.6 
843. SUV39H1 L08238 
suppressor of variegation 3-9 homolog 1 
(Drosophila) 
-1.6 
844.    -1.6 
845. FLJ10971 AL834250 hypothetical protein FLJ10971 -1.6 
846. MKL2 BC047761 MKL/myocardin-like 2 -1.6 
847. MGA BX648098 MAX gene associated -1.6 
848. PHF20 AK054597 PHD finger protein 20 -1.6 
849. INSIG2 AF125392 insulin induced gene 2 -1.6 
850. WDR67 BC105800 WD repeat domain 67 -1.6 
851. SRGAP1 AK023899 SLIT-ROBO Rho GTPase activating protein 1 -1.6 
852.    -1.6 
853. KIAA1303 BC064515 raptor -1.6 
854. ZNF24 AF542097 zinc finger protein 24 -1.6 
855. P2RY5 BC045651 purinergic receptor P2Y, G-protein coupled, 5 -1.6 
856. CCNA2 NM_001237 cyclin A2 -1.6 
857. ZNF671 NM_024833 zinc finger protein 671 -1.6 
858.    -1.6 
859. ZNF449 BC065938 zinc finger protein 449 -1.6 
860.  BX538248 
Homo sapiens mRNA; cDNA 
DKFZp686O04200 (from clone 
-1.6 
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DKFZp686O04200). 
861. ZNF286A AF086305 zinc finger protein 286A -1.6 
862. ZNF687 NM_020832 zinc finger protein 687 -1.6 
863. ZNF672 BC035140 zinc finger protein 672 -1.6 
864. PDXDC2 BC063633 
pyridoxal-dependent decarboxylase domain 
containing 2 
-1.6 
865. FAM40A AK125054 family with sequence similarity 40, member A -1.6 
866. ZNF212 NM_012256 zinc finger protein 212 -1.6 
867. CARD8 BC056891 caspase recruitment domain family, member 8 -1.6 
868.    -1.6 
869.  AB209312 
Homo sapiens mRNA for DNA-repair protein 
complementing XP-G cells variant protein. 
-1.6 
870. RASA3 X89399 RAS p21 protein activator 3 -1.6 
871. PSEN1 L76517 presenilin 1 (Alzheimer disease 3) -1.6 
872. NDUFV3 BC033766 
NADH dehydrogenase (ubiquinone) 
flavoprotein 3, 10kDa 
-1.6 
873. SNORD113-3 NR_003231 
Homo sapiens small nucleolar RNA, C/D box 
113-3 (SNORD113-3) on chromosome 14. 
-1.6 
874. KIAA0329 BC142667 KIAA0329 -1.6 
875. ZNF286A NM_020652 zinc finger protein 286A -1.6 
876. UBTF BC031423 
upstream binding transcription factor, RNA 
polymerase I 
-1.6 
877. ZSWIM1 NM_080603 zinc finger, SWIM-type containing 1 -1.6 
878. DAPK3 AK097643 death-associated protein kinase 3 -1.6 
879. PARP2 AF085734 
poly (ADP-ribose) polymerase family, 
member 2 
-1.6 
880. ZNF83 BC032867 zinc finger protein 83 -1.6 
881. EXOC6 BC041403 exocyst complex component 6 -1.6 
882. NCOA6 NM_014071 nuclear receptor coactivator 6 -1.6 
883. C6orf47 NM_021184 chromosome 6 open reading frame 47 -1.6 
884. ZNF526 NM_133444 zinc finger protein 526 -1.6 
885.    -1.6 
886. ESPL1 AK128350 
extra spindle pole bodies homolog 1 (S. 
cerevisiae) 
-1.6 
887. DTWD1 AF168717 DTW domain containing 1 -1.6 
888.  BX537508 
Homo sapiens mRNA; cDNA 
DKFZp686L21223 (from clone 
DKFZp686L21223). 
-1.5 
889. PHF15 BC021962 PHD finger protein 15 -1.5 
890. KIAA1462 BX648192 KIAA1462 -1.5 
891. TMEM144 BC054487 transmembrane protein 144 -1.5 
892. MAEA AK127875 macrophage erythroblast attacher -1.5 
893. ZNF624 AB037770 zinc finger protein 624 -1.5 
894. AP4M1 BC018705 
adaptor-related protein complex 4, mu 1 
subunit 
-1.5 
895. TIA1 BC015944 
TIA1 cytotoxic granule-associated RNA 
binding protein 
-1.5 
896. TSHZ3 NM_020856 teashirt zinc finger homeobox 3 -1.5 
897. ZNF605 BC020877 zinc finger protein 605 -1.5 
898. CXorf40A AK055235 chromosome X open reading frame 40A -1.5 
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899. C4orf29 BC128142 chromosome 4 open reading frame 29 -1.5 
900. TFIP11 AK025443 tuftelin interacting protein 11 -1.5 
901. SRP68 AK097962 signal recognition particle 68kDa -1.5 
902. GDPD1 AY271346 
glycerophosphodiester phosphodiesterase 
domain containing 1 
-1.5 
903. GUSBL2 BC065547 glucuronidase, beta-like 2 -1.5 
904. DSN1 BC026011 
DSN1, MIND kinetochore complex 
component, homolog (S. cerevisiae) 
-1.5 
905. ZNF431 BX647597 zinc finger protein 431 -1.5 
906. WDR6 BC002826 WD repeat domain 6 -1.5 
907. TUT1 NM_022830 
terminal uridylyl transferase 1, U6 snRNA-
specific 
-1.5 
908. TFAP2A M61156 
transcription factor AP-2 alpha (activating 
enhancer binding protein 2 alpha) 
-1.5 
909. RECQL5 AF193041 RecQ protein-like 5 -1.5 
910. RC3H2 BC044642 
ring finger and CCCH-type zinc finger 
domains 2 
-1.5 
911. C19orf10 AK097251 Chromosome 19 open reading frame 10 -1.5 
912. C14orf32 AK025580 chromosome 14 open reading frame 32 -1.5 
913. NAT10 NM_024662 N-acetyltransferase 10 -1.5 
914. LIN37 NM_019104 lin-37 homolog (C. elegans) -1.5 
915. EGLN2 AL133009 egl nine homolog 2 (C. elegans) -1.5 
916.    -1.5 
917. ZNF658 BC031626 zinc finger protein 658 -1.5 
918. LOC645332 AK055771 hypothetical protein LOC645332 -1.5 
919. VAV2 S76992 vav 2 guanine nucleotide exchange factor -1.5 
920. DNAJB5 NM_012266 
DnaJ (Hsp40) homolog, subfamily B, member 
5 
-1.5 
921. CCDC75 BC071798 coiled-coil domain containing 75 -1.5 
922. USP54 BX649087 ubiquitin specific peptidase 54 -1.5 
923. ZNF228 NM_001083335 zinc finger protein 228 -1.5 
924. HTATIP AK130717 HIV-1 Tat interacting protein, 60kDa -1.5 
925. ZNF410 BC050683 zinc finger protein 410 -1.5 
926. CCRL1 AF110640 chemokine (C-C motif) receptor-like 1 -1.5 
927. LOC283331 AK093900 hypothetical protein LOC283331 -1.5 
928. ST6GAL1 AK128726 
ST6 beta-galactosamide alpha-2,6-
sialyltranferase 1 
-1.5 
929. KIF14 BC098582 kinesin family member 14 -1.5 
930. MTHFR AJ237672 
5,10-methylenetetrahydrofolate reductase 
(NADPH) 
-1.5 
931. RNF8 NM_003958 ring finger protein 8 -1.5 
932. EPB41L4A BC031042 
erythrocyte membrane protein band 4.1 like 
4A 
-1.5 
933. SASH1 BX537611 SAM and SH3 domain containing 1 -1.5 
934. BLZF1 U79751 basic leucine zipper nuclear factor 1 (JEM-1) -1.5 
935. FNBP4 AK123898 formin binding protein 4 -1.5 
936. DUSP14 AK027210 dual specificity phosphatase 14 -1.5 
937. ZNF177 U37251 zinc finger protein 177 -1.5 
938. YIPF5 NM_001024947 Yip1 domain family, member 5 -1.5 
939. C9orf90 BC021580 chromosome 9 open reading frame 90 -1.5 
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940.    -1.5 
941. DDI2 BC006011 
DDI1, DNA-damage inducible 1, homolog 2 
(S. cerevisiae) 
-1.5 
942. BRAP AF035950 BRCA1 associated protein -1.5 
943. TROAP BC011597 trophinin associated protein (tastin) -1.5 
944. GTSE1 NM_016426 G-2 and S-phase expressed 1 -1.5 
945. NCK1 NM_006153 NCK adaptor protein 1 -1.5 
946.    -1.5 
947. JARID1A NM_005056 jumonji, AT rich interactive domain 1A -1.5 
948. PSMD5 AK001065 
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 5 
-1.5 
949. PAXIP1 AK123044 
PAX interacting (with transcription-activation 
domain) protein 1 
-1.5 
950. MRPS18B BC005373 mitochondrial ribosomal protein S18B -1.5 
951.    -1.5 
952. MRPS18B BC005373 mitochondrial ribosomal protein S18B -1.5 
953.    -1.5 
954. CCAR1 NM_018237 cell division cycle and apoptosis regulator 1 -1.5 
955. ZNF445 AY279350 zinc finger protein 445 -1.5 
956. LOC400566 BC141806 hypothetical gene supported by AK128660 -1.5 
957. SHROOM4 AY044234 shroom family member 4 -1.5 
958. KLHL12 BC003183 kelch-like 12 (Drosophila) -1.5 
959. HERC4 BX537563 hect domain and RLD 4 -1.5 
960. MRPS18B BC005373 mitochondrial ribosomal protein S18B -1.5 
961. KIAA0692 AK093451 KIAA0692 -1.5 
962. CLK4 BC063116 CDC-like kinase 4 -1.5 
963. SLC6A6 U16120 
solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 
-1.5 
964.    -1.5 
965. GEMIN7 NM_024707 gem (nuclear organelle) associated protein 7 -1.5 
966. UTP15 NM_032175 
UTP15, U3 small nucleolar ribonucleoprotein, 
homolog (S. cerevisiae) 
-1.5 
967. CDK9 NM_001261 cyclin-dependent kinase 9 -1.5 
968. GTF3C2 BC000212 
general transcription factor IIIC, polypeptide 
2, beta 110kDa 
-1.5 
969. LOC728340 BC105980 
general transcription factor IIH, polypeptide 2, 
44kDa-like 
-1.5 
970. CTNS NM_004937 cystinosis, nephropathic -1.5 
971. SBNO2 AK125139 strawberry notch homolog 2 (Drosophila) -1.5 
972. TCHP BC004285 trichoplein, keratin filament binding -1.5 
973. ARNT AB209877 aryl hydrocarbon receptor nuclear translocator -1.5 
974. FLJ30403 AK093799 Hypothetical protein LOC729975 -1.5 
975. C14orf119 BC056255 chromosome 14 open reading frame 119 -1.5 
976. TOE1 AK093320 target of EGR1, member 1 (nuclear) -1.5 
977. RMND1 BC012081 
required for meiotic nuclear division 1 
homolog (S. cerevisiae) 
-1.5 
978. TRAIP NM_005879 TRAF interacting protein -1.5 
979.    -1.5 
980. ZBTB45 AK027392 zinc finger and BTB domain containing 45 -1.5 
981.    -1.5 
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982. ZMYM2 AF012126 zinc finger, MYM-type 2 -1.5 
983. MAP3K12 BC050050 
mitogen-activated protein kinase kinase kinase 
12 
-1.5 
984. CLOCK BC041878 clock homolog (mouse) -1.5 
985. ZNF658B NM_001032297 zinc finger protein 658B -1.5 
986. ZNF79 NM_007135 zinc finger protein 79 -1.5 
987. ZNF773 NM_198542 zinc finger protein 773 -1.5 
988. RAB3GAP2 AK021928 
RAB3 GTPase activating protein subunit 2 
(non-catalytic) 
-1.5 
989. LSM8 BC045532 
LSM8 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
-1.5 
990. E2F5 U15642 E2F transcription factor 5, p130-binding -1.5 
991. ZSWIM3 NM_080752 zinc finger, SWIM-type containing 3 -1.5 
992. ING4 BC095434 inhibitor of growth family, member 4 -1.5 
993. ANKRD40 NM_052855 ankyrin repeat domain 40 -1.5 
994.  BC067737 
Homo sapiens cDNA clone IMAGE:5298595, 
partial cds. 
-1.5 
995. ANKRD26 AK128577 ankyrin repeat domain 26 -1.5 
996. C15orf17 BC064575 chromosome 15 open reading frame 17 -1.5 
997. C9orf85 BC028019 chromosome 9 open reading frame 85 -1.5 
998. YEATS4 NM_006530 YEATS domain containing 4 -1.5 
999.    -1.5 
1000.    -1.5 
1001.  PIGM NM_145167 
phosphatidylinositol glycan anchor 
biosynthesis, class M 
-1.5 
1002.  HIST2H3PS2 BC073925 histone cluster 2, H3, pseudogene 2 -1.5 
1003.  ABI3 NM_016428 ABI gene family, member 3 -1.5 
1004.  C11orf79 BX648946 Chromosome 11 open reading frame 79 -1.5 
1005.  FANCM AK093422 Fanconi anemia, complementation group M -1.5 
1006.  ABCF3 AK097073 
ATP-binding cassette, sub-family F (GCN20), 
member 3 
-1.5 
1007.  ANKRD25 AK000011 ankyrin repeat domain 25 -1.5 
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Appendix 10: p38 dependent TNFα induced transcripts 
p<0.05 
No. 
Primary 
Sequence 
Name 
Accession no. Sequence Description 
Fold 
Change 
1.     1.05 
2.   X75315 H.sapiens seb4B mRNA. 1.13 
3.   U12597 
Human tumor necrosis factor type 2 receptor 
associated protein (TRAP3) mRNA, complete 
cds. 
1.14 
4.  HYOU1 NM_006389 hypoxia up-regulated 1 1.16 
5.  IRGQ NM_001007561 immunity-related GTPase family, Q 1.17 
6.  LYSMD3 BC058027 
LysM, putative peptidoglycan-binding, domain 
containing 3 
1.17 
7.  MTE AF348997 metallothionein E 1.17 
8.  GFPT1 AF334737 glutamine-fructose-6-phosphate transaminase 1 1.17 
9.  UGDH NM_003359 UDP-glucose dehydrogenase 1.22 
10.  WTAP AK127822 Wilms tumor 1 associated protein 1.24 
11.  XBP1 AK093842 X-box binding protein 1 1.24 
12.   AK123998 
Homo sapiens cDNA FLJ42004 fis, clone 
SPLEN2030736. 
1.26 
13.  BTG3 NM_006806 BTG family, member 3 1.27 
14.  SLC7A1 NM_003045 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
1.29 
15.  CCDC93 NM_019044 coiled-coil domain containing 93 1.30 
16.  NDEL1 AK123802 
nudE nuclear distribution gene E homolog (A. 
nidulans)-like 1 
1.30 
17.  PITPNB NM_012399 phosphatidylinositol transfer protein, beta 1.31 
18.     1.31 
19.  RNF145 BX537635 ring finger protein 145 1.33 
20.  CDV3 BC007338 CDV3 homolog (mouse) 1.35 
21.  SDCBP AK128645 syndecan binding protein (syntenin) 1.40 
22.  SGK AK055077 serum/glucocorticoid regulated kinase 1.41 
23.  STK4 BC005231 serine/threonine kinase 4 1.42 
24.  SNN NM_003498 stannin 1.43 
25.  ZNF71 NM_021216 zinc finger protein 71 1.46 
26.  HERPUD1 BC009739 
homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 
1.54 
27.  APOL2 NM_030882 apolipoprotein L, 2 1.68 
28.  GRAMD3 NM_023927 GRAM domain containing 3 1.94 
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Appendix 11: p38 dependent transcripts 
p<0.05 
No 
Primary 
Sequence Name 
Accession # Sequence Description 
Fold 
Change 
1.     -7.6 
2.     -3.3 
3.     -2.4 
4.  TNFRSF11B NM_002546 
tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
-2.1 
5.  IL1A NM_000575 interleukin 1, alpha -2.0 
6.  IL6 NM_000600 interleukin 6 (interferon, beta 2) -2.0 
7.  TNFSF18 BC112032 
tumor necrosis factor (ligand) superfamily, 
member 18 
-1.9 
8.     -1.9 
9.     -1.9 
10.     -1.9 
11.   AB209899 
Homo sapiens mRNA for Hypothetical protein 
DKFZp434O1826 variant protein. 
-1.8 
12.     -1.8 
13.     -1.8 
14.     -1.7 
15.     -1.7 
16.  IL8 NM_000584 interleukin 8 -1.7 
17.     -1.7 
18.     -1.7 
19.  FLJ38379 AK126530 hypothetical protein FLJ38379 -1.7 
20.     -1.6 
21.     -1.6 
22.  GAGE6 NM_001476 G antigen 6 -1.6 
23.  C13orf15 AK095079 chromosome 13 open reading frame 15 -1.6 
24.  FLJ39257 AK096576 hypothetical protein LOC650346 -1.6 
25.  RBMY2EP NR_001574 
Homo sapiens RNA binding motif protein, Y-
linked, family 2, member E pseudogene 
(RBMY2EP) on chromosome Y. 
-1.5 
26.     -1.5 
27.     -1.5 
28.  HSPC072 XR_017985 
PREDICTED: Homo sapiens HSPC072 protein 
(HSPC072), misc RNA. 
-1.5 
29.     -1.5 
30.  MMP24 AK096805 Matrix metallopeptidase 24 (membrane-inserted) -1.5 
31.  CD69 NM_001781 CD69 molecule -1.5 
32.  DDIT4 NM_019058 DNA-damage-inducible transcript 4 -1.5 
33.     -1.5 
34.     -1.5 
35.     -1.5 
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